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ABSTRACT 
 
 
Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed, essential enzymes that charge 
tRNA with cognate amino acids, a critical step in protein translation. Mutations in multiple ARS 
family members have been implicated in dominant and recessive diseases, which span a broad 
spectrum of phenotypes, including multi-organ disease and tissue specific peripheral neuropathy. 
The allelic heterogeneity at these loci and the mechanism by which these mutations lead to 
disease are currently unknown. In this work we sought to: (1) expand the locus and allelic 
heterogeneity for ARS-mediated recessive and dominant disease;  (2) functionally characterize 
the effects of disease-associated mutations on ARS activity; and (3) investigate the mechanism 
of pathogenesis in ARS-mediated peripheral neuropathy.  Our studies have identified and/or 
characterized 30 mutations at six ARS loci. Importantly, we identified mutations in four ARS 
loci not previously associated with recessive phenotypes; provided the necessary genetic 
evidence to implicate histidyl-tRNA synthetase in inherited peripheral neuropathy; expanded the 
allelic heterogeneity of glycyl-, alanyl-, and tyrosyl-tRNA synthetase mutations in peripheral 
neuropathy; and excluded one previously disease-associated mutation (S581L glycyl-tRNA 
synthetase) in disease pathogenesis. Functional studies of ARS mutations demonstrate that 
impaired function is a common characteristic of disease-associated ARS mutations and that there 
is a direct correlation between the level of impaired ARS function and the occurrence of 
dominant or recessive phenotypes. These data indicate that reduced function is a component of 
pathogenesis in both recessive and dominant ARS-associated disease. To identify the precise 
 xvii 
loss-of-function mechanism involved in dominant ARS-mediated peripheral neuropathy, we 
performed studies to assess GARS variants for a dominant-negative effect and for altered protein 
interactions that may explain protein mislocalization. Initial results indicate differential 
interactions between wild-type and mutant GARS that have the potential to address both loss- 
and gain-of-function hypotheses in the field. Together, this dissertation expands the genetic and 
allelic heterogeneity in dominant and recessive ARS-associated disease, provides insight into the 
pathomechanism of ARS-mediated peripheral neuropathy, and has the potential to inform future 
attempts at therapeutic development. 
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CHAPTER 1 
Introduction to the role of aminoacyl-tRNA synthetases in human 
disease 
 
Protein translation and human disease 
 
Cells are constantly inundated with internal and external signals. In response to these cues, cells 
must make alterations to their proteomes (Mathews et al. 2007). This process requires protein 
translation, a coordinated effort that includes mRNA processing and transport, translation 
initiation, and peptide synthesis. DNA is transcribed into RNA, which is processed into mRNA 
that can be used as a template for protein synthesis in the ribosome. Ribosomes are protein and 
RNA complexes that facilitate peptide bond formation in elongating peptide chains. This process 
occurs in three stages: initiation, elongation, and termination. In eukaryotes, initiation begins 
when eukaryotic initiation factors (eIFs) bind the 40S ribosomal subunit and methionine ligated 
tRNAMet . This complex, termed the 43S preinitiation complex (PIC), binds the 5’cap of mRNA. 
Once bound, the complex scans the mRNA until the AUG start codon is recognized by tRNAMet. 
eIFs subsequently hydrolyze GTP and bind the 60S ribosomal subunit to form the 80S ribosome, 
where elongation occurs. The ribosome binds aminoacyl-tRNAs (tRNAs ligated to cognate 
amino acids; AA-tRNA) and assembles the growing peptide chain based on the codon sequence 
in the mRNA. tRNA contains an anticodon that is complementary to the mRNA codon for its 
cognate amino acid. AA-tRNA binds in the acceptor site (A‐ site) in the ribosome. As the ligated 
amino acid is added to the growing peptide chain, the tRNA is transferred to the peptidyl or P-
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site. After the amino acid has been incorporated into the peptide chain, the tRNA moves to the 
exit or E-site just prior to being released from the ribosome. Elongation factors are proteins that 
facilitate the movement of tRNA between sites and aid in the movement of the ribosome along 
the mRNA. The elongation process continues until the ribosome reaches the “stop” codon, a 
codon that lacks a corresponding tRNA. Peptide elongation then halts and the complex 
disassembles releasing the protein in the termination phase.  
Dysfunction of any single component of the protein translation process can lead to human 
disease. Defects in components of this process have been shown to lead to a spectrum of disease 
that ranges from systemic to tissue specific phenotypes. For example, mutations in EIF2AK3 
result in Wolcott–Rallison syndrome, a disease of infancy that affects multiple tissues and results 
in diabetes mellitus, epiphyseal dysplasia, kidney and liver dysfunction, mental retardation, 
central hypothyroidism and dysfunction of the exocrine pancreas (Mihci et al. 2012). In contrast, 
mutations in EIF2B1–5 result in a neurologic condition that includes childhood ataxia with 
central nervous system hypomyelination (Wilson et al. 2005).  Interestingly, neurodegenerative 
diseases are increasingly associated with impairments in many stages of protein translation. For 
example, mutations in the RNA binding protein FUS leads to ALS (Vance et al. 2009), while 
mutations in CLP1, a kinase involved in tRNA biogenesis, results in brain malformations and 
peripheral nerve dysfunction (Hanada et al. 2013; Karaca et al. 2014; Schaffer et al. 2014). One 
family of proteins that is critical for protein translation and has been implicated in a variety of 
human disease, including many neurologic conditions, is the aminoacyl-tRNA synthetase (ARS) 
family. This work was initiated with the goal of expanding our understanding of the spectrum of 
phenotypes that occur in ARS-mediated disease and how mutations in ubiquitously expressed 
proteins lead to tissue-specific disease.  
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Aminoacyl-tRNA synthetases serve a critical housekeeping role in cells. 
 
The incorporation of appropriate amino acids during the elongation of peptide chains is critical in 
the protein translation process. This step requires that tRNAs are properly ligated to cognate 
amino acids for use by the ribosome (Lodish 2008). Aminoacyl-tRNA synthetases (ARSs) are 
the ubiquitously expressed, essential enzymes that charge tRNA with cognate amino acids in a 
two-step reaction (equation shown below) (Figure 1.1) (Delarue 1995).  In the first step, the ARS 
enzyme binds its respective amino acid and ATP and generates an amino-adenylate intermediate 
(AA-AMP), releasing a pyrophosphate (PPi) byproduct. In the second step, the ARS enzyme 
binds the appropriate tRNA, covalently ligates the amino acid to tRNA, and releases the 
aminoacyl-tRNA (AA-tRNA) for use during protein translation.  
1. ARS + AA + ATP → ARS(AA-AMP) + PPi 
2. ARS(AA-AMP) + tRNA → AA-tRNA + AMP + ARS 
Protein synthesis, and therefore tRNA charging, must occur in both the cytoplasm and the 
mitochondria (Bonnefond et al. 2005; Lodish 2008). To meet these demands, human nuclear 
DNA encodes 37 ARS genes that code for 36 functional enzymes: 17 genes encode 16 
cytoplasmic ARS enzymes, 17 genes code for 17 mitochondrial ARS enzymes, and 3 genes 
encode products that function in both the cytoplasm and the mitochondria, termed ‘bifunctional’ 
ARS enzymes (Table 1.1).  The nomenclature of ARS enzymes is the single-letter amino acid 
code followed by ‘ARS’. To distinguish between cytoplasmic and mitochondrial ARS enzymes, 
a “2” is added to denote mitochondrial enzymes. For example, cytoplasmic histidyl-tRNA 
synthetase is represented by ‘HARS’, while mitochondrial histidyl-tRNA synthetase is signified 
as ‘HARS2”. In general, one gene encodes one ARS enzyme, which charges all the tRNAs for 
the cognate amino acid. There are two exceptions to this rule. First, a single gene codes for 
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Figure 1.1. Cartoon of the aminoacylation reaction. Aminoacyl-tRNA synthetases (ARS) charge tRNA in a two-step reaction. In the 
first step, ARS enzymes (grey) bind the amino acid (AA; green) and adenosine triphosphate (ATP; purple) and form an aminoacyl-
adenylate intermediate (green and red). During this step, a pyrophosphate is released (PPi; blue).  In the second step, ARS binds the 
tRNA molecule (black), transfers the amino acid onto the tRNA, and releases adenosine monophosphate (AMP; red). The aminoacyl-
tRNA is then released for use during protein translation and the ARS enzyme is available for subsequent rounds of aminoacylation.   
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Table 1.1. Human aminoacyl-tRNA synthetases 
Gene Symbol Gene Name Class 
Oligomerization 
Status 
Cell 
Compartment 
Multisynthetase 
complex 
AARS alanyl-tRNA synthetase II Dimer Cytoplasm No 
CARS cysteinyl-tRNA synthetase I Monomer Cytoplasm No 
DARS aspartyl-tRNA synthetase II Dimer Cytoplasm Yes 
EPRS   glutamyl-prolyl-tRNA synthetase I Monomer/Dimer Cytoplasm Yes 
FARSA phenylalanyl-tRNA synthetase alpha II Heterotetramer Cytoplasm No 
FARSB phenylalanyl-tRNA synthetase beta II Heterotetramer Cytoplasm No 
HARS histidyl-tRNA synthetase II Dimer Cytoplasm No 
IARS isoleucyl-tRNA synthetase I Monomer Cytoplasm Yes 
LARS leucyl-tRNA synthetase I Monomer Cytoplasm Yes 
MARS methionyl-tRNA synthetase I Dimer Cytoplasm Yes 
NARS asparaginyl-tRNA synthetase II Dimer Cytoplasm No 
RARS arginyl-tRNA synthetase I Monomer Cytoplasm Yes 
SARS seryl-tRNA synthetase II Dimer Cytoplasm No 
TARS threonyl-tRNA synthetase II Dimer Cytoplasm No 
VARS valyl-tRNA synthetase I Monomer Cytoplasm No 
WARS tryptophanyl-tRNA synthetase II Dimer Cytoplasm No 
YARS tyrosyl-tRNA synthetase I Dimer Cytoplasm No 
AARS2 alanyl-tRNA synthetase 2 II Dimer Mitochondria No 
CARS2 cysteinyl-tRNA synthetase 2 I Monomer Mitochondria No 
DARS2 aspartyl-tRNA synthetase 2 II Dimer Mitochondria No 
EARS2   glutamyl-tRNA synthetase 2 I Monomer Mitochondria No 
FARS2 phenylalanyl-tRNA synthetase 2 II Heterotetramer Mitochondria No 
HARS2 histidyl-tRNA synthetase 2 II Heterotetramer Mitochondria No 
IARS2 isoleucyl-tRNA synthetase 2 II Dimer Mitochondria No 
LARS2 leucyl-tRNA synthetase 2 I Monomer Mitochondria No 
MARS2 methionyl-tRNA synthetase 2 I Monomer Mitochondria No 
NARS2 asparaginyl-tRNA synthetase 2 II Monomer Mitochondria No 
PARS2 prolyl-tRNA synthetase II Dimer Mitochondria No 
RARS2 arginyl-tRNA synthetase I Monomer Mitochondria No 
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Gene Symbol Gene Name Class 
Oligomerization 
Status 
Cell 
Compartment 
Multisynthetase 
complex 
SARS2 seryl-tRNA synthetase II Dimer Mitochondria No 
TARS2 threonyl-tRNA synthetase II Dimer Mitochondria No 
VARS2 valyl-tRNA synthetase I Monomer Mitochondria No 
WARS2 tryptophanyl-tRNA synthetase II Dimer Mitochondria No 
YARS2 tyrosyl-tRNA synthetase I Dimer Mitochondria No 
GARS glycyl-tRNA synthetase II Dimer Bifunctional No 
KARS lysyl-tRNA synthetase II Dimer Bifunctional Yes 
QARS glutaminyl-tRNA synthetase I Monomer Bifunctional Yes 
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glutamyl-prolyl tRNA synthetase (EPRS), a fusion ARS enzyme that charges both tRNAGlu and 
tRNAPro in the cytoplasm (Berthonneau and Mirande 2000). The second exception is 
phenylalanyl-tRNA synthetase (FARS), the enzyme responsible for charging tRNAPhe. FARS is 
a heterotetramer comprised of two subunits independently encoded by the FARSA and FARSB 
genes (Rodova et al. 1999). 
ARS enzymes can be classified into two structural classes (Arnez and Moras 1997). Class I ARS 
enzymes have three distinguishing characteristics, including (i) HIGH and KMSKS sequence 
motifs that form the ATP binding site, (ii) a Rossman fold (parallel β-sheet nucleotide binding 
motif) in the catalytic domain, and (iii) ligation of the amino acid to the 2'-OH of the terminal 
adenosine of tRNA. With the exception of the dimeric tyrosyl-tRNA synthetase (YARS) and 
tryptophyl-tRNA synthetase (WARS), Class I ARS enzymes function as monomers (Arnez and 
Moras 1997). Alternatively, Class II ARS enzymes contain three homologous motifs (motif 1, 2, 
and 3). Motif 1 consists of a long α-helix linked to a β-strand and comprises part of the dimer 
interface, while motif 2 (two antiparallel β -strands connected by a long loop) and motif 3 (β-
strand immediately followed by an α-helix) comprise the active site.  Class II enzymes function 
as dimers or tetramers. With the exception of FARS, which utilizes the 2’-OH of tRNA for 
amino acid ligation, class II enzymes attach amino acids to the 3'-OH of the tRNA (Arnez and 
Moras 1997). In higher eukaryotes, some ARS enzymes complex in the Multisynthetase 
Complex (MSC) (Park et al. 2008). The MSC is known to be comprised of eight ARS proteins 
(EPRS, IARS, LARS, RARS, QARS, MARS, KARS, DARS) and three aminoacyl-tRNA 
synthetase complex-interacting multifunctional proteins  (AIMP1, 2, and 3) that stabilize the 
complex (Bandyopadhyay and Deutscher 1971; Kerjan et al. 1994; Quevillon et al. 1999; 
Robinson et al. 2000). Although the remaining ARS proteins have not been purified as part of the 
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MSC, their association with the MSC cannot be ruled out.  It is currently unknown why some 
ARS enzymes function in this complex, while others appear to charge tRNA independently.  
Some ARS enzymes have secondary, non-canonical functions. 
 
In this work, studies will focus on understanding the effects of disease-associated ARS mutations 
on the primary tRNA charging activity of ARS enzymes; however, it is important to note that 
some ARS enzymes have non-canonical or secondary functions (reviewed in (Smirnova et al. 
2012). For example, KARS regulates transcription involved in HIV virion packaging in human 
cells (Cen et al. 2002), while EPRS is released from the MSC in response to γ-IFN and regulates 
translation of mRNA in the inflammatory response (Sampath et al. 2004). Although to date 
alterations in ARS secondary functions have not been implicated in disease, they may play an 
unknown role and therefore warrant continued investigation.  
Aminoacyl-tRNA synthetase (ARS) genes are mutated in human disease. 
 
To date, mutations in 22 ARS genes have been implicated in a spectrum of inherited human 
diseases (Table 1.2). More specifically, mitochondrial ARS genes have been implicated in 
recessive syndromes, while cytoplasmic ARS genes have been implicated in both dominant and 
recessive phenotypes.  
Mitochondrial tRNA synthetase mutations in human disease  
Mutations in nuclear-encoded mitochondrial tRNA synthetases have been identified in a wide 
range of recessive syndromes (Table 1.2). As is typical with mitochondrial disorders, 
mitochondrial ARS mutations often affect tissues with high metabolic demands such as the brain, 
muscle, and liver. Recessive mutations in mitochondrial aspartyl- (DARS2), glutamyl- (EARS2), 
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Table 1.2. Human diseases associated with ARS mutations 
Gene Locus 
Location of 
Function 
Mode of 
Inheritance Disease 
OMIM 
no. Clinical Description Reference 
GARS 7p15 
Cytoplasm & 
Mitochondria 
Autosomal 
dominant 
CMT2D or 
dSMA-V 
601472 
600794 
Upper limb predominant, axonal 
motor neuropathy with variable 
sensory involvement 
(Antonellis et al. 
2006) 
YARS 1p35.1 Cytoplasm 
Autosomal 
dominant 
DI-CMT 608323 
Motor and sensory neuropathy 
with intermediate nerve 
conduction velocities 
(Jordanova et al. 
2006) 
AARS 16q22 Cytoplasm 
Autosomal 
dominant 
CMT2N 613287 
Motor and sensory neuropathy 
with variable sensorineural 
deafness 
(Latour et al. 2010) 
HARS 5q31.3 Cytoplasm Unknown 
Not 
applicable 
142810 
Single individual with sensory > 
motor axonal neuropathy 
(Vester et al. 2012) 
MARS 12q13.3 Cytoplasm 
Autosomal 
dominant 
CMT2U 616280 Motor and sensory neuropathy (Gonzalez et al. 2013) 
MARS 12q13.3 Cytoplasm 
Autosomal 
recessive 
ILLD 615486 Interstitial lung and liver disease 
(Hadchouel et al. 
2015) 
KARS 16q23.1 
Cytoplasm & 
Mitochondria 
Autosomal 
recessive 
RI-CMTB 613641 
Single individual with 
intermediate CMT, developmental 
delay, self-abusive behavior, 
dysmorphic features and 
vestibular Schwannoma 
(McLaughlin et al. 
2010) 
DARS 2q21.3 Cytoplasm 
Autosomal 
recessive 
HBSL 615281 
Hypomyelination with brainstem 
and spinal cord involvement and 
leg spasticity 
(Taft et al. 2013) 
QARS 3p21.31 
Cytoplasm & 
Mitochondria 
Autosomal 
recessive 
MSCCA 615760 
Microcephaly, progressive, 
seizures, and cerebral and 
cerebellar atrophy 
(Zhang et al. 2014) 
RARS 5q34 Cytoplasmic 
Autosomal 
recessive 
Leuko-
dystrophy 
616140 Leukodystrophy, hypomyelination (Wolf et al. 2014) 
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Gene Locus 
Location of 
Function 
Mode of 
Inheritance Disease 
OMIM 
no. Clinical Description Reference 
AARS2 6p21.1 Mitochondria 
Autosomal 
recessive 
Mitochondri
al Infantile 
CMP 
614096 
Mitochondrial infantile 
cardiomyopathy 
(Götz et al. 2011) 
DARS2 1q25.1 Mitochondria 
Autosomal 
recessive 
LBSL 611105 
Leukoencephalopathy with 
brainstem and spinal cord 
involvement and lactate elevation 
(Scheper et al. 2007a) 
EARS2 16p12.2 Mitochondria 
Autosomal 
recessive 
LTBL 614924 
Infantile leukoencephalopathy 
involving thalamus and brainstem, 
high lactate, myopathy, hypotonia, 
seizures, retinitis pigmentosa, 
respiratory failure 
(Steenweg et al. 2012) 
FARS2 6p25.1 Mitochondria 
Autosomal 
recessive 
Alpers 
encephalo-
pathy 
614946 
Neonatal encephalopathy, 
developmental delay, refractory 
seizures, lactic acidosis, liver 
disease 
(Elo et al. 2012) 
HARS2 5q31.3 Mitochondria 
Autosomal 
recessive 
Perrault 
Syndrome 2 
614926 
Sensorineural deafness (both 
sexes), ovarian dysgenesis 
(females) 
(Pierce et al. 2011) 
IARS2 1q41 Mitochondria 
Autosomal 
recessive 
CAGSSS; 
Leigh 
Syndrome 
616007 
Cataracts, growth hormone 
deficiency with short stature, 
partial sensorineural deafness, 
peripheral neuropathy 
(Schwartzentruber et 
al. 2014) 
LARS2 3p21.31 Mitochondria 
Autosomal 
recessive 
Perrault 
Syndrome 4 
615300 
Premature ovarian failure (POF) 
in females and by progressive 
hearing loss in both females and 
males 
(Pierce et al. 2013) 
MARS2 2q33.1 Mitochondria 
Autosomal 
recessive 
Spastic 
Ataxia 3 
611390 
Spastic ataxia, 
leukoencephalopathy 
(Bayat et al. 2012) 
RARS2 6q16.1 Mitochondria 
Autosomal 
recessive 
Spastic 
Ataxia 3 
611390 
Spastic ataxia, 
leukoencephalopathy 
(Edvardson et al. 
2007) 
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Gene Locus 
Location of 
Function 
Mode of 
Inheritance Disease 
OMIM 
no. Clinical Description Reference 
SARS2 19q13.2 Mitochondria 
Autosomal 
recessive 
HUPRA 
Syndrome 
613845 
Hyperuricemia, pulmonary 
hypertension, infantile renal 
failure, and alkalosis syndrome 
(Belostotsky et al. 
2011) 
YARS2 
12p11.2
1 
Mitochondria 
Autosomal 
recessive 
MLASA2 613561 
Myopathy, lactic acidosis, and 
sideroblastic anemia, muscle 
weakness, dysphagia, exercise 
intolerance 
(Riley et al. 2010) 
TARS2 1q21.2 Mitochondria 
Autosomal 
recessive 
COXPD21 615918 
Axial hypotonia, limb hypertonia, 
psychomotor delay, and increased 
serum lactate, thin corpus 
callosum, cerebral spongiosis, 
hepatic stenosis 
(Diodato et al. 2014) 
VARS2 6p21.33 Mitochondria 
Autosomal 
recessive 
COXPD20 615917 
Ophthalmoplegia, ptosis, ataxia, 
seizure 
(Diodato et al. 2014; 
Taylor et al. 2014) 
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and methionyl-tRNA synthetase (MARS2) result in various forms of leukoencephalopathy 
(Scheper et al. 2007a; Bayat et al. 2012; Steenweg et al. 2012), while phenylalanyl- (FARS2) and 
arginyl-tRNA synthetase (RARS2) mutations result in encephalopathy and pontocerebellar 
hypoplasia, respectively (Pierce et al. 2011; Elo et al. 2012; Cassandrini et al. 2013). 
Mitochondrial valyl- (VARS2) and threonyl-tRNA synthetase (TARS2) mutations have been 
identified in patients with combined oxidative phosphorylation deficiency leading to hypotonia 
and central nervous system symptoms that include ataxia and a thin corpus callosum (Diodato et 
al. 2014). Mutations in mitochondrial ARS genes have also been implicated in syndromes that 
include peripheral nerve dysfunction. Mitochondrial histidyl- (HARS2) and leucyl-tRNA 
synthetase (LARS2) both cause Perrault syndrome, a condition characterized by sensorineural 
hearing loss in both males and females and ovarian failure in females (Pierce et al. 2011; Pierce 
et al. 2013). Mitochondrial isoleucyl-tRNA synthetase (IARS2) mutations have been identified in 
multiple patients with a syndromic phenotype that includes partial sensorineural deafness and 
peripheral neuropathy, in addition to cataracts and growth hormone deficiency 
(Schwartzentruber et al. 2014). In contrast to the mitochondrial mutations that cause neuronal 
phenotypes, mitochondrial tyrosyl-tRNA synthetase (YARS2) mutations result in recessive 
myopathy characteristic of mitochondrial respiratory chain disorders (Riley et al. 2010). 
Recessive mutations in mitochondrial alanyl- (AARS2) and seryl-tRNA synthetase (SARS2) lead 
to cardiomyopathy and pulmonary and renal failure, respectively (Belostotsky et al. 2011; Götz 
et al. 2011). Functional studies (see below) performed on a subset of these mutations indicate 
that although the mutations result in dramatically reduced aminoacylation activity, the alleles 
retain some level of activity sufficient to support patient viability (Edvardson et al. 2007; 
Scheper et al. 2007a; Belostotsky et al. 2011; Pierce et al. 2011; Bayat et al. 2012; Elo et al. 
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2012; Cassandrini et al. 2013).  To date, effects on non-canonical ARS functions have not been 
reported for any of the mitochondrial ARS disease alleles. 
Cytoplasmic ARS mutations in recessive disease 
Similar to mitochondrial ARS mutations, cytoplasmic ARS mutations have been identified in a 
spectrum of recessive syndromes, including multiple with neurologic manifestations. Loss-of-
function cytoplasmic methionyl-tRNA synthetase (MARS) mutations were identified in patients 
with interstitial lung and liver disease (Hadchouel et al. 2015).  Lysyl-tRNA synthetase (KARS) 
mutations were identified in an individual with motor and sensory neuropathy, developmental 
delay, self-abusive behavior, dysmorphic features and vestibular Schwannoma, and shown to 
adversely affect enzyme function (McLaughlin et al. 2010). Glutamyl-tRNA synthetase  (QARS) 
mutations that dramatically reduce aminoacylation activity were identified in children in two 
unrelated families who presented with seizures and progressive microcephaly due to cerebral and 
cerebellar atrophy (Zhang et al. 2014). Lastly, mutations in cytoplasmic aspartyl-tRNA 
synthetase (DARS) result in hypomyelination of the brain stem and spinal cord and leg spasticity 
(Taft et al. 2013), while those in arginyl-tRNA synthetase (RARS) result in hypomyelination in 
all areas of the brain (Wolf et al. 2014). Although predicted to be loss-of-function, DARS or 
RARS mutations have not been tested for effects on aminoacylation. As with the mitochondrial 
ARS alleles, only effects on the primary tRNA charging activity have been observed for disease-
associated mutations; effects on non-canonical functions have not been described. Taken 
together, the mechanism for cytoplasmic and mitochondrial ARS-associated recessive diseases is 
believed to be the result of loss of tRNA charging in cells.    
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Cytoplasmic ARS mutations in dominantly inherited peripheral neuropathy 
Mutations in five cytoplasmic ARS genes have been identified in patients with inherited 
peripheral neuropathy (Antonellis et al. 2003; Jordanova et al. 2006; Latour et al. 2010; 
McLaughlin et al. 2011; Vester et al. 2012; Gonzalez et al. 2013). Peripheral neuropathies 
include toxic, syndromic, or inherited neurodegenerative diseases that affect peripheral nerves 
(Dyck and Thomas 2005). The peripheral nervous system (PNS) includes motor and sensory 
neurons and myelinating Schwann cells that reside outside the brain and spinal cord, which 
comprise the central nervous system (CNS) (Levitan and Kaczmarek 2002). Peripheral nerves 
are responsible for transmitting information bi-directionally between the tissues of the body and 
the CNS. Dysfunction of the PNS leads to impaired movement and sensation that have a negative 
impact on the health and quality of life of affected individuals. It is estimated that up to 10% of 
the population worldwide suffer from peripheral neuropathy (Martyn and Hughes 1997).  
Inherited peripheral neuropathies (IPNs) are a group of heterogeneous neurologic disorders 
characterized by impaired motor and sensory nerve function in the distal extremities that are 
caused by genetic lesions passed down through generations (Murakami et al. 1996). These 
genetic mutations result in IPN by disrupting the health or maintenance of one of the cell types 
that comprise a peripheral nerve: neurons or myelinating Schwann cells. Charcot-Marie-Tooth 
(CMT) disease is the most common class of inherited peripheral neuropathies, affecting up to 
one in 2,500 individuals worldwide (Skre 1974). CMT disease is diagnosed based on the 
presence of both motor and sensory nerve dysfunction and is named for the three physicians, 
Drs. Jean-Martin Charcot, Pierre Marie, and Howard Henry Tooth, who first described the 
condition in the 1880s. As CMT disease progresses, loss of nerve function ultimately leads to 
severe muscle wasting, reduced or absent deep-tendon reflexes, pes cavus (high foot arches), and 
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steppage gait (high stepping gait due to foot drop) (Dyck and Lambert 1968). Patients with CMT 
disease primarily suffer from loss of motor and sensory nerve function in the distal extremities, 
leading to impaired movement and sensation in the hands and lower legs that moves proximally 
as the disease progresses (Patzkó and Shy 2010). Although individuals with CMT disease 
typically live normal life spans, quality of life can be dramatically affected due to loss of 
mobility (e.g. reliance on walking aids) and other secondary consequences of loss of sensation 
(e.g. limb amputations) (Timmerman et al. 2013). CMT disease is extremely heterogeneous, with 
disease severity (i.e. mild to severe neuropathy) and age of onset (i.e. childhood through late 
adulthood) varying dramatically not only between subtypes of CMT disease, but also among 
individuals within the same family (Reilly et al. 2011).  
Clinical evaluation of affected individuals is necessary to determine if CMT disease is a result of 
Schwann cell dysfunction or defects in the neurons themselves. Patients undergo an 
electrophysiologic test to determine motor nerve conduction velocity (MNCVs) of the affected 
nerves (Dyck and Thomas 2005). MNCVs are determined by introducing an electrical impulse to 
a nerve and measuring the time required for a muscle at a fixed distance away to respond to the 
stimulation (i.e. latency of response). The distance (millimeters) is then divided by the latency of 
response (milliseconds) to calculate the MNCV. Decreased MNCVs (<38m/s) indicate the 
myelin sheath is impaired due to a defect in the Schwann cell and the patient receives a diagnosis 
of CMT type 1 (CMT1) or demyelinating CMT disease. If performed, sural nerve biopsies from 
patients with CMT1 demonstrate evidence of reoccurring demyelination and attempts at 
remyelination by the Schwann cells that lead to loose concentric rings of myelin termed “onion 
bulb” formations (Dyck and Thomas 2005). Alternatively, patients can have normal MNCV (> 
38m/s), but decreased nerve amplitudes. These patients are diagnosed with CMT type 2 (CMT2) 
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or axonal CMT disease. In these cases, the genetic lesion is presumed to affect the neuron itself 
and nerve biopsies can demonstrate loss of myelinated fibers, axonal degeneration, and 
regenerating clusters. A third class, termed intermediate CMT disease, designates cases where 
the MNCVs are in the intermediate range (25-45 m/s) or when there is evidence of both axonal 
and demyelinating disease in a single individual (Nicholson and Myers 2006).  
For each of the three classes of CMT described above, autosomal dominant, recessive and X-
linked disease have been identified clinically. To date over 80 genetic loci and 1000 genetic 
mutations have been implicated in various forms of CMT disease, with an estimated 80-100 
genetic loci still undiscovered (Timmerman et al. 2014). Mutations in CMT1 have been 
identified in Schwann cell-specific genes involved in myelination (Lupski et al. 1991; 
Raeymaekers et al. 1991; Hayasaka et al. 1993), while genes associated with CMT2 disease 
encode proteins critical for neuronal function (Shy and Patzkó 2011), including axonal transport 
proteins (Millecamps and Julien 2013). As a result of molecular diagnostics, CMT disease is 
further sub-classified based on the genetic lesion responsible for disease. For example, patients 
with demyelinating CMT disease caused by a duplication of peripheral myelin protein 22 
(PMP22) are diagnosed with CMT1A (Lupski et al. 1991; Raeymaekers et al. 1991), while 
individuals with decreased MNCVs and a mutation in myelin protein zero (MPZ) are diagnosed 
with CMT1B (Hayasaka et al. 1993). However, it is important to note that different genetic 
lesions at the same locus can result in different phenotypes. For example, PMP22 duplications 
lead to CMT1A; however PMP22 deletions lead to Hereditary Neuropathy with liability to 
Pressure Palsies (HNPP) (Chance et al. 1993) and individuals with PMP22 missense mutations 
can have CMT1A, HNPP or CMT1E (van Paassen et al. 2014), classified based on differences in 
clinical presentation. Lastly, patients with the identical genetic lesion can also have different 
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phenotypes. For example, clinical, electrophysiologic, and histologic analysis of 61 patients with 
a duplication of PMP22 showed variable involvement of the corticospinal tract (indicating CNS 
involvement), MNCVs that ranged from 5-34m/s, and a variety of histologic changes, indicating 
that genetic modifiers or environmental exposures may also play a role in disease (Thomas et al. 
1997).  
In 2003, mutations in glycyl-tRNA synthetase (GARS) were implicated in IPN, marking the first 
report of ARS enzymes in human disease (Antonellis et al. 2003). Charcot-Marie-Tooth Disease 
type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are two autosomal 
dominant axonal IPNs that are characterized by an upper limb predominant presentation 
(Christodoulou et al. 1995; Ionasescu et al. 1996; Pericak-Vance et al. 1997; Sambuughin et al. 
1998; Ellsworth et al. 1999). This phenotype is in contrast to the more typical lower limb 
predominant affects seen for IPNs (Reilly et al. 2011). Patients with CMT2D display motor and 
sensory defects, while patients with dSMA-V have motor deficits, but demonstrate normal 
sensory nerve activity. Prior to the implication of GARS in disease, five families were identified 
with CMT2D or dSMA-V (Christodoulou et al. 1995; Ionasescu et al. 1996; Pericak-Vance et al. 
1997; Sambuughin et al. 1998; Ellsworth et al. 1999). By pooling the genetic information from 
the 5 families into a single cohort for genetic studies, Antonellis and colleagues utilized a 
systematic genetic approach to implicate GARS in upper limb predominant peripheral neuropathy 
(Antonellis et al. 2003; Burton et al. 2005).  
Genetic tools for the identification of novel loci in dominantly inherited CMT disease 
 
To identify a novel genetic locus in disease pathogenesis, investigators can utilize linkage studies 
to narrow the genomic region harboring the responsible mutation. However, investigators must 
first ensure the phenotype of interest is both monogenetic (i.e. caused by a single gene) and 
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measurable (e.g. upper limb predominant peripheral neuropathy) (Burton et al. 2005).  To 
determine that the disease trait is monogenic, a careful family history of disease and familial 
structure can be ascertained to determine if the phenotype is transmitted according to Mendelian 
laws of dominant, recessive, or X-linked inheritance. Phenotypic information must be carefully 
considered for confounding factors such as disease age of onset, incomplete penetrance, variable 
expressivity, and phenocopy. Phenocopy refers to the presence of the trait of interest (e.g. 
peripheral neuropathy) that is due to environmental conditions (e.g. diabetic or toxin-induced 
neuropathy) rather than a genetic variant. Furthermore, to be confident that a monogenic disease 
and not familial clustering (i.e. distant family members that happen to have that same trait by 
chance) is being observed, the trait must occur within the family at a rate greater than expected 
by chance in the general population (Burton et al. 2005).  
Once the mode of inheritance is determined, linkage analysis can be used to narrow the region of 
interest containing the pathogenic genetic lesion (Dawn Teare and Barrett 2005). Genetic linkage 
analysis evaluates the co-segregation of genetic loci and phenotypic traits and utilizes the 
likelihood that a stretch of DNA is inherited intact based on the distance between the two ends 
and the rate of recombination between those ends (Burton et al. 2005; Dawn Teare and Barrett 
2005). To perform genetic linkage, DNA from affected and unaffected individuals is evaluated 
for the presence of genetic markers that exist at known locations throughout the genome. The 
genetic markers used for linkage studies are either microsatellite repeats (sequences that vary in 
length) or single nucleotide polymorphisms that have no known functional consequences. 
Individuals from a family are genotyped at these loci and the smallest haplotype (set of DNA 
variations inherited together) that is common among all affected family members is denoted as a 
region of interest (ROI). Linkage analysis may result in one or multiple ROIs depending on the 
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number of informative segregation events. Although both affected and unaffected individuals are 
used for linkage studies, once a ROI is established, only recombination events in affected 
individuals should be used to narrow the ROI to minimize confounding factors, such as 
phenotyping concerns, late onset of disease, and incomplete penetrance, which may improperly 
exclude genomic segments (Dawn Teare and Barrett 2005).  The length of the ROI may vary 
considerably depending on the number of informative recombination events that occurred 
between generations. Thus, ROIs may be small and contain only one or a few genes or large and 
contain many genes.  
A logarithm of the odds of linkage (LOD) score is often used to report linkage (MORTON 
1955). LOD scores are calculated using the equation 
log10[(1- Θ)NR*ΘR / (0.5)NR+R] 
where Θ is the recombination fraction (the probability of recombination between two genetic loci 
during meiosis; Θ = R / [NR + R]), ‘NR” is the number of non-recombinant offspring, and ‘R’ is 
the number of recombinant offspring. A positive LOD score is suggestive of linkage, while a 
negative LOD score indicates an absence of linkage. A LOD score of +3 is the threshold for 
accepting linkage with a 5% error rate (Kruglyak and Lander 1995). However, when performing 
a genome wide analysis, a LOD of 3.3 must be met in order to correct for multiple testing 
(Kruglyak and Lander 1995).  A LOD score <-2 excludes linkage, a score from -2 to +3 is 
inconclusive, and a score < 5 should be considered provisional.  Limitations for genetic linkage 
include errors both in genotyping and phenotyping of individuals (misdiagnosis, phenocopy, late 
onset, incomplete penetrance, etc.) and the limited resolution of genotyping platforms (i.e the 
number of genetic markers assessed).  
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In the event that multiple or a single large ROI results from a linkage study of a single family, 
linkage analysis from multiple families with the same phenotype can be combined to further 
narrow the region. In this case, LOD scores are additive (Dawn Teare and Barrett 2005).  For 
example, the linkage of GARS mutations in IPN was performed through the genetic evaluation of 
five unrelated families with upper limb predominant IPN, whose disease was all linked to the 
short arm of chromosome 7 (Christodoulou et al. 1995; Ionasescu et al. 1996; Pericak-Vance et 
al. 1997; Sambuughin et al. 1998; Ellsworth et al. 1999; Antonellis et al. 2003). Combining the 
linkage data from the five families allowed researchers to narrow the region of interest to ~980kb 
of chromosome 7p that contained only 11 candidate genes (Antonellis et al. 2006).  
Once an ROI that contains a tractable number of candidate genes is established, mapping of the 
specific pathogenic variant(s) can begin. Investigators can either prioritize genes based on 
evidence in the literature (i.e. a candidate gene approach) or sequence all the genes in the ROI to 
look for variants in a single gene that may explain the common phenotype seen in affected 
families. In the case of GARS, the exons of the 11 candidate genes were sequenced in affected 
individuals from each family (Antonellis et al. 2006). The only gene to contain mutations in all 
five families was GARS, including one mutation that was present in two families (Table 1.3). 
Segregation studies were performed to determine if GARS mutations were present in all affected 
individuals. Indeed, all affected family members carried a GARS variant. Further analysis of 
ethnically matched control individuals with no evidence of peripheral neuropathy did not reveal 
the presence of GARS mutations. Taken together, the genetic evidence strongly implicated GARS 
mutations in CMT disease (Antonellis et al. 2003). Subsequent to this initial study, nine 
additional GARS mutations have been identified in patients with CMT disease (Table 1.3). 
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 Table 1.3. Characteristics of ARS variants identified in dominantly inherited CMT disease 
Gene Variant Conservation 
Enzyme 
Activity 
Yeast 
Viability 
Fly 
Comp. 
Puncta 
Formation Dimerization References 
GARS A57V NP NP NP NP NP NP 
(Rohkamm et al. 
2007) 
GARS E71G Yeast Normal Viable Reduced Yes NP 
(Antonellis et al. 
2006; Nangle et al. 
2007) 
GARS L129P Bacteria Reduced Reduced No No Reduced 
(Antonellis et al. 
2006; Nangle et al. 
2007) 
GARS D146N NP NP NP NP NP NP (Lee et al. 2012a) 
GARS S211F NP NP NP NP NP NP (Lee et al. 2012a) 
GARS G240R Bacteria Reduced Viable NP No Reduced 
(Antonellis et al. 
2006; Nangle et al. 
2007) 
GARS P244L NP NP NP NP NP NP 
(Abe and Hayasaka 
2009) 
GARS I280F NP NP NP NP NP NP (James et al. 2006) 
GARS H418R NP NP Lethal NP No Reduced 
(Antonellis et al. 
2006; Nangle et al. 
2007) 
GARS D500N NP Normal NP NP NP Normal 
(Del Bo et al. 2006; 
Nangle et al. 2007; 
Stum et al. 2011) 
GARS G526R Bacteria Reduced Lethal NP Yes Normal 
(Antonellis et al. 
2006; Nangle et al. 
2007; Xie et al. 2007) 
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Gene Variant Conservation 
Enzyme 
Activity 
Yeast 
Viability 
Fly 
Comp. 
Puncta 
Formation Dimerization References 
GARS S581L NP Normal NP NP NP Normal 
(James et al. 2006; 
Cader et al. 2007; 
Nangle et al. 2007) 
GARS G598A NP Reduced Viable NP No NP 
(James et al. 2006; 
Stum et al. 2011) 
YARS G41R Bacteria Reduced Lethal  NP No NP 
(Jordanova et al. 
2006) 
YARS E196K Yeast Reduced Reduced NP No NP 
(Jordanova et al. 
2006) 
YARS 
153-156 
ΔVKQV 
Yeast NP NP NP NP NP 
(Jordanova et al. 
2006) 
AARS N71Y Yeast Reduced Lethal NP NP NP 
(Lin et al. 2011; 
McLaughlin et al. 
2011) 
AARS R329H Zebrafish Reduced Lethal NP NP NP 
(Latour et al. 2010; 
McLaughlin et al. 
2011) 
AARS D893N Mouse NP NP NP NP NP (Zhao et al. 2012) 
HARS R137Q Yeast NP Lethal NP NP NP (Vester et al. 2012) 
MARS R618C Bacteria NP Lethal NP NP NP 
(Gonzalez et al. 
2013) 
Red text indicates a result consistent with a loss-of-function effect. 
We considered a >90% reduction in activity as dramatically ‘Reduced’. 
NA – not applicable; mutation could not be modeled in yeast ortholog. 
NP- not performed; analysis not included in the literature.   
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(Sivakumar et al. 2005; Del Bo et al. 2006; James et al. 2006; Rohkamm et al. 2007; Abe and 
Hayasaka 2009; Eskuri et al. 2012). For a subset of these mutations, the genetic and functional 
evidence is insufficient to implicate these variants in disease. Therefore, these mutations must be 
viewed cautiously as variants of unknown significance until appropriate studies have been 
performed (see chapter 4). 
Since the identification of GARS mutations in CMT2D and dSMA-V, mutations in two 
additional ARS enzymes were identified in linkage studies of families with CMT disease 
(Jordanova et al. 2006; Latour et al. 2010; Vester et al. 2012; Gonzalez et al. 2013). The 
identification of tyrosyl-tRNA synthetase (YARS) mutations followed a similar pipeline as 
described above for GARS. Linkage analysis in two unrelated families who were affected by 
dominant intermediate CMT disease (DI-CMT), enabled Jordanova and colleagues to identify 
pathogenic mutations in YARS (Table 1.3) (Jordanova et al. 2006). The first family had 15 
affected and 11 unaffected individuals spanning four generations that were included in the 
linkage analysis, while the second family had a family history of disease that spanned seven 
generations and including 39 affected individuals, 18 of whom were included in the study along 
with nine unaffected family members (Jordanova et al. 2003). The ROI calculated using linkage 
analysis in both families contains 37 genes and 19 predicted genes. Genes were prioritized for 
sequencing and ultimately a mutation in YARS (either G41R or E196K YARS) was found to 
segregate with disease in each family. Candidate gene screening of YARS in unrelated individuals 
with CMT revealed a third YARS mutation (153-156ΔVKQV). Subsequent to the genetic 
implication of YARS in CMT disease, Latour et al. used linkage analysis in two families with 
individuals in four and five generations who were affected by dominant axonal CMT disease to 
narrow the ROI to 130 genes on chromosome 16 (Latour et al. 2010). Using a candidate gene 
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approach, the investigators selected five genes for sequencing based on evidence in the literature, 
including alanyl-tRNA synthetase (AARS).  The R329H AARS mutation was found to segregate 
in both families. Subsequently, this mutation was determined to have independently arisen in an 
unrelated Australian family, classifying R329H AARS as a recurrent mutation (McLaughlin et al. 
2011).  Two additional AARS mutations (N71Y and D893N) have since been identified in 
patients with CMT disease (Lin et al. 2011; Zhao et al. 2012). Based on the evidence thus far, 
three ARS genes have strong genetic evidence supporting their role in the pathogenesis of CMT 
disease.  
Since three members of the ARS family had been implicated in CMT disease using genetic 
approaches, researchers hypothesized that mutations in other members of the ARS enzyme 
family could also result in peripheral neuropathy. To test this hypothesis, 355 patients with CMT 
disease and no known disease causing mutations in a CMT associated gene were screened for 
mutations in the 37 ARS enzymes (McLaughlin et al. 2010; Vester et al. 2012). Biallelic lysyl-
tRNA synthetase (KARS) mutations were identified in an individual with a recessive syndrome 
that included axonal peripheral neuropathy (Table 1.2) (McLaughlin et al. 2010). Additionally, a 
mutation in histidyl-tRNA synthetase (HARS), R137Q HARS, was identified in a single 
individual with CMT disease (Table 1.3). Unfortunately, no additional family members were 
available for genetic studies to determine the inheritance pattern and segregation of the HARS 
variant; therefore, the genetic evidence was insufficient to implicate HARS in CMT disease 
(Vester et al. 2012).  
As the cost of high throughput sequencing rapidly decreases, the utilization of whole exome 
sequencing (WES) (Ng et al. 2009; Turner et al. 2009) and whole genome sequencing (WGS) 
(Ng and Kirkness 2010) in the clinical setting is increasingly utilized to identify genetic variants 
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(Boyd 2013). WES allows for the identification of variants in coding regions of the genome (Ng 
et al. 2010); however, this technique is limited in that it only identifies variants in exons or at 
splice sites and thus does not cover non-coding or copy number variations that may be important 
to disease. In contrast, WGS provides coverage of both coding and non-coding regions; however, 
the significance of variation in non-coding regions is more difficult to interpret as the role of 
many of these regions is still underappreciated (Dewey et al. 2014). Currently, WES is more 
commonly used for identifying pathogenic variants since the majority of disease-associated 
variants identified to date affect coding regions. WES is a powerful tool in cases of idiopathic 
disease where linkage studies cannot be performed due to small pedigree size or limited access to 
DNA samples. Using WES, R618C methionyl-tRNA synthetase (MARS) was identified in a 
single small pedigree with late onset, incompletely penetrant axonal CMT disease (Table 1.3) 
(Gonzalez et al. 2013); however, until additional variants are identified, the role of MARS in 
CMT disease is still unknown.  
Functional characterization of ARS mutations 
 
Gene mutations can result in disease by a variety of mechanisms, which can be broadly classified 
into loss-of-function or gain-of function mechanisms (Rosenberg 2008). Loss-of-function 
mechanisms are caused by reduced or absent expression and/or activity of a mutant gene 
product, and are often the pathogenic mechanisms responsible for recessive disease. However, 
dominant loss-of-function mechanisms occur when gene dosage is critical to normal cell 
function. Loss-of-function alleles can be classified as null (protein product is non-functional), 
hypomorphic (protein product has a reduced, but not absent, level of activity), or antimorphic 
(product antagonizes the activity of the wild-type gene product). Haploinsufficiency occurs when 
a 50% reduction in protein function (i.e. one null allele in a heterozygous individual) is sufficient 
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to cause a disease phenotype. This mechanism occurs in diseases such as Marfan syndrome that 
results from heterozygosity of a loss-of-function mutation in the fibrillin gene (Dietz et al. 1991). 
Alternatively, a dominant-negative mechanism of disease occurs when a mutation leads to 
decreased protein function that is able to bind and antagonize the activity of the wild-type gene 
product (i.e. antimorphic).  Antimorphs occur in cases where the protein subunits must form a 
homodimer to function, thus enabling the mutant subunit to interfere with the wild-type subunit’s 
activity. For example, loss-of-function mutations in the transcriptional repressor Forkhead L2 
(FOXL2) lead to premature ovarian failure by dimerizing with wild-type FOXL2 and impairing 
the FOXL2 heterodimer’s ability to maintain transcriptional repression of genes involved in 
ovarian follicle differentiation (Kuo et al. 2011). Loss-of-function mutations typically affect 
evolutionarily conserved residues. When a high degree of allelic heterogeneity (i.e. multiple 
alleles in the same gene leading to the same phenotype) is observed, a loss-of-function 
mechanism should be strongly considered.  
A gain-of-function mechanism should be suspected when multiple unrelated cases of a dominant 
disease are caused by a specific recurrent mutation. In contrast to loss-of-function mechanisms, 
gain-of-function mechanisms occur when a mutant protein either has increased activity 
(hypermorphic) or gains a novel function (i.e. protein aggregation or a novel binding partner; 
neomorphic) that leads to cellular toxicity. An example of a hypermorphic gain-of-function 
mutation is the activating mutation in the c-kit gene that results in constitutive activation of the 
KIT receptor tyrosine kinase, and the formation of gastrointestinal stromal tumors (GISTs) 
(Hirota et al. 1998). Neomorphic mutations have been reported in dihydrolipoamide 
dehydrogenase (DLD), a dimeric protein component of the pyruvate, α-ketoglutarate, and 
branched chain amino acid dehydrogenase complexes. Interestingly, DLD mutations located at 
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the homodimer interface impair dimer formation and allow DLD to acquire a neomorphic 
protease activity that leads to cardiomyopathy in patients (Brautigam et al. 2005; Babady et al. 
2007). Importantly, all DLD mutations cause a loss of enzyme function that leads to a metabolic 
syndrome in infancy. This example illustrates an important point: loss- and gain-of-function 
mechanisms may not be mutually exclusive in disease pathogenesis. Loss of canonical protein 
function may be a prerequisite for disease pathogenesis by allowing the mutant protein product 
to adopt neomorphic activity resulting in a toxic gain of function. This dual mechanism has been 
hypothesized in some dominantly inherited neurodegenerative diseases (Winklhofer et al. 2008; 
Paine 2015). In Huntington disease, a toxic gain-of-function mutation causes the huntingtin 
protein to aggregate in neurons, leading to neurotoxicity; however, new evidence has been 
presented that wild-type huntingtin protects neurons, which may indicate a loss-of-function 
component in disease (Paine 2015). Deletion of huntingtin is not sufficient for disease, indicating 
that loss-of-function alone is not the pathomechanism.  Thus the loss of normal huntingtin 
protein function and the gain of the toxic aggregates may both be required for Huntington’s 
disease to manifest (Paine 2015).  
While there is evidence that ARS mutations associated with both dominant and recessive disease 
demonstrate loss-of-function (Table 1.3), not all mutations have been functionally characterized 
(Taft et al. 2013; Wallen and Antonellis 2013). Thus, much is currently unknown about the 
mechanism of pathogenesis for ARS-mediated disease. Functional studies evaluating the 
consequences of ARS mutations on enzyme activity is a critical step toward implicating ARS 
variants in both dominant and recessive disease and understanding the mechanism by which 
ARS mutations lead to inherited disease. 
 28 
Methods to test for loss of ARS function 
Biochemical studies: pyrophosphate release and aminoacylation assays 
 
Since the primary function of ARS enzymes is to charge tRNA, it is critical to understand how 
mutations impact aminoacylation activity. Pyrophosphate and aminoacylation assays are 
commonly used to determine the ability of mutant ARS enzymes to complete steps necessary for 
successful aminoacylation in vitro (Francklyn et al. 2008). Pyrophosphate release assays are 
colorimetric assays that detect pyrophosphate release upon the completion of first step of the 
aminoacylation reaction (Kiga et al. 2002). In this assay, varying concentrations of purified 
recombinant ARS enzyme is incubated with tRNA, ATP, cognate amino acid, and 
pyrophosphatase. A colorimetric indicator that reacts to the presence of free phosphates that are 
produced by the cleavage of pyrophosphates (PPi) released during amino acid activation by 
pyrophosphatase is added at set intervals. Absorbance is then used to calculate the phosphate 
release as an indicator of the efficiency of formation of the amino-adenylate intermediate. This 
assay has been used to study YARS and HARS2 mutations (Jordanova et al. 2006; Pierce et al. 
2011), but is limited in that it only assess the amino acid activation step of the aminoacylation 
reaction.  
To assess an ARS enzyme’s ability to complete both steps of the tRNA charging reaction, in 
vitro aminoacylation assays are employed (Francklyn et al. 2008). Aminoacylation assays 
calculate the steady state kinetics of the aminoacylation reaction by monitoring the formation of 
amino acid-ligated tRNA. Recombinant purified ARS enzyme is incubated with tRNA, ATP, and 
varying concentrations of radiolabeled 3H or 14C amino acid under optimal temperature and 
buffer conditions for the ARS enzyme of interest.  Aliquots of the reaction mixture are taken at 
various time points and spotted on Whatmann filter paper that binds the tRNA. The filter paper 
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contains trichloroacetic acid (TCA) to quench the reaction and precipitate the aminoacylated 
tRNA. After washing the filter paper to remove any unincorporated amino acids, the filter paper 
is dried and a liquid scintillation counter is used to assess for radioactivity levels. The amount of 
radioactivity retained on filter pads is corrected for quenching effects to determine the amount of 
synthesized amino acid-ligated tRNA. Steady-state kinetics is then determined by fitting the 
initial rate of aminoacylation as a function of tRNA concentration to the Michaelis–Menten 
equation (Schreier and Schimmel 1972). Aminoacylation assays are more commonly used than 
pyrophosphate release assays to test the impact of ARS mutations on enzyme function since it 
assesses for completion of the entire reaction. The consequences of mutations in GARS, AARS, 
KARS, QARS, and FARS2 have been evaluated using the aminoacylation assay (Antonellis et al. 
2006; Nangle et al. 2007; McLaughlin et al. 2010; McLaughlin et al. 2011; Elo et al. 2012; 
Zhang et al. 2014). The predominant limitation of these assays is that they are performed outside 
of the context of a cell. Thus any post-translational modification and/or stabilizing cellular 
factors that may have an impact on the function of the ARS enzyme in vivo are absent. 
Nonetheless, aminoacylation assays provide important insights into the effects of mutations on 
the primary tRNA charging function of ARS enzymes.  
Yeast complementation assays 
 
To study ARS mutations in vivo, investigators have adopted Saccharomyces cerevisiae, baker’s 
yeast, as a model organism. Yeast are small, single cell, eukaryotic organisms that are genetically 
tractable (Xiao 2006). Importantly, knockout allele strains exist for the majority of yeast genes 
and haploid yeast can be easily generated, making it an excellent model to assess the effect of a 
single allele in vivo (Winzeler et al. 1999). To evaluate the effects of ARS mutations, mutant 
ARS alleles are introduced into haploid yeast strains lacking the ARS locus of interest to see if 
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the alleles retain enough activity to support yeast cell viability.  To generate haploid yeast 
strains, diploid yeast that have one orthologous ARS allele disrupted by a selective marker, either 
HIS3 or KanMX (Winzeler et al. 1999; Turner et al. 2000), are induced to undergo sporulation. 
Since ARS enzymes are essential, a URA3-bearing plasmid containing a wild-type copy of the 
yeast ARS locus (including the promoter and 3’ downstream sequence) is introduced into the 
diploid yeast strain prior to sporulation. During sporulation, a yeast cell produces four meiotic 
products that each contains one allele per gene. These meiotic spores are dissected and selected 
on appropriate media to isolate individual haploid yeast that have the endogenous ARS locus 
deleted and viability maintained by the ARS locus on the URA3 maintenance vector. Human 
mutations can then be modeled in the yeast ortholog on a LEU2-bearing experimental vector and 
introduced into the haploid yeast strain (Figure 1.2). Yeast carrying both the URA3 and LEU2 
vectors are selected for on media lacking uracil and leucine and subsequently plated on 5-
fluoroorotic acid (5-FOA) media and incubated for 2-3 days. 5-FOA is toxic to yeast expressing 
URA3 and thus selects for yeast that have spontaneously lost the URA3-bearing maintenance 
vector (Boeke et al. 1987). Therefore, only yeast with a functional copy of the ARS gene on the 
LEU2 vector will survive on 5-FOA media. Visual inspection of growth on solid 5-FOA medium 
or OD600 absorbance readings in liquid 5-FOA medium are used to determine if the experimental 
(wild-type or mutant) ARS allele can complement loss of the endogenous allele. Wild-type and 
other functional ARS alleles will support robust yeast cell growth while functionally null alleles 
are unable to sustain yeast viability, similar to an empty vector control. Some mutations will 
support an intermediate level of growth compared to the wild-type ARS and the empty vector; 
these alleles would be considered hypomorphic. A slight modification to this approach was used 
by Jordanova et al. to test YARS mutations (Jordanova et al. 2006). In their study, the LEU2
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Figure 1.2. Cartoon of the yeast complementation assay. A haploid yeast strain [that has the endogenous ARS locus deleted and bearing 
a URA3 maintenance vector containing the wild-type ARS locus (blue)] is transformed with a LEU2-bearing pRS315 vector containing 
wild-type or mutant ARS or no insert (green). Liquid cultures for each strain are grown to saturation in media lacking uracil and leucine 
to select for the presence of the two vectors. Yeast are spotted on selective solid growth medium containing 5-FOA to select for the 
spontaneous loss of the URA3 maintenance vector (Boeke et al. 1987). Visual inspection of growth is used determine whether the 
mutant ARS allele complements loss of endogenous ARS.  
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vector containing wild-type or mutant yeast TYS1, the yeast ortholog of YARS, was introduced 
into the diploid strain that lacked a URA3 maintenance vector. Tetrad dissections were performed 
to determine if the experimental allele could sustain yeast viability in the haploid yeast lacking 
the endogenous ARS allele. 
It is important to note that the yeast complementation assay does not directly test for enzyme 
activity; instead it tests for the ability of the enzyme to complement all aspects of ARS function 
in vivo. However, there are limitations to this assay: primarily the use of the orthologous yeast 
gene to model human mutations. Mutations that affect residues not conserved between human 
and yeast or in domains that are absent in the yeast ortholog (i.e. WHEP domain, a domain that is 
a found in five human ARS enzymes, but is absent in all S. cerevisiae ARS proteins (Ray and 
Fox 2014)) cannot be modeled. Additionally, some mutations may affect human protein 
function, but may not have a severe enough effect on the yeast enzyme to cause a reduction in 
cell growth. To date, all mutations that demonstrate decreased yeast cell growth also show 
impaired function in aminoacylation assays, though the converse is not true (Antonellis et al. 
2006; Nangle et al. 2007; McLaughlin et al. 2010). This may be due to post-translational 
modifications or stabilization of ARS by cellular components in yeast that are not present in the 
in vitro aminoacylation assay. It has been shown that some human ARS genes, such as YARS 
(Jordanova et al. 2006), can complement loss of the yeast ortholog. Therefore, modifications to 
the standard yeast complementation assays that allow use of the human protein will help address 
some of these limitations. Lastly, yeast are small, unicellular organisms that are unable to 
recapitulate the demands of long, terminally differentiated cells (i.e. neurons). Since dominant 
ARS-associated disease only affects neurons, impairment of ARS function that may be 
significant in neurons may be too subtle to detect an effect in yeast. Nonetheless, yeast 
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complementation assays are currently the best in vivo screen for pathogenicity of ARS mutations 
(Motley et al. 2015).  
Protein localization studies 
 
Many proteins must localize to specific sites in the cell for proper functioning. Disruption of this 
localization pattern can result in impaired protein function. For example, loss-of-function 
mutations in the CFTR gene, a chloride channel, lead to cystic fibrosis (Kerem et al. 1989). A 
subset of these mutations have no effect on the proper conduction of the channel in functional 
assays, but instead cause disease by impairing the localization of CFTR to the membrane where 
its function is required (Smit et al. 1995; Fanen et al. 2014). Thus, it is important to consider 
whether ARS enzymes have site-specific localization requirements necessary for proper ARS 
activity. As previously discussed, a subset of ARS enzymes localize to the MSC while other 
ARS enzymes appear to function independent of the complex (Park et al. 2008). GARS and 
YARS proteins are not known to associate with the MCS and have both been shown to form 
punctate structures in cells (Antonellis et al. 2006; Jordanova et al. 2006). Specifically, 
endogenous wild-type GARS localize to ‘puncta’ within the soma and axons in the human 
peripheral nerve and in a variety of non-neuronal and neuronal cultured cells (Antonellis et al. 
2006). YARS was shown to localize in a “tear-drop” pattern that was specific to growth cones 
and axonal termini in cells that form neurite projections (Jordanova et al. 2006). In contrast to the 
ubiquitous presence of GARS puncta in all cells, YARS tear-drops were not observed in non-
neuronal cells. Specifically, COS-7 cells, which are derived from monkey kidney tissue, 
demonstrated a homogenous distribution of YARS (Jordanova et al. 2006). To test the effect of 
mutations on GARS and YARS localization, the open reading frame of each human enzyme was 
tagged with enhanced green fluorescent protein (EGFP; C-terminal tag for GARS; N-terminal 
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tag for YARS) and wild-type and mutant constructs were overexpressed in neuronal cell lines 
(Antonellis et al. 2006; Jordanova et al. 2006). When modeled in vitro, wild-type GARS-EGFP 
forms puncta consistent with endogenous GARS; however, three of the five GARS mutations 
impair the punctate localization in cultured neurons (Table 1.3) (Antonellis et al. 2006), 
suggesting altered localization in axons may be a component of CMT2D and dSMA-V disease 
pathogenesis. The remaining two mutant GARS proteins formed puncta in cell bodies and 
neurite projections, consistent with previous observations of wild-type GARS localization to 
axons. Similar to GARS, overexpressed wild-type YARS-EGFP forms axonal tear-drop 
structures consistent with endogenous YARS, and YARS mutations tested result in loss of these 
structures (Table 1.3) (Jordanova et al. 2006). It is important to note that the composition, 
function, and relevance to disease are currently unknown for GARS and YARS puncta (see 
chapter 6). However, these studies imply that protein localization may be an important loss-of-
function component for some GARS and YARS CMT-associated mutations.  
Not all disease-associated ARS enzymes form punctate structures in cells. Localization studies of 
AARS demonstrated a diffuse pattern of localization for the endogenous protein (McLaughlin et 
al. 2011); furthermore overexpression of AARS revealed a similar localization pattern for both 
wild-type and mutant AARS (McLaughlin et al. 2011). Still, to determine if abnormal 
localization may be playing a role in disease, it will be important to assess newly identified 
GARS and YARS mutations and any newly implicated ARS enzymes for localization effects in 
neuronal cells.  
Drosophila neuron complementation assay 
 
Although aminoacylation, yeast complementation, and localization assays provide valuable 
information regarding ARS function in vitro and in vivo; however, many ARS mutations lead to 
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tissue-specific disease, which is not be reflected in these studies. For example, E71G GARS leads 
to peripheral neuropathy, but has not demonstrated abnormal function in aminoacylation, yeast 
complementation, or localization studies (Antonellis et al. 2003; Antonellis et al. 2006). 
Therefore, it is critical to evaluate mutations, such as E71G, in the context of a neuron to 
understand its functional consequences.  During a forward genetic screen for mutations that 
result in dendritic and axonal morphology defects of olfactory projection neurons, a mutation 
was identified in Drosophila gars, P98L gars (Chihara et al. 2007). These neurons each innervate 
a single glomerulus in the Drosophila brain in a stereotypical arborization pattern. garsP98L/P98L 
flies showed normal growth and guidance of dendritic and axonal stalks but failed to properly 
arborize the distal axons and dendrites. To elucidate if the axonal arborization defect was a result 
of gars loss-of-function, investigators generated a null gars allele (garsE34). Flies homozygous 
for garsE34 in olfactory neurons demonstrated the same arborization defects. To test whether 
human wild-type, E71G or L129P GARS demonstrated loss-of-function characteristics in their 
Drosophila model, investigators performed rescue experiments with each allele (Table 1.3). 
Wild-type GARS rescued the defect, but L129P GARS did not complement. E71G GARS partially 
rescued the arborization defect, but not to the same extent as wild-type GARS. This study 
provided the first functional data indicating that E71G is a loss-of-function GARS allele and was 
the first to evaluate ARS mutations in the context of axons in vivo. Thus, evaluating ARS 
mutations in a fly complementation model may provide the resolution necessary to detect subtle 
loss of function characteristics of ARS alleles that are only detrimental in the context of neurons.  
Dimerization assays 
A subset of ARS enzymes function as dimers. In fact, with the exception of MARS, whose role in 
CMT disease is still unclear (Gonzalez et al. 2013), all ARS enzymes identified in dominantly-
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inherited CMT disease function as dimers (Antonellis et al. 2003; Jordanova et al. 2006; Latour 
et al. 2010; Vester et al. 2012). Loss of dimerization may result in loss of enzyme function. 
Alternatively, ARS mutants that have impaired function in other assays may maintain the ability 
to dimerize with wild-type ARS, potentially leading to an antagonization of wild-type activity 
(i.e. dominant negative pathogenic mechanism). Therefore, it is important to determine if 
disease-associated mutations affect dimerization as this may be a critical component of ARS-
mediated disease. To test for dimerization, three assays have been used. First, mutant ARS 
enzymes can be tagged and overexpressed in cells and immunoprecipitation (IP) of the tagged 
mutant protein can be performed. Western blots of IP products can then be used to detect tagged 
and endogenous ARS to determine if wild-type and mutant proteins dimerize (Nangle et al. 
2007; Xie et al. 2007). Alternatively, analytical centrifugation can be used to determine if a 
mutant protein exists primarily as a monomer or dimer in solution. For analytical 
ultracentrifugation experiments, high velocity centrifugation is used to sediment proteins 
(Howlett et al. 2006). Dimers and monomers will sediment at different rates due to differences in 
mass, thus allowing investigators to quantify the difference between monomeric and dimeric 
interactions. These studies have been used to evaluate the dimerization of mutant GARS proteins 
(Table 1.3) and have shown that GARS mutations variably affect dimerization; some GARS 
mutations increase dimerization (ex. G598A GARS) while others nearly ablate dimeric 
interactions (ex. G240R GARS) (Table 1.3) (Nangle et al. 2007; Xie et al. 2007). As the 
mechanism of ARS-mediated CMT is further investigated, increasing or inhibiting wild-type 
/mutant dimerization may prove to be an important consideration in therapeutic development.  
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Methods to evaluate for dominant toxicity 
Evaluation of dominant neuronal toxicity in C. elegans 
Genetic studies have clearly defined a role for ARS mutations in dominantly inherited CMT 
disease (Antonellis et al. 2006; Jordanova et al. 2006; Latour et al. 2010). Thus, when a variant 
of unknown significance is identified in a case where segregation studies cannot be performed 
(e.g. sporadic CMT disease), assessing the mutation for dominant neurotoxicity may be an 
important step in implicating the variant in disease.  Caenorhabditis elegans (C. elegans) is a 
transparent nematode (roundworm) that provides an excellent model system for testing for ARS-
mediated toxicity. In contrast to biochemical and yeast studies, C. elegans can be used to 
understand a variant’s effect in the context of an axon, a particularly important consideration in 
understanding the axonal pathology of ARS-mediated peripheral neuropathy. Furthermore, C. 
elegans have characteristics that make them particularly useful for studying neuron biology 
(Yook 2005). First, C. elegans have a short lifespan and can be synchronized to specific 
developmental stages that allows for efficient assessment of variants associated with late-onset 
disease in large cohorts of animals. Second, C. elegans have a well-characterized non-myelinated 
nervous system that makes axonal defects easy to visualize. Specifically, the GABAergic 
nervous system consists of 26 GABAergic neurons, including 19 inhibitory (D-type) GABA 
motor neurons that project commissural axons from the nerve cell bodies in the ventral nerve 
cord to the dorsal nerve cord (Schuske et al. 2004). These neurons are responsible for innervating 
the body wall muscles of the worm and are critical for locomotion. Dysfunction of these neurons 
can be assessed using a thrash assay, which quantifies the bending locomotion of individual 
animals and can be used as an indicator of mutant protein toxicity on neuromuscular function in 
transgenic animals (Vester et al. 2012). Specifically, animals with abnormal D-type GABA 
neuron function will fail to bend and the number of bends over time can be quantified and 
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compared to control worms. Finally, C. elegans are genetically tractable and transgenes can be 
expressed in single or multiple copy allowing for overexpression and gene dosage studies.  
A C. elegans model was developed to study the HARS mutation R137Q (Vester et al. 2012). In 
this model, wild-type or mutant cDNA sequences are cloned downstream of the glutamic acid 
decarboxylase gene (a GABA biosynthetic enzyme; unc-25) promoter and are injected into the 
C. elegans oxIs-12 strain that expresses GFP under the GABA vesicular transporter gene (unc-
47) promoter to illuminate the GABA neurons for microscopy (Hobert 2002). Offspring from 
stably transmitting lines are synchronized to the fourth larval stage and aged to 1 or 4 day old 
adults to assess for developmental versus degenerative effects, respectively, of mutant ARS 
expression. Confocal imaging can be used to visualize malformations of the ventral or dorsal 
nerve cords or abnormal branching of axon projections. Overexpression of R137Q HARS, but not 
wild-type HARS, resulted in abnormal axonal morphology, including abnormal branching and 
axonal blebbing, failure of axonal commissures to extend to the dorsal nerve cord, and large 
dorsal nerve cord gaps (Vester et al. 2012). These abnormalities of the GABA nervous system 
progressed as animals aged. When assessed for neuromuscular function using thrash assays, 
impaired motor function was evident in older (4 day old) adult animals, but not in larval or 1-day 
old adults, indicating a worsening of neurotoxicity with age. Decreased locomotion directly 
correlated with the increase in abnormal axon morphology, suggesting a progressive loss of 
motor neuron function and muscular innervation, consistent with the late onset, progressive 
peripheral neuropathy phenotype associated with human ARS mutations. This C. elegans model 
demonstrated that R137Q HARS was dominantly neurotoxic. A similar approach could be used 
to assess additional ARS variants of unknown significance for dominant neurotoxicity, providing 
evidence for their role in dominantly inherited CMT disease. In addition, this system can be used 
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for mechanistic studies. For example, this assay could be employed to compare variants with 
variable activity of levels or dimerization ability to determine which characteristics are critical 
components of ARS-mediated disease.  
Vertebrate models of ARS mutations 
 
While invertebrate models have been valuable in studying aspects of ARS mutations, vertebrate 
models offer a unique resource to understanding the pathogenesis of ARS-mediated disease. To 
date there are four mouse models of ARS mutations. The “sticky” mouse is homozygous for 
A734E Aars and suffers from progressive ataxia (Sarna and Hawkes 2011). A743E Aars affects 
the editing activity of AARS, resulting in the mischarging of tRNAAla, misincorporation of 
amino acids into proteins, and the accumulation of misfolded proteins in neurons. This 
accumulation ultimately leads to neurotoxicity, Purkinje cell loss, and ataxia.  Three mouse 
models contain mutations in Gars. Two models carry missense alleles, C201R and P234KY, that 
lead to mild and severe peripheral neuropathy, respectively, in heterozygous animals (Seburn et 
al. 2006; Achilli et al. 2009). Homozygosity for either allele is lethal by two weeks of age 
(Motley et al. 2011). The third Gars mutation is a gene-trap allele (Seburn et al. 2006). Unlike 
mice heterozygous for the missense mutations, mice heterozygous for the gene-trap allele have a 
wild-type phenotype. Researchers have used these models to test hypotheses pertaining to both 
loss- and gain-of-function mechanisms in GARS-mediated CMT disease (Motley et al. 2011; He 
et al. 2015).  
Potential Mechanisms of ARS-mediated disease 
 
As discussed above, there is a growing body of evidence suggesting that loss of ARS function 
plays an important role in both recessive and dominant disease. In this section I will discuss the 
hypotheses that have been proposed to explain the mechanism of ARS-mediated disease and the 
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current evidence in support of each hypothesis. 
For recessive disorders, the loss of tRNA charging activity is believed to be the pathogenic 
mechanism. In fact, all mutations functionally characterized to date result in a dramatic reduction 
of enzyme activity (Scheper et al. 2007a; McLaughlin et al. 2010; Riley et al. 2010; Belostotsky 
et al. 2011; Götz et al. 2011; Pierce et al. 2011; Bayat et al. 2012; Elo et al. 2012; Steenweg et al. 
2012; Cassandrini et al. 2013; Pierce et al. 2013; Diodato et al. 2014; Wolf et al. 2014; Zhang et 
al. 2014; Hadchouel et al. 2015). Mutant ARS enzymes do retain a basal level of activity to 
sustain life in these individuals, but it appears inadequate for normal growth and development. It 
remains unclear why recessive mutations in ARS enzymes lead to a wide spectrum of disease 
(i.e. microcephaly to interstitial lung and liver disease) phenotypes and why some tissues (e.g. 
brain and muscle) are more often affected than others. One could hypothesize that the demands 
on protein synthesis are greater in some tissues (such as muscle) or that some tissues are less 
resistant to defects in protein synthesis (such as neuronal tissue). Further investigation is 
necessary to discern the mechanisms underlying each disease and to identify other ARS loci that 
may be involved in recessive phenotypes. These studies will be paramount to understanding ARS 
biology and to informing therapeutic development. Although the details of the loss-of-function 
mechanisms are still being elucidated, efforts to improve tRNA charging, such as increasing 
amino acid concentrations or identification of pharmacologic agents that increase 
aminoacylation, would be logical initial avenues for therapeutic exploration in ARS-mediated 
recessive disease.  
The implication of multiple ARS family members in a similar phenotype strongly suggests that a 
common pathogenic mechanism is involved in ARS-mediated CMT disease; however, the 
precise mechanism by which ARS mutations lead to dominant disease remains an open question 
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in the field. To date, there are five major hypotheses regarding the mechanism (Wallen and 
Antonellis 2013): (1) haploinsufficiency due to impaired tRNA charging in the cytoplasm or 
axon projections leads to decreased protein synthesis; (2) protein mislocalization leads to 
impaired local protein translation; (3) a dominant-negative effect results in a severe reduction in 
tRNA charging (>50%) sufficient for disease; (4) increased levels of uncharged tRNA results in 
a reduction in global protein synthesis; and (5) a toxic gain-of-function (i.e. abnormal protein or 
RNA binding) leads to neurotoxicity (Figure 1.3).  
Multiple observations support a loss-of-function mechanism in ARS-mediated CMT disease. 
First, ARS mutations associated with CMT disease affect conserved residues (Table 1.3) and do 
not cluster in a specific functional domain. Secondly, 12 CMT-associated ARS alleles have been 
functionally characterized to date (Table 1.3) revealing that: (a) nine of 11 result in impaired 
tRNA charging in biochemical assays (Antonellis et al. 2006; Jordanova et al. 2006; Nangle et al. 
2007; Xie et al. 2007; McLaughlin et al. 2011); (b) seven of 10 impair cellular growth when 
modeled in yeast (Antonellis et al. 2006; Jordanova et al. 2006; McLaughlin et al. 2011; Stum et 
al. 2011; Vester et al. 2012); (c) five of seven impair puncta formation within cultured neurons 
(Antonellis et al. 2006; Jordanova et al. 2006); and (d) two of two mutations tested are unable to 
complement deletion of the fly ortholog (Chihara et al. 2007). Together, 10 of 12 characterized 
ARS mutations have at least one loss-of-function characteristic, indicating that impaired tRNA 
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Figure 1.3. Potential pathogenic mechanisms of ARS-mediated CMT disease. There are five proposed mechanisms by which ARS 
mutations lead to CMT disease. Loss-of-function ARS enzymes could result in a 50% reduction in tRNA charging in the neuron cell 
body (1a) or in the axon (1b). Mutant ARS protein may mislocalize in cells (2). Mutant ARS protein may bind wild-type ARS and 
antagonize aminoacylation activity, resulting in a severe reduction in tRNA charging (dominant-negative effect; 3). Uncharged 
tRNA may lead to a global decreased in protein synthesis (4). Lastly, mutant ARS may acquire a novel binding partner (proteins or 
RNA) that results in neurotoxicity (5) (adapted from (Wallen and Antonellis 2013). 
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charging is a component of ARS-mediated CMT disease. However, the precise loss-of-function 
mechanism by which impaired ARS function leads to CMT disease has not been elucidated. All 
dominantly inherited ARS alleles are missense mutations (Wallen and Antonellis 2013); 
frameshift and nonsense alleles have not been identified. As previously discussed, mice 
heterozygous for Gars loss-of-function missense mutations demonstrate axonal degeneration 
(Seburn et al. 2006; Achilli et al. 2009), while mice heterozygous for the null gene-trap Gars 
allele are phenotypically normal (Seburn et al. 2006), suggesting that haploinsufficiency is not 
the pathological mechanism. The apparent discrepancy between impaired ARS function and 
dominant CMT disease may be explained by a dominant-negative effect. A dominant-negative 
mechanism is supported by data showing that: (1) ARS enzymes implicated in CMT disease 
function as oligomers (Antonellis et al. 2006; Jordanova et al. 2006; Latour et al. 2010; Vester et 
al. 2012); (2) ARS missense mutations tested to date result in stable proteins; (3) ARS mutations 
demonstrate loss-of-function characteristics (Wallen and Antonellis 2013); (4) GARS and YARS 
mutations allow wild-type:mutant dimer formation (Jordanova et al. 2006; Nangle et al. 2007; 
Qin et al. 2014); and (5) YARS mutations co-expressed with wild-type YARS in yeast lead to a 
negative effect on yeast growth (Jordanova et al. 2006). 
Additional studies in the literature have addressed the remaining hypotheses. A reduction in ARS 
enzyme function would be predicted to lead to a decrease in charged tRNA. It is known that at 
times of nutrient deprivation uncharged tRNAHis can lead to activation of general control non-
repressible 2 kinase (GCN2) (Dong et al. 2000). GCN2 phosphorylates eukaryotic initiation 
factor 2a (eIF2a) to inhibit global protein translation. Although increased eIF2a phosphorylation 
has not been reported, a recent study of a Gars fly model showed a decrease in global protein 
translation in neurons expressing mutant Gars (Niehues et al. 2015). However, overexpression of 
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wild-type Gars in these flies did not rescue the phenotype, suggesting to the authors that a toxic 
gain of function, not a decrease in tRNA charging, was responsible for the global protein 
translation defect.  Studies on mouse Gars mutations that result in a peripheral neuropathy 
phenotype were also not rescued by overexpression of wild-type mouse GARS (Motley et al. 
2011). Finally, evidence in the literature suggests that GARS mutations may alter the structure of 
GARS proteins and that these changes could result in novel protein interactions for mutant 
GARS (He et al. 2015). Researchers exploring this possibility in a mouse model of Gars 
identified an interaction between the neuronal receptor neuropillin1 (NRP1) and mouse P234KY 
GARS, but not with wild-type GARS. However, this interaction was not observed for human 
GARS mutations in vivo and its significance to other disease-associated ARS mutations is 
unknown. 
Two additional hypotheses for ARS-mediated CMT have largely been excluded, namely protein 
aggregation and editing defects. To date there is no evidence that protein aggregation is involved 
in ARS-mediated CMT disease. Since some ARS enzymes have the ability to inappropriately 
charge amino acids onto tRNA, editing domains in these enzymes evolved to minimize this 
occurrence. As discussed above, a mutation in the mouse Aars gene that affects the editing 
activity of mouse AARS leads to ataxia (Sarna and Hawkes 2011). Since the phenotype in ARS-
mediated disease does not include ataxia, tRNA mischarging is not thought to be part of the 
mechanism of ARS-mediated CMT disease.  
Significance of this thesis work 
 
Peripheral neuropathies pose a significant health-care burden. Currently, there is no treatment for 
any of the 80+ forms of CMT disease (Timmerman et al. 2014). Instead, general physical and 
occupational therapy, orthopedic surgery, ankle-foot orthosis and mobility assisting devices (i.e. 
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walking aids and wheel chairs) are the only options for patients. Since CMT disease has a high 
level of locus and allelic heterogeneity, therapeutic interventions will likely need to be specific to 
the genetic lesion (Reilly et al. 2011). Thus, it is critical to identify new CMT-associated genes 
and alleles to help elucidate the specific mechanism by which mutated ARS genes lead to CMT 
disease to inform the development of targeted therapies. In order to do so, functional studies of 
specific gene lesions will play a critical role in elucidating the pathogenic mechanisms of genetic 
disease (Bouhy and Timmerman 2013). 
In this thesis, I will describe genetic and functional studies implicating novel ARS alleles in both 
recessive and dominantly inherited human disease (Chapter 2, 3 and 4). The findings of these 
functional studies will then serve as the rationale for studies into the mechanism of ARS-
mediated CMT disease (Chapter 5 and 6). Together, this body of work aspires to make 
contributions to understanding the allelic spectrum of ARS mutation and the pathomechanism of 
ARS-mediated diseases with the ultimate goal of informing therapeutic studies in the future.
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CHAPTER 2 
Evaluating ARS mutations for a pathogenic role in recessive disease 
 
INTRODUCTION 
With advancements in next generation sequencing, new genes and variants are continually being 
identified in cases of idiopathic disease. High throughput sequencing can be extremely useful in 
understanding the genetic underpinnings of de novo and recessive diseases where linkage studies 
cannot be used; however, careful evaluation of these variants is needed before classifying 
mutations as pathogenic (MacArthur et al. 2014). Recently, the National Institutes of Health 
(NIH) established a program to expedite the diagnosis in medical cases where standard clinical 
evaluations have proved inadequate. This program, termed the Undiagnosed Disease Program 
(UDP) (http://www.genome.gov/27544402), chooses individual clinical cases submitted by 
physicians for further study. Selected patients undergo an extensive clinical evaluation to 
carefully characterize their phenotype. Whole exome sequencing (WES) is performed on patient 
DNA to identify putative disease-causing mutations. Variants identified are then provided to 
researchers for follow-up studies investigating the pathogenicity of these mutations and the 
pathomechanism by which these variants cause disease. Interestingly, of the cases considered by 
the UDP, multiple patients have been found to be compound heterozygous for mutations in ARS 
enzymes. These ARS variants are particularly interesting for follow-up studies as 18 ARS genes 
have already been reported in the literature in patients with recessive syndromes, including 14 
implicated in phenotypes that include neurologic deficits (Scheper et al. 2007a; McLaughlin et 
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al. 2010; Riley et al. 2010; Belostotsky et al. 2011; Götz et al. 2011; Pierce et al. 2011; Bayat et 
al. 2012; Elo et al. 2012; Steenweg et al. 2012; Cassandrini et al. 2013; Pierce et al. 2013; Taft et 
al. 2013; Diodato et al. 2014; Wolf et al. 2014; Zhang et al. 2014; Hadchouel et al. 2015). In 
addition to mutations identified as part of the UDP, ARS mutations have recently been identified 
in patients with recessive diseases by clinicians at the University of Michigan (Ann Arbor, MI) 
and the Clinic for Special Children (Lancaster, PA).   
While ARS mutations identified in recessive phenotypes are presumed to cause disease by a loss-
of-function mechanism, not all ARS variants reported in the literature have been functionally 
characterized.  Cataloging the functional consequences of alleles identified in patients with 
recessive diseases will expand our understanding of ARS variants and may lead to potential 
insights into the relationship between a particular ARS gene and a given phenotype. Importantly, 
understanding the relationship between the function of an ARS variant and the phenotype in 
heterozygotic carriers may also lead to insights into dominantly inherited ARS-mediated CMT 
disease. Although literature on ARS-associated CMT has revealed loss-of-function 
characteristics for some implicated variants, the role of loss of ARS function in disease 
pathogenesis is still widely debated in the field (see Chapters 3-5).  
In this chapter, we will evaluate the functional consequences of recessive ARS mutations that 
were identified as part of the UDP (GARS, AARS, and DARS) and by physicians at the University 
of Michigan (FARSB) and the Clinic for Special Children (YARS). We will consider the role of 
these variants in both dominant and recessive phenotypes in these families. Of the genes 
discussed in this chapter, only DARS mutations have been previously implicated in recessive 
disease (Taft et al. 2013); thus this work has the potential to implicate novel ARS genes in 
recessive phenotypes. We hypothesize that recessive mutations will result in a dramatic 
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reduction in ARS activity; however, at least one of the two alleles carried by each patient is 
predicted to retain some level of activity necessary to sustain viability, as complete loss of ARS 
function would not be predicted to be compatible with life (Delarue 1995).   
 
A subset of data in this chapter was previously published in the American Journal of Human 
Genetics (Simons et al. 2015). Permission was requested for the reproduction of figures. The 
author performed all the studies in this chapter with the following exceptions: (1) Clinical 
collaborators collected the phenotypic data and performed mutation sequencing; (2) 
Aminoacylation assays were performed by Katrina Lu and Ya-ming Hou at Thomas Jefferson 
University; (3) The University of Michigan Sequencing core performed the DNA sequencing 
reactions described in this work; and (4) Haploid ΔALA1 and ΔGRS1 yeast strains were 
previously generated by Heather McLaughlin (Antonellis Laboratory, University of Michigan) 
(McLaughlin et al. 2011) and by the Schimmel Laboratory at Scripps Research Institute (Turner 
et al. 2000).  
MATERIALS AND METHODS 
Patient sample collection, identification of ARS mutations, and linkage studies 
Collaborating physicians performed the clinical evaluation and subsequent classification of 
patient phenotypes based on exam findings. DNA samples were collected with patient consent as 
per Institutional Review Board protocols at the participating institutions. GARS, AARS, and 
DARS mutations were identified as part of the NIH UDP.  Additional DARS mutations 
previously reported by Taft et al. were also evaluated (Taft et al. 2013).  YARS mutations were 
identified at the Regeneron Genetics Center in collaboration with clinicians at the Clinic for 
Special Children (Strasburg, PA). FARSB mutations were identified at the Michigan Molecular 
Genetic Laboratory at University of Michigan. Variants were identified via whole exome 
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sequencing and segregation studies were performed in additional family members when possible.  
Each identified ARS mutation was assessed for its presence in the general population via 
database searches of the Exome Variant Server (snp.gs.washington.edu/EVS), the 1000 Genomes 
Project database (www.1000genomes.org), and dbSNP (www.ncbi.nlm.nih.gov/snp). 
Conservation of the affected amino acid residue was determined by comparison of evolutionarily 
divergent species using ClustalW2 (Larkin et al. 2007).  
Aminoacylation assays 
 
Wild-type and mutant human AARS open reading frames were cloned in frame with a 6X His C-
terminal tag in the pET-DEST42 gateway vector (Life Technologies) and expressed in E. coli. 
Protein was purified with the Co2+-affinity resin per manufacturer’s protocol (Novagen). Human 
tRNAAla was prepared, purified, and annealed as previously described (Hou et al. 1993). 
Aminoacylation assays were performed to determine the steady-state kinetics of mutant AARS 
enzymes. Briefly, 20 mM of recombinant human wild-type or mutant AARS was incubated at 
37°C with tRNAAla in varying concentrations (0.6–16 mM) and 3H-alanine (20 mM) in a buffer 
containing 20 mM KCl, 50 mM HEPES (pH 7.5), 4.0 mM DTT, 0.2 mg/ml BSA, 10 mM 
MgCl2, and 2 mM ATP. Incorporation of 
3H-Ala (specific activity of 16,500 dpm/pmole) onto 
tRNAAla to generate 3H-Ala-tRNAAla was determined by calculating acid precipitable counts on 
filter pads. Counts were corrected for the filter quench factor and were calculated as pmoles of 
3H-Ala-tRNAAla. Data were fit to the Michaelis-Menten equation. Four independent experiments 
were performed, and error bars represent standard deviations. 
Generation of yeast ARS expression constructs and haploid yeast strains  
PCR primers were designed to amplify the orthologous S. cerevisiae ARS locus (Table 2.1) 
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Table 2.1. Human and Yeast orthologous ARS locus 
Human ARS
 
 Yeast ARS
 
 
AARS ALA1 
DARS DPS1 
GARS GRS1 
FARSB FRS1 
YARS TYS1 
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including the endogenous promoter from yeast genomic DNA.  Gateway (Invitrogen) cloning 
sequences (attB1 (forward) and attB2 (reverse); primer sequences in Appendix A) were included 
to facilitate recombination into the pDONR221 vector. Subsequent to PCR, BP Clonase 
(Invitrogen) reactions were employed to clone the wild-type ARS locus into pDONR221 and 
resulting colonies were fully sequenced to rule out PCR-induced errors. Next, mutation-
containing oligonucleotides (primer sequences in Appendix A) were employed to model the 
human mutations at the corresponding residue in the orthologous yeast gene (Table 2.1). The 
QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene) was used to mutate each locus in 
the pDONR221 entry construct. Resulting clones were purified and sequenced to confirm 
successful mutagenesis and rule out PCR-induced errors. The wild-type and mutant 
ARS/pDONR221 entry clones were subsequently recombined into a Gateway-compatible URA3-
bearing pRS316 or LEU2-bearing pRS315 destination vector using LR Clonase (Invitrogen). 
Resulting clones were purified and digested with BsrGI (New England Biosystems) to confirm 
successful recombination.  
ΔALA1 and ΔGRS1 haploid strains containing a wild-type copy of the ALA1 or GRS1 locus, 
respectively, on a URA3-bearing vector were previously generated (Turner et al. 2000; 
McLaughlin et al. 2011). To test the remaining ARS variants, commercially available diploid 
heterozygous yeast strains were purchased for each ARS ortholog of interest (Open Biosystems) 
to generate additional haploid yeast strains. The strains utilized were: (1) YARS: diploid 
heterozygous ΔTYS1 yeast strain (MATa/α, his3Δ1/ his3Δ1, leu2Δ0/ leu2Δ0, met15Δ0/ MET15, 
ura3Δ0/ ura3Δ0); (2) DARS: diploid heterozygous ΔDPS1 yeast strain (MATa/α, his3Δ1/ his3Δ1, 
leu2Δ0/ leu2Δ0, met15Δ0/ MET15, ura3Δ0/ ura3Δ0); and (3) FARSB: diploid heterozygous 
ΔFRS1 yeast strain (MATa/α, his3Δ1/ his3Δ1, leu2Δ0/ leu2Δ0, met15Δ0/ MET15, ura3Δ0/ 
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ura3Δ0). Each diploid strain was generated by replacing one endogenous locus of interest with a 
KANR cassette (Winzeler et al. 1999). The heterozygous diploid strain was transformed with an 
URA3-bearing pRS316 vector containing the wild-type ARS locus (Table 2.1) (see above for 
construct generation). Lithium acetate yeast transformations were performed at 30°C using 200 
ng of plasmid DNA. Transformed yeast were grown on yeast media lacking uracil. Resulting 
diploid yeast containing the wild-type pRS316 maintenance vector were treated to induce 
sporulation. Briefly, the diploid strain was patched twice onto GNA presporulation plates (5% D-
glucose [Fisher Scientific], 3% nutrient broth [Becton, Dickinson and Company], 1% yeast 
extract [Acros Organics], and 2% agar [Teknova]). One microliter of cells was then transferred 
into 2 ml of supplemented liquid sporulation medium (1% potassium acetate [Fisher Scientific], 
0.005% zinc acetate [Fisher Scientific], 1X ura supplement, 1X his supplement, and 1X leu 
supplement) and incubated for 5 days at 25°C followed by 3 days at 30°C. Sporulated yeast were 
dissected using a MSM 400 dissection microscope (Singer Instruments) and plated on yeast 
extract, peptone, and dextrose (YPD) plates (Becton, Dickinson and Company). Resulting spores 
were individually patched onto solid growth medium containing Geneticin (G418) or 0.1% 5-
fluoroorotic acid (5-FOA), or media lacking uracil (Teknova, Hollister, CA). Two resulting 
haploid yeast clones that grew on G418 medium and medium lacking uracil, but failed to grow 
on 5-FOA medium, were selected for use in the yeast complementation assays.  
Yeast complementation assays 
 
Two haploid ΔARS strains [harboring a maintenance vector to express wild-type ARS and 
URA3] per locus were then transformed with an empty vector (‘Empty pRS315’ in figures) or the 
appropriate wild-type or mutant ARS in a LEU2-bearing pRS315 vector and selected on medium 
lacking uracil and leucine (Teknova). For each transformation, at least two independent pRS315 
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plasmid preparations were used and at least two colonies from each plasmid were selected for 
additional analysis. Selected colonies were grown to saturation for 2 days at 37°C in liquid 
media lacking uracil and leucine. A 10 μl aliquot of each culture was spotted undiluted or diluted 
1:10 or 1:100 in H2O on plates containing 0.1% 5-FOA (Teknova) or medium lacking uracil and 
leucine and incubated at 30°C for 48-72 hours. Survival was determined by visual inspection of 
growth. 
Yeast growth curves  
Growth curves were generated using pseudo-heterozygous yeast, which contain both wild-type 
TYS1 on the URA3-bearing maintenance vector and wild-type, G41R, or P167T TYS1 or no insert 
on the LEU2-bearing vector. Three yeast colonies from each transformation were selected for 
growth curves. Yeast were grown to saturation for 2 days at 30°C in liquid media lacking uracil 
and leucine. Saturated cultures were diluted to an OD600 = 0.200 +/- 0.015 based on OD600 
readings recorded on the Absorbance module E7061 on the Glomax®-Multi Microplate 
Multimode Reader Detection System (Promega, Madison, WI).  20 μl of OD600 = 0.200 +/- 0.015 
cultures was added to 4 mL of media lacking uracil and leucine or media contain 0.1% 5FOA 
and incubated at 30°C shaking. Growth curves were generated using the average OD600 
measurements from three biological replicate cultures for each pseudo-heterozygous strain at the 
indicated time points. Error bars represent standard deviation. Growth curves were performed 
twice using independent yeast transformation samples.   
Global protein assessment  
 
To compare total protein levels in wild-type and K81T/R751G AARS fibroblasts, total protein 
was extracted from 500,000 cells per culture using 200 μl of a cocktail containing RIPA buffer 
and 100X protease inhibitor (Thermo Scientific, Rockford, IL).  Cells were lysed by rocking for 
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30 min at 4°C. Lysates were centrifuged at 4°C for 30 min at 15,000 rpm to remove cellular 
debris. 20 μl of lysates were mixed with 20 μl of 2X SDS-Glycine running buffer (Life 
Technologies, Grand Island, NY) and 2 μl of β-mercaptoethanol and run on a 4-12% Tris-glycine 
for 2 hours at 100 volts (Life Technologies). The protein gel was then washed in distilled water, 
stained with SimplyBlue SafeStain (Invitrogen, Carlsbad, CA) for 1 hour, and washed again in 
distilled water overnight. Relative protein levels were determined by visual inspection of 
staining.    
RESULTS 
AARS mutations identified in patients with early-onset epileptic encephalopathy. 
Three children, including two siblings and one unrelated child, were diagnosed with 
microcephaly and refractory myoclonic epilepsy in infancy. All three children demonstrated 
spasticity, blepharospasm (involuntary tight closure of eyelids), orobuccal dyskinesia 
(involuntary movement of the mouth), dystonia of limbs, chorea, and absent peripheral deep 
tendon reflexes. MRI studies revealed progressive atrophy of both grey and white matter and 
hypomyelination in all patients. Whole exome sequencing determined that all three patients 
carried biallelic AARS mutations. The two siblings were compound heterozygous for K81T 
(c.242A>C; p.Lys81Thr) and R751G (c.2251A>G; p.Arg751Gly) AARS. The K81T AARS allele 
was maternally inherited and was neither identified in general population databases nor in any of 
the control exomes examined. The AARS R751G mutation was paternally inherited and was 
present at an allele frequency of 0.00005% (6/120,000) in the dbSNP database, but absent from 
other general population databases and control exomes. Of note, all six occurrences of the 
R751G AARS allele were in heterozygous individuals. The third child tested was homozygous for 
the R751G AARS allele. K81T AARS is located in the aminoacylation domain of AARS, while 
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Figure 2.1. Localization and conservation of human AARS mutations. (A) A cartoon of the 
known functional domains of the AARS protein including the catalytic domain (red), the tRNA 
binding domain (green), the editing domain (orange), and the C-terminal domain (purple). The 
residues of each domain are indicated (bottom). K81T and R751G AARS are mapped on the 
protein structure (top). (B) A multiple-species sequence alignment demonstrates the conservation 
of the affected residues for K81T and R751G AARS mutations and the flanking protein 
sequences in multiple and evolutionarily diverse species. The affected residue is in red text.  
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R751G is located in the editing domain (Figure 2.1A). Both residues are conserved from human 
to E. coli (Figure 2.1B).  
K81T and R751G AARS demonstrate decreased aminoacylation activity in vitro. 
ARS mutations previously implicated in recessive disease have demonstrated decreased 
aminoacylation, including recessive KARS and QARS mutations (McLaughlin et al. 2010; Zhang 
et al. 2014). In vitro aminoacylation assays were used to test the ability of human K81T and 
R751G AARS to charge tRNAAla with tritium labeled alanine. Both the Km (a measure of the 
substrate concentration necessary for effective catalysis) and the kcat (a direct measure of 
catalysis generating the final product under ideal conditions including enzyme saturation) were 
determined. The Km/kcat was used to calculate aminoacylation for wild-type and mutant AARS. 
The ratio of mutant AARS activity compared to wild-type activity was used to determine the 
overall effects of each mutation on aminoacylation. K81T AARS had a 2-fold increase Km, 
resulting in a 2-fold decrease in aminoacylation (Km/kcat) compared to wild-type AARS (Table 
2.2). In contrast, R751G AARS showed both an increase in Km by 2-fold and a decrease in kcat 
by 5-fold, resulting in a 90% reduction in tRNA charging efficiency compared to wild-type 
AARS (Table 2.2). These data indicate that both K81T and R751G AARS are loss of function in 
vitro.  
K81T ALA1 results in reduced growth in yeast complementation assays.  
 
Disease-associated aminoacyl-tRNA synthetases mutations have been tested for loss-of-function 
characteristics in vivo using yeast complementation assays, including mutations in AARS that 
have been implicated in peripheral neuropathy (Antonellis et al. 2006; Jordanova et al. 2006; 
McLaughlin et al. 2010; McLaughlin et al. 2011; Pierce et al. 2011; Vester et al. 2012; 
Cassandrini et al. 2013; Gonzalez et al. 2013; Diodato et al. 2014; Griffin et al. 2014; Gonzaga-
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Jauregui et al. 2015; Hadchouel et al. 2015; Safka Brozkova et al. 2015). To assess the functional 
consequences of K81T and R715G AARS in vivo, a previously validated haploid yeast strain that 
has the endogenous yeast ortholog of AARS, ALA1, deleted and viability maintained by 
expression of wild-type ALA1 on a URA3 selective vector (McLaughlin et al. 2011) was 
transformed with either an empty vector or one containing the wild-type, K81T, or R751G ALA1 
alleles. The mutations were modeled by mutating the orthologous amino acid residue in the yeast 
protein (Table 2.3), and mutations are referred to by the human mutation for clarity. Yeast were 
then selected on media containing 5-FOA to select for yeast cells that have spontaneously lost 
the URA3- maintenance vector (Boeke et al. 1987). Only yeast cells that express a functional 
ALA1 allele on the LEU2-bearing pRS315 vector are able to survive. Wild-type ALA1 sustained 
yeast viability, while the empty vector (‘Empty pRS315’) was unable to complement loss of the 
endogenous ALA1 allele (Figure 2.2), consistent with the ALA1 being an essential gene in yeast 
(McLaughlin et al. 2011). Yeast expressing R751G ALA1 showed survival comparable to 
expression of wild-type ALA1, while yeast expressing K81T ALA1 demonstrated reduced growth 
on 5-FOA media (Figure 2.2). These results strongly suggest that K81T AARS represents a 
hypomorphic AARS allele in vivo.   
K81T / R751G AARS fibroblasts do not show a dramatic reduction in total protein levels. 
 
tRNA charging is an essential first step in protein translation. Thus, mutations that result in 
impaired charging could impair global protein translation, resulting in decreased protein levels in 
cells (Wallen and Antonellis 2013). To determine if the K81T and R751G AARS mutations 
resulted in decreased protein translation, protein was extracted from patient fibroblasts generated 
from an individual who was compound heterozygous for K81T and R751G AARS and from wild-
type control fibroblasts. Protein was extracted from equal cell numbers based on cell counts and 
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Table 2.2. Aminoacylation Kinetics of AARS Variants 
Variant Km (μM) kcat (s-1) 
Km/ kcat  
(μM-1s-1) 
 Ratio to WT 
Wild-type
 
3.1 ± 0.7 0.4 ± 0.1 0.13 ± 0.04  1 
K81T 6.0 ± 1.8 0.4 ± 0.1 0.07 ± 0.03  1/2 
R751G 6.3 ± 1.4 0.07 ± 0.03 0.01 ± 0.005  1/10 
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Table 2.3. Human AARS Variants Modeled in the Yeast Ortholog ALA1 
Human AARSa
 
 Yeast ALA1b
 
 
K81T
 
K85T 
R751G R747G 
aAmino acid coordinates correspond to GenBank accession number BAA06808.1. 
bAmino acid coordinates correspond to GenBank accession number EDV1089. 
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Figure 2.2. Yeast complementation assays for recessive AARS alleles. Haploid ΔALA1 yeast 
strains were transformed with a vector containing an insert to express wild-type, K81T, or R751G 
ALA1 or no insert (‘pRS315 Empty’). Resulting cultures were spotted (undiluted and diluted 1:10 
and 1:100) on complete agar growth medium plates containing 5-FOA (top panel) or on SD –leu -
ura agar growth medium plates (bottom panel) and incubated at 30oC for two days. Experiments 
were performed using independently generated ALA1 expression constructs for each mutant allele 
(indicated by ‘A’ and ‘B’ along the top). Culture dilutions are indicated on the left and media 
conditions are indicated on the right. 
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Figure 2.3. Evaluation of protein levels in AARS fibroblasts. Protein extracted K81T / R751G AARS 
patient fibroblasts were compared to protein from wild-type fibroblasts. Protein lysates were 
prepared from equal numbers of cells for each sample. Three independently prepared protein lysates 
from patient fibroblasts are shown (1, 2, and 3) with two replicates from each isolation included for 
comparison (A and B).  
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equal volumes of total protein were evaluated. The total protein levels in patient fibroblast 
samples were comparable to levels of total protein from control fibroblast extracts (Figure 2.3), 
indicating that compound heterozygosity of K81T and R751G AARS does not lead to a severe 
reduction in global protein levels.  
GARS mutations identified in patients with microcephaly. 
An individual with idiopathic microcephaly was evaluated at the NIH as part of the UDP. The 
patient was diagnosed with growth retardation in utero and had decreased body weight and short 
stature at the time of clinical evaluation. The patient also had an atrial septal defect, abnormal 
facial features, including a smooth philtrum and increased distance between the eyes 
(hypertelorism), and demonstrated a failure to thrive.  Whole exome sequencing revealed the 
patient was compound heterozygous for E29Ifs*6 [c.84_87del, p.Glu29Ilefs*6] and R256Q 
[c.767G>A, p.Arg265Gln] GARS. mRNA transcribed from the E29Ifs*6 GARS allele is 
predicted to undergo nonsense-mediated decay (NMD) and thus would not be expected to 
produce protein product (Amrani et al. 2006). In contrast, the R256Q GARS allele is predicted to 
code for an expressed, stable protein that affects a residue in the catalytic domain that is 
conserved from human to worm (Figure 2.4A and B).  
R256Q GRS1 complements loss of endogenous GRS1. 
 
To test the functionality of R256Q GARS, we utilized the yeast complementation assay that had 
been previously developed to study CMT2D-associated GARS mutations (Antonellis et al. 2006; 
Turner et al. 2009). Briefly, based on conservation of the surrounding amino acids, we were 
confident that the orthologous residue to human R256 GARS in yeast is K239 GRS1 (Table 2.4). 
Both residues are polar basic amino acids, and thus the presence at this position of an arginine or 
lysine is not predicted to have a dramatic impact on the structure and function of the enzyme. 
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Figure 2.4. Localization and conservation of GARS mutations. (A) The position of E29Ifs*6 and 
R256Q GARS are indicated on a cartoon of GARS protein structure (top).  The functional 
domains of GARS are depicted with the amino acid positions marked for each domain (bottom): 
WHEP-TRS (blue), catalytic domains (red), insertion domains (yellow), and anticodon-binding 
domain (green). (B) Alignment of R256 GARS (red text) and surrounding amino acids in 
evolutionarily diverse species are shown. Note that the predicted orthologous residue in yeast is a 
lysine (purple text).   
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Table 2.4. Human GARS Variants Modeled in the Yeast Ortholog GRS1 
Human GARSa Yeast GRS1b 
R256Q K239Q 
aAmino acid coordinates correspond to GenBank accession number AAA57001.1. 
bAmino acid coordinates correspond to GenBank accession number NP_009679.2. 
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However, the substitution of an uncharged polar residue, such as glutamine that would occur as a 
result of the R256Q mutation, may have an appreciable effect on GARS activity.  For 
consistency with other variants described in this thesis, the mutation in yeast is referred to by the 
human nomenclature (R256Q). Yeast strains lacking GRS1 with viability maintained by a URA3-
bearing vector encoding wild-type GRS1 (Turner et al. 2009) were transformed with wild-type or 
R256Q GRS1 or an empty LEU2-bearing vector. Resulting yeast were plated on 5-FOA media to 
select for yeast that spontaneously lost the URA3 maintenance vector (Boeke et al. 1987). Visual 
inspection of yeast growth revealed that the R256Q expressing yeast grew to levels comparable 
to yeast expressing wild-type GRS1 (Figure 2.5). This indicates that in yeast, the R256Q variant 
is sufficiently active to complement loss of endogenous GRS1.   
DARS mutations identified in patients with hypomyelination.  
Mutations in DARS had been previously identified in ten patients with recessive 
leukoencephalopathy (Taft et al. 2013); however, functional studies were not performed on any 
of these variants. Recently, two additional DARS mutations, H280L (c.1099G>C, p.Asp367His) 
and D367H (c.839A>T, p.His280Leu), were identified in a patient with recessive 
hypomyelination enrolled in the NIH’s UDP protocol. Similar to the previously reported cases 
(Taft et al. 2013), this patient had decreased myelination in both the brain and the spinal cord and 
spasticity. Both H280L and D367H DARS mutations reside in the catalytic domain of DARS and 
are conserved from human to yeast (Figure 2.6A and B). Interestingly, D367H DARS affects the 
same residue as D367Y, a mutation previously implicated in recessive hypomyelination (Taft et 
al. 2013). Of the previously reported mutations used in this study, A274V, D367Y, and R494G 
DARS reside in the catalytic domain and are conserved from human to yeast (Figure 2.6A and 
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Figure 2.5. Yeast Complementation assay for R256Q GRS1. Haploid yeast lacking endogenous 
GRS1 were transformed with wild-type or R256Q GRS1 or an empty vector (‘Empty pRS315) (top) 
and grown on plates containing 5-FOA or lacking leucine and uracil at various concentrations. Yeast 
expressing wild-type or R256Q GRS1 grew robustly, while yeast containing only an empty vector 
were unable to survive on 5-FOA.  
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Figure 2.6. Localization and conservation of DARS mutations. (A) DARS has two major functional domains, the anticodon-binding 
domain (green) and the catalytic domain (red). All DARS mutations used in this study affect residues in the catalytic domain (indicated 
on top of cartoon). The newly identified mutations, H280L and D367H DARS, are in red text. (B) DARS protein alignments of 
multiple evolutionarily diverse species is depicted. The affected residue is in red, bold text. All affected residues are conserved from 
human to yeast except R460 DARS, which has a serine (purple, bold text) at the orthologous residue.  
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B). R460H DARS also affects an amino acid in the catalytic domain, but is only conserved in 
vertebrates. 
DARS mutations support yeast viability.  
 
Although predicted to be deleterious using multiple damage-prediction algorithms, DARS 
mutations previously implicated in recessive leukoencephalopathy have not been previously 
tested for effects on enzyme activity (Taft et al. 2013). As such, we developed a yeast 
complementation assay to test previously implicated mutations (A274V, D367Y, R460H, and 
R494G DARS) and the two newly identified DARS mutations (H280L and D367H). Haploid 
yeast strains lacking DPS1, the yeast ortholog of DARS, were generated. Viability of the strain 
was maintained using an URA3-bearing plasmid that contains the wild-type DPS1 locus. A274V, 
H280L, D367H, D367Y, R460H, and R494G DARS were modeled in the DPSI gene based on 
conservation (Table 2.5). Wild-type or mutant DPS1 or an empty vector control was introduced 
into the haploid ΔDPS1 strain. Yeast were subsequently selected for the spontaneous loss of the 
URA3-maintenance vector using 5-FOA media (Boeke et al. 1987). Visual inspection of the 
plates revealed that all alleles were able to sustain yeast viability; however A274V and D367Y 
DPS1 showed decreased growth compared to wild-type DPS1 expressing yeast that could be 
appreciated at 1:10 and 1:100 dilutions (Figure 2.7). Thus, when modeled in yeast, none of the 
tested DARS alleles had a dramatic reduction in activity.  
FARSB mutations identified in a patient with interstitial lung and liver disease.  
 
An infant presented to the University of Michigan Medical Genetics clinic with liver and 
interstitial lung disease. Exome sequencing revealed the patient was compound heterozygous for 
T256M (c.767C>T; pThr256Met) and H496Kfs*14 (c.1486delCinsAA; p.His496Lysfs*14)
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Table 2.5. Human DARS Variants Modeled in the Yeast Ortholog DPS1 
Human DARSa Yeast DPS1b 
A274V A326V 
H280L H332L 
D367H D421H 
D367Y D421Y 
R460H S516H 
R494G R550G 
 
 
aAmino acid coordinates correspond to GenBank accession number AAI07750.1. 
bAmino acid coordinates correspond to GenBank accession number CAA66172.1. 
 
  
 70 
 
 
 
 
 
  
Figure 2.7. Yeast expressing disease associated DPS1 alleles. Yeast lacking endogenous DPS1 
were transformed with LEU2-bearing vectors containing wild-type of mutant DPS1 or no insert 
(‘pRS315 Empty’) (top). All mutations were able to sustain yeast viability; however, A274V and 
D367Y DPS1 showed a mild reduction in yeast growth. Note the subtle differences at 1:10 and 
1:100 dilutions on 5-FOA.  
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FARSB. The H496Kfs*14 FARSB mRNA is predicted to undergo nonsense mediated decay 
(Amrani et al. 2006). T256M FARSB, in contrast, is expected to be expressed and stable and 
affects a residue in the tRNA binding domain that is conserved from human to yeast (Figure 
2.8A and B). 
FARSB mutations support yeast viability. 
In order to functionally test the T256M FARSB mutation, we developed a haploid yeast strain, 
similar to strains used in previously described studies. T256M FARSB was modeled in the yeast 
ortholog FRS1 (Table 2.6). ΔFRS1 [containing the FRS1 locus on a URA3 maintenance vector] 
was transformed with a LEU2-vector containing wild-type or T256M FRS1 or an empty vector. 
After plating on 5-FOA plates to select against cells carrying the maintenance vector (Boeke et 
al. 1987), it was determined that T256M FRS1 supports yeast growth to wild-type FRS1 levels, 
indicating T256M FRS1 does not demonstrate loss of function in this assay (Figure 2.9). 
Recessive YARS mutations identified in a child with microcephaly. 
 
An infant child from a consanguineous family presented to the Clinic for Special Children with 
microcephaly. This child and a sibling both ultimately died in early infancy. Exome sequencing 
performed by Regeneron revealed that these patients were homozygous for P167T (c.499C>A; 
p.Pro167Thr) YARS. Because mutations in YARS had been previously implicated in dominant 
intermediate CMT (DI-CMT), a family history of neuropathy was investigated. The parents 
reported symptoms consistent with a mild peripheral neuropathy. P167T YARS affects a residue 
conserved from human to yeast that is located in the catalytic domain (Figure 2.10).  
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Figure 2.8. Localization and conservation of FARSB mutations. (A) The position of T256M and 
H496Kfs*14 FARSB are depicted on the cartoon of the FARSB protein. FARSB contains a 
tRNA-binding domain (green), but lacks a catalytic domain. (B) T256M FARSB affects a residue 
conserved from human to yeast (bold, red text). 
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Table 2.6 Human FARSB Variant Modeled in the Yeast Ortholog FRS1 
Human FARSBa Yeast FRS1b 
T256M T246M 
aAmino acid coordinates correspond to GenBank accession number NP_005678.3. 
bAmino acid coordinates correspond to GenBank accession number P15624.3. 
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Figure 2.9. Yeast complementation assay for T256M FRS1. Yeast lacking endogenous FRS1 
were transformed with a LEU2-bearing vector containing wild-type or T256M FRS1 or an empty 
vector (‘Empty pRS315’) (top) and spotted on 5-FOA plates. T256M FRS1 sustained yeast 
viability to levels comparable to wild-type FRS1. Transformations were performed with three 
independent plasmid preps (1, 2 and 3) and two colonies (A and B) were selected from each 
transformation for evaluation.  
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Figure 2.10. Localization and conservation of YARS mutations. (A) A cartoon depiction of 
YARS illustrates the location of the catalytic domain (red) and an anticodon-binding domain 
(green). The amino acid residues comprising each domain are listed below the cartoon. The 
position of P167T YARS in the catalytic domain is illustrated on top of the cartoon. (B) P167T 
YARS affects a residue conserved from human to yeast.  
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Yeast complementation studies suggest P167T YARS is a hypomorphic allele. 
 
To understand the functional consequences of the P167T YARS on enzyme activity, we employed 
a haploid yeast strain that was deleted for the endogenous TYS1 locus, the yeast ortholog of 
YARS. As with other ARS yeast models, viability was maintained using a wild-type copy of 
TYS1 on an URA3-containing vector, allowing for selection against the maintenance vector using 
5-FOA media (Boeke et al. 1987). Mutations of interest were modeled based on conservation 
between human YARS and yeast TYS1 (Table 2.7). Wild-type, G41R (a previously reported loss 
of function allele implicated in dominantly inherited CMT disease (Jordanova et al. 2006)), or 
P167T TYS1 or an empty vector were introduced into the haploid yeast strain. After selection on 
solid 5-FOA media, P167T TYS1 showed a dramatic reduction in yeast growth compared to 
wild-type (Figure 2.11); however the P167T TYS1 allele supported significantly more yeast 
growth than either the functional null G41R TYS1 and the empty vector control. To quantify the 
difference in growth between wild-type and P167T TYS1 expressing yeast, we performed growth 
curves in liquid 5-FOA media using pseudo-heterozygous strains carrying both a wild-type allele 
on a URA3-bearing vector and the experimental allele on a LEU2-bearing vector (Figure 2.12). 
Yeast carrying the G41R allele or an empty vector were unable to grow in liquid 5-FOA media. 
Wild-type TYS1 expressing yeast entered mid log phase at ~ 90 hours. P167T TYS1 expressing 
yeast had a 15-hour lag in growth before reaching mid-log phase compared to wild-type 
expressing yeast (Figure 2.12). This is consistent with the slower growth observed for P167T 
TYS1 yeast on solid 5-FOA media. These data suggest that P167T YARS is a hypomorphic allele. 
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Table 2.7 Human YARS Variant Modeled in the Yeast Ortholog TYS1 
Human YARSa Yeast TYS1b 
G41R G45R 
P167T P171T 
aAmino acid coordinates correspond to GenBank accession number AAH16689.1. 
bAmino acid coordinates correspond to GenBank accession number AAB59329.1. 
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Figure 2.11. Yeast complementation assays of P167T TYS1. Yeast lacking endogenous TYS1 
were transformed with vectors containing wild-type, G41R, or P167T TYS1 or an empty vector 
(pRS315 empty) and plated undiluted and diluted (1:10 and 1:100) on 5-FOA or –leu -ura media. 
Yeast expressing P167T TYS1 showed an intermediate level of growth on 5-FOA media 
compared to the wild-type and the empty vector control yeast strains. G41R TYS1, a known 
complete loss-of-function allele in yeast (Jordanova et al. 2006), did not support yeast cell 
growth.    
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Figure 2.12. Growth curve analysis of P167T TYS1. Yeast expressing wild-type, G41R, or 
P167T TYS1, or no insert (‘Emp’) from a LEU2-bearing vector and carrying a URA3 
maintenance vector were grown in liquid 5-FOA media to select for the spontaneous loss of the 
URA3 vector (Boeke et al. 1987) for 150 hours. OD600 readings were taken at the intervals 
indicated on the X-axis (hours). Error bars represent standard deviation of the average OD600 of 
three biological replicates for each strain. Note the ~15 hour lag between mid-log phase of wild-
type and P167T TYS1 expressing yeast. 
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Discussion 
 
Here we present the functional characterization of mutations identified in patients who suffer 
from autosomal recessive syndromes with no known etiology. Recessive mutations in AARS, 
GARS, DARS, FARSB, and YARS were found to have varying levels of activity. K81T and 
R751G AARS and P167T YARS demonstrated loss-of-function characteristics in either 
aminoacylation or yeast complementation assays, while mutations in GARS, FARSB and DARS 
did not show reduced function when modeled in yeast. Thus, these data indicate a loss-of-
function mechanism for recessive AARS- and YARS-associated syndromes, but is insufficient to 
implicate or refute a similar mechanism for GARS, FARSB, and DARS mutations.  
Aminoacylation and yeast complementation assays have been used to evaluate ARS-mutations 
associated with a variety of human diseases (Antonellis et al. 2006; Jordanova et al. 2006; 
McLaughlin et al. 2010; McLaughlin et al. 2011; Pierce et al. 2011; Vester et al. 2012; 
Cassandrini et al. 2013; Gonzalez et al. 2013; Diodato et al. 2014; Griffin et al. 2014; Gonzaga-
Jauregui et al. 2015; Hadchouel et al. 2015; Safka Brozkova et al. 2015). Direct comparison of 
results from these two assays has demonstrated that all mutations that show loss of function in 
yeast assays result in a dramatic reduction in aminoacylation activity in vitro. However, the 
converse is not true. A subset of mutations that support yeast cell growth show decreased activity 
in aminoacylation assays. For example, L133H KARS, which is implicated in a recessive 
syndrome that includes peripheral neuropathy and developmental delay, has a >90% decrease in 
aminoacylation studies, but supports yeast cell growth to wild-type levels (McLaughlin et al. 
2010). This may indicate that the mutation has a greater impact on the activity of the human 
protein than the yeast ortholog or that the tissues affected in disease (i.e. neurons) are exquisitely 
sensitive to ARS dysfunction compared to yeast cells. Thus while decreased ARS activity 
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appears detrimental to a subset of specialized cells as evidenced by the tissue specific phenotypes 
observed in dominant and recessive ARS-mediated disease, decreased activity in yeast may not 
be sufficient to cause impaired growth. This may be due to the size of a yeast cell compared to a 
neuron (Wallen and Antonellis 2013) or the metabolic demands of yeast compared to specialized 
human tissues.  There are two approaches to address this issue. The first is to perform 
aminoacylation assays on mutations that do not demonstrate loss of function in yeast 
complementation assays. Indeed, we have generated constructs to express human GARS and 
DARS mutant alleles and aminoacylation studies are underway. Alternatively, recent studies have 
demonstrated that deletion of some endogenous yeast loci can be rescued by the expression of 
the human ortholog (Jordanova et al. 2006; Chien et al. 2014; Kachroo et al. 2015). For example, 
deletion of TYS1 was rescued by expression of human wild-type YARS, but not G41R YARS 
(Jordanova et al. 2006). Recently, it was shown that deletion of GRS1 could be rescued by a 
plasmid expressing a truncated form of human GARS that lacks the mitochondrial targeting 
sequence and WHEP domain, two domains not conserved between human and yeast (Chien et al. 
2014). Human mutations can be modeled in be this truncated form of GARS and assessed from 
complementation in a ‘humanized’ yeast assay. This would allow testing of disease-associated 
mutations for effects on the human protein in vivo. The humanized yeast assay would also 
expand the spectrum of mutations that can be evaluated, as conservation would no longer be a 
limiting factor. Indeed, R256Q GARS has already been tested in the humanized yeast assay and it 
is unable to support yeast viability compared to wild-type GARS (Stephanie Oprescu, personal 
communication). However, we would predict since GARS is critical for organismal viability and 
the compound heterozygous genotype E26Ifs6*/ R256Q GARS is not embryonic lethal, R256Q 
GARS must retain at least a low level of activity. Indeed, aminoacylation data show that R256Q 
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GARS activity is 1/920 of wild-type levels (Ya-ming Hou, personal communication). The 
detectable activity of R256Q GARS in the aminoacylation assays compared to the humanized 
yeast assay may be due to increased stabilization of the full length GARS protein compared to 
the truncated protein used to complement in yeast. Together these data indicate that R256Q 
GARS is a severe, but not complete, loss-of-function mutation.  
Developing “humanized” yeast complementation assays for other ARS genes will be important 
for expanding our ability to assess variants for an effect on ARS enzyme function. It is currently 
unknown how many human ARS enzymes can complement in yeast. A recent study found that of 
11 full-length ARS enzymes tested, seven (KARS, AARS, QARS, CARS, SARS , LARS, and YARS) 
were able to complement, while four (DARS, FARSB, FARSA, and IARS) were unable to support 
yeast viability (Kachroo et al. 2015). However, modifications, such as removal of non-conserved 
domains (e.g. the WHEP domain of GARS), may improve rescue by human genes and allow for 
complementation of most, if not all, human ARS genes in yeast.    
Although a loss-of-function mechanism is likely the pathomechanism in recessive ARS-
associated syndromes, it is unknown how these mutations lead to cell specific phenotypes. For 
example, AARS mutations that lead to hypomyelination may be due to an abnormality in myelin 
development or a delay in myelination due to a defect in the neuron. GARS, AARS, and YARS 
mutations have been implicated in dominantly inherited CMT disease. For GARS and AARS 
mutations, the resulting CMT disease is axonal in nature, indicating that dysfunction of these 
enzymes primarily affects the neurons, not the myelinating Schwann cells. Patients with YARS 
mutations have DI-CMT and demonstrate evidence of both neuron and Schwann cell 
dysfunction. However, future research into how these cells are specifically affected by ARS 
mutations is needed (see chapter 6). 
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Since mutations in some genes cause both recessive and dominant disorders, it appears that the 
level of ARS function in a cell is critical to the severity of disease.  Mouse models of Gars 
mutations have shown a dose dependent spectrum of phenotypes.  Heterozygosity for one of two 
loss-of-function missense Gars alleles leads to a peripheral neuropathy phenotype and 
homozygosity or compound heterozygosity of these alleles leads to an even more severe 
phenotype than what is seen in heterozygous state, including decreased life span (Seburn et al. 
2006; Achilli et al. 2009; Motley et al. 2015). Thus, one would predict that heterozygous parents 
of the probands described in this chapter would be at risk for developing dominant CMT disease. 
In fact, family members who are heterozygous for the P167T YARS allele reported mild 
neuropathy symptoms. This provides the first evidence that both dominantly and recessively 
inherited disease can be due to the same loss-of-function ARS mutation and that the severity of 
disease is likely due overall reduction in enzyme function. Heterozygous parents carrying AARS 
and GARS mutations do not currently demonstrate symptoms of a peripheral neuropathy; 
however, because ARS-mediated CMT disease often presents late in life, these individuals 
should be continually screened for evidence of disease as they age. Based on the mouse studies 
of null and missense GARS alleles, we would hypothesize that individuals that carry the missense 
AARS and GARS alleles (K81T and R751G AARS and R256Q GARS) will develop late-onset 
axonal neuropathy, while the parent carrying a null allele (E29Ilefs6* GARS) would not develop 
disease. This would further support the hypothesis that an expressed stable, loss-of-function 
protein is necessary for CMT disease pathogenesis. Although mutations in DARS and FARSB 
have not been identified in patients with peripheral neuropathy, continued follow-up of these 
families would be informative in determining if additional ARS genes are capable of causing 
both recessive and dominant disease. 
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Future research on ARS-mediated recessive disorders should focus on improving ARS function 
in cells. One option would be to screen for pharmacologic compounds that improve mutant ARS 
function in yeast models. A second therapeutic avenue that should be considered is altering the 
kinetics of ARS aminoacylation reactions. This may be accomplished by providing more 
substrate, specifically the cognate amino acid in cases where the Km is increased, to improve 
activity of the mutant enzyme. Although a very simplistic approach, there are currently no other 
therapeutic options; therefore every conceivable treatment option should be explored. Altogether, 
understanding recessive ARS mutations not only provides opportunities to understand these rare 
diseases, but may also shed light into the mechanism of dominantly inherited ARS-mediated 
disease.   
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CHAPTER 3 
Expanding the allelic heterogeneity of ARS mutations in dominant 
peripheral neuropathy 
 
INTRODUCTION 
Mutations in five ARS loci have been identified in patients with dominant peripheral neuropathy: 
GARS, YARS, AARS, HARS, and MARS (Antonellis et al. 2006; Jordanova et al. 2006; Latour et 
al. 2010; Vester et al. 2012; Gonzalez et al. 2013). However, only variants in GARS, YARS, and 
AARS have strong genetic evidence, specifically segregation studies in large pedigrees and 
identification of variants in multiple unrelated families, supporting their role in CMT disease 
(Antonellis et al. 2003; Jordanova et al. 2006; Latour et al. 2010; Lin et al. 2011; McLaughlin et 
al. 2011; Zhao et al. 2012). To date, 13 GARS mutations have been identified in patients with 
CMT2D or dSMA-V (James et al. 2006; Rohkamm et al. 2007; Abe and Hayasaka 2009; Lee et 
al. 2012a; Lee et al. 2012b), while only three YARS variants and three AARS variants have been 
implicated in DI-CMT and CMT2N, respectively. (Jordanova et al. 2006; Latour et al. 2010; Lin 
et al. 2011; McLaughlin et al. 2011; Zhao et al. 2012). While the functional consequences for 
many GARS variants remains uncertain (see chapter 4), biochemical and yeast complementation 
assays have demonstrated that all previously tested YARS and AARS mutations demonstrate loss 
of function in at least one of these assays (Jordanova et al. 2006; McLaughlin et al. 2011). 
Specifically, G41R and E196K YARS result in decreased activity in pyrophosphate assays, which 
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test for the completion of the first step in tRNA charging, and in yeast complementation assays 
(Jordanova et al. 2006). N71Y and R329H AARS both result in a severe reduction in 
aminoacylation and fail to support yeast cell growth in complementation assays (McLaughlin et 
al. 2011). Importantly, a non-disease associated mutation, E778A AARS, supported yeast 
viability and had normal aminoacylation kinetics. Taken together, the functional characterization 
of YARS and AARS mutations provide evidence that loss of function is a characteristic of disease-
associated ARS alleles. However, additional mutations are needed to further support this 
hypothesis and allow for a greater understanding of the mechanism of ARS- mediated disease.   
When this thesis work commenced, the genetic evidence for the pathogenic role of HARS and 
MARS variants in CMT disease was insufficient to implicate these loci. Only one HARS mutation 
(R137Q) had been identified by candidate gene sequencing of a single individual with late-onset, 
sporadic axonal peripheral neuropathy (Vester et al. 2012). When tested in yeast 
complementation assays, R137Q HTS1, the yeast ortholog of HARS, was unable to complement 
loss of the endogenous HTS1, consistent with the loss-of-function characteristics previously 
reported for other pathogenic ARS variants (Antonellis et al. 2006; Jordanova et al. 2006; 
McLaughlin et al. 2011; Stum et al. 2011). Additionally, R137Q HARS was neurotoxic when 
overexpressed in the GABA neurons of C. elegans, supporting its role in dominant neurotoxicity 
(Vester et al. 2012). However, this variant was also identified in a single individual included in 
the ClinSeqTM database (Biesecker et al. 2009) who showed no evidence of peripheral 
neuropathy. Given the late onset of the disease and known pattern of incomplete penetrance for 
some ARS mutations (Sivakumar et al. 2005), the inclusion of this variant in the ClinSeqTM 
database is not sufficient to exclude R137Q HARS as a pathogenic variant. However, the lack of 
segregation studies of the R137Q HARS prevented the implication of HARS as a CMT disease 
 87 
gene (Vester et al. 2012).  
Similar to HARS, only one MARS variant has been identified in patients with peripheral 
neuropathy. Specifically, exome sequencing identified R618C MARS in two individuals with 
peripheral neuropathy and an unaffected obligate carrier in a small pedigree with late-onset, 
incompletely penetrant axonal CMT disease (Gonzalez et al. 2013). Yeast complementation 
studies revealed that R618C MARS could not support yeast viability. While the genetic evidence 
is insufficient to implicate MARS in peripheral neuropathy, these data indicate MARS variants  
identified in individuals with peripheral neuropathy should be carefully evaluated for a role in 
the pathogenesis CMT disease (Gonzalez et al. 2013). Although the loss-of-function data for 
HARS and MARS variants is consistent with other disease-associated ARS variants, the 
identification of additional variants in patients with CMT disease is required to implicate these 
ARS loci in CMT disease.  
ARS variants are increasingly being screened for and, subsequently, identified in patients with 
CMT disease. In the absence of strong genetic evidence, it is critical to functionally evaluate 
these variants before implicating them in disease for multiple reasons (MacArthur et al. 2014): 
First, identification of a novel ARS variant in an individual with CMT disease is not sufficient to 
implicate the variant in disease. As discussed above, loss-of-function characteristics have proven 
to be the best predictor of pathogenesis for ARS variants (Wallen and Antonellis 2013); 
however, since the pathomechanism of disease is still unknown, the question remains as to 
whether loss of function is the sole indicator of pathogenicity. Thus, functional characterizations 
of new variants will not only help establish a pipeline for implicating rare or de novo ARS 
mutations in CMT disease, but also will provide evidence for the mechanism of ARS-mediated 
pathogenesis. Expanding the allelic heterogeneity of ARS mutations will not only provide 
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critical information for patients and clinicians to consider, but also provide researchers with both 
active and loss-of-function alleles for use in future studies into the mechanism of ARS-mediated 
CMT disease. Second, identification of new variants in patients with CMT disease is necessary 
to provide the genetic evidence to implicate HARS, MARS, and any additional ARS enzymes not 
previously associated CMT disease. Third, characterization of novel ARS mutations in patients 
with a variety of peripheral neuropathy phenotypes (e.g. axonal versus demyelinating disease; 
peripheral neuropathy versus myeloneuropathy) would expand our understanding of the 
spectrum of disease manifestations for ARS-mediated disease; Finally, implication of new ARS 
loci in CMT disease would provide valuable information as to the ARS characteristics necessary 
for disease pathogenesis. For example, the three strongly implicated ARS enzymes (GARS, 
YARS, and AARS), as well as HARS, all function as dimers. However, MARS functions as a 
monomer.  Thus further research may support or refute a role for oligomerization in the 
mechanism of ARS-associated CMT disease.   
This chapter focuses on the identification, genetic validation, and functional characterization of 
newly identified mutations in YARS, AARS, and HARS in patients with dominant peripheral 
neuropathy. Mutations were identified using various sequencing techniques, evaluated for 
segregation in pedigrees when available, screened for inclusion in general population databases, 
assessed for conservation, and functionally characterized based on previous studies evaluating 
ARS mutations. We hypothesize that pathogenic ARS variants will segregate with disease in 
pedigrees, be absent or present at very low frequency in the general population, affect highly 
conserved amino acid residues, and demonstrate loss-of-function characteristics in yeast 
complementation assays.  
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A subset of data in this chapter was previously published in Cell Reports, Brain, and Neurology 
(Gonzaga-Jauregui et al. 2015; Motley et al. 2015; Safka Brozkova et al. 2015). Permission was 
requested to reproduce figures. The author performed all the studies in this chapter with the 
following exceptions: (1) Clinical collaborators collected the phenotypic data and performed 
sequencing and segregation studies for the mutations presented; (2) Haploid ΔALA1 and ΔHTS1 
yeast strains were generated by Heather McLaughlin (McLaughlin et al. 2011) and Aimee Vester 
(Vester et al. 2012), respectively; and (4) The University of Michigan Sequencing core 
performed the DNA sequencing reactions described in this work.   
MATERIALS AND METHODS 
Patient sample collection, identification of ARS mutations, and linkage studies 
Clinical collaborators performed the clinical evaluation, classified patient phenotypes based on 
clinical exam findings, and collected DNA samples with patient consent as per the Institutional 
Review Board protocols from the participating institutions. YARS and HARS variants were 
identified via whole exome sequencing. AARS variants were identified upon candidate gene 
sequencing of disease-associated ARS loci. Genetic studies were performed to determine 
segregation.  Each identified ARS mutation was assessed for its presence in the general 
population via database searches of the Exome Variant Server (snp.gs.washington.edu/EVS), the 
1000 Genomes Project database (www.1000genomes.org), and dbSNP 
(www.ncbi.nlm.nih.gov/snp). Conservation of the affected amino acid residues was determined 
by comparison of evolutionarily divergent species using ClustalW2 (Larkin et al. 2007).  
Generation of yeast ARS expression constructs and haploid yeast strains  
PCR primers were designed to amplify the orthologous S. cerevisiae ARS locus (Table 3.1) 
including the endogenous promoter from yeast genomic DNA.  Gateway (Invitrogen) cloning 
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sequences (attB1 (forward) and attB2 (reverse); primer sequences in Appendix A) were included 
to facilitate recombination into the pDONR221 vector. Subsequent to PCR, BP Clonase 
(Invitrogen) reactions were employed to clone the wild-type ARS locus into pDONR221 and 
resulting colonies were fully sequenced to rule out PCR-induced errors. Next, mutation-
containing oligonucleotides (primer sequences in Appendix A) were employed to model the 
human mutations at the corresponding residue in the orthologous yeast gene (Table 3.1). The 
QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene) was used to mutate each locus in 
the pDONR221 entry construct. Resulting clones were purified and sequenced to confirm 
successful mutagenesis and rule out PCR-induced errors. The wild-type and mutant 
ARS/pDONR221 entry clones were subsequently recombined into a Gateway-compatible URA3-
bearing pRS316 or LEU2-bearing pRS315 destination vector using LR Clonase (Invitrogen). 
Resulting clones were purified and digested with BsrGI (New England Biosystems) to confirm 
successful recombination.  
Commercially available diploid heterozygous yeast strains were purchased for each ARS 
ortholog of interest (Open Biosystems). The strains utilized were: (1) YARS: diploid 
heterozygous ΔTYS1 yeast strain (MATa/α, his3Δ1/ his3Δ1, leu2Δ0/ leu2Δ0, met15Δ0/ MET15, 
ura3Δ0/ ura3Δ0); (2) AARS: diploid heterozygous ΔALA1 yeast strain (MATa/α, his3Δ1/ his3Δ1, 
leu2Δ0/ leu2Δ0, met15Δ0/ MET15, ura3Δ0/ ura3Δ0) (McLaughlin et al. 2011); and (3) HARS: 
diploid heterozygous ΔHTS1 yeast strain (MATa/α, his3Δ1/ his3Δ1, leu2Δ0/ leu2Δ0, met15Δ0/ 
MET15, ura3Δ0/ ura3Δ0) (Vester et al. 2012). Each strain was transformed with a URA3-bearing 
pRS316 vector containing the wild-type ARS locus (see above). Lithium acetate yeast 
transformations were performed at 30°C using 200 ng of plasmid DNA. Transformed yeast were 
grown on yeast media lacking uracil. Resulting haploid yeast containing the wild-type pRS316 
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maintenance vector were treated to induce sporulation. Briefly, the diploid strain was patched 
twice onto GNA presporulation plates (5% D-glucose [Fisher Scientific], 3% nutrient broth 
[Becton, Dickinson and Company], 1% yeast extract [Acros Organics], and 2% agar [Teknova]). 
One microliter of cells was then transferred into 2 ml of supplemented liquid sporulation medium 
(1% potassium acetate [Fisher Scientific], 0.005% zinc acetate [Fisher Scientific], 1X ura 
supplement, 1X his supplement, and 1X leu supplement) and incubated for 5 days at 25°C 
followed by 3 days at 30°C. Sporulated yeast were dissected using a MSM 400 dissection 
microscope (Singer Instruments) and plated on yeast extract, peptone, and dextrose (YPD) plates 
(Becton, Dickinson and Company). Resulting spores were individually patched onto solid 
growth medium containing Geneticin (G418) or 0.1% 5-fluoroorotic acid (5-FOA), or media 
lacking uracil (Teknova, Hollister, CA). Two spores that grew on G418 and yeast medium 
lacking uracil, but failed to grow on 5-FOA medium, were selected for use in the yeast viability 
assays.  
Yeast complementation assays 
 
Two haploid ΔARS strains [harboring a maintenance vector to express wild-type ARS and 
URA3] per locus were then transformed with an empty vector (‘Empty pRS315’ in figures) or the 
appropriate wild-type or mutant ARS in a LEU2-bearing pRS315 vector and selected on medium 
lacking uracil and leucine (Teknova). For each transformation, at least two independent pRS315 
plasmid preparations were used and at least two colonies from each plasmid were selected for 
additional analysis and grown to saturation for 2 days at 37°C in liquid media lacking uracil and 
leucine. A 10 μl aliquot of each culture was spotted undiluted or diluted 1:10 or 1:100 in H2O 
onto plates containing 0.1% 5-FOA (Teknova) or medium lacking uracil and leucine and 
incubated at 30°C for 48-72 hours. Survival was determined by visual inspection of growth. 
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Table 3.1. Human and yeast orthologous ARS locus 
Human ARS
 
 Yeast ARS
 
 
AARS
 
ALA1 
HARS HTS1 
YARS TYS1 
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Yeast growth curves 
 
Growth curve assays were performed on pseudo-heterozygous yeast containing both wild-type 
TYS1 on the URA3-bearing maintenance vector and wild-type, G41R, or E196Q TYS1 or empty 
LEU2-bearing vector (see above). Three yeast colonies from each transformation were selected 
for growth curves. Yeast were grown to saturation for 2 days at 30°C in liquid media lacking 
uracil and leucine. Saturated cultures were diluted to an OD600 = 0.200 +/- 0.015 based on OD600 
readings recorded on the Absorbance module E7061 on the Glomax®-Multi Microplate 
Multimode Reader Detection System (Promega, Madison, WI).  20 μl of OD600 = 0.2 +/- 0.015 
cultures was added to 4 mL of media lacking uracil and leucine or media contain 0.1% 5-FOA 
(Teknova) and incubated at 30°C shaking. The average OD600 reading from the three biological 
replicate cultures for each strain were used to generate the growth curves based on the average 
OD600 measurements at the indicated time points. Error bars represent standard deviation. 
Growth curves were performed twice on yeast generated from independent transformations.  
RESULTS 
Identification and functional characterization of ARS variants 
 
High-throughput sequencing of DNA from patients with dominant peripheral neuropathy is 
rapidly identifying variants in ARS genes. Recently, novel variants in YARS, AARS, and HARS 
were identified; however these variants remained classified as variants of unknown significance 
until genetic and functional studies were performed to assess their role in disease pathogenesis.  
YARS mutation identified in a family with DI-CMT.  
 
E196Q [c.568G>C; p.Glu196Gln] YARS segregates in a three-generation family affected by 
autosomal dominant intermediate CMT (DI-CMT; CMTDIC; MIM #608323) (Figure 3.1A). 
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Figure 3.1. Segregation and conservation of E196Q YARS. (A) Pedigree of a the family 
affected with dominant intermediate CMT disease is depicted. All three affected family members 
available for genetic testing carry the E196Q YARS variant. Traces from Sanger sequencing 
confirm the presence of E196Q YARS mutation in affected individuals. Empty symbols indicate 
unaffected individuals and filled symbols indicate affected individuals. (B) The YARS protein 
sequence fragment surrounding residue E196 is aligned using multiple, evolutionarily diverse 
species. The amino acid change is listed at the top. The affected amino acid is in bold, red text.  
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E196Q YARS affects a residue in the catalytic domain of YARS that is conserved between 
human and yeast (Figure 3.1B) and was not identified in any general population databases.  
E196Q YARS demonstrates decreased function in yeast.  
 
Two alleles, G41R and E196K YARS, were previously associated with DI-CMT and were 
characterized using biochemical and yeast complementation assays as a functionally null and 
hypomorphic allele, respectively (Jordanova et al. 2006). The newly identified mutation reported 
here, E196Q YARS, affects the same residue as E196K YARS. To determine the effects of E196Q 
YARS in vivo, we developed a haploid ΔTYSI (the yeast ortholog of YARS) yeast strain bearing a 
URA3-maintenance vector containing wild-type TYS1 to use in yeast complementation assays. 
We modeled G41R, E196K, and E196Q YARS mutations in the corresponding orthologous 
residues in TYS1 (Table 3.2) in a LEU2-bearing vector and transformed yeast with wild-type or 
mutant TYS1 or an empty vector control. Our results indicate that the G41R variant is a loss-of-
function allele, as previously shown (Jordanova et al. 2006), while both variants affecting E196, 
the previously reported E196K and our newly identified E196Q variant, are hypomorphic alleles 
(Figure 3.2). Specifically, the G41R allele is unable to complement loss of endogenous TYS1, 
similar to what is observed for yeast transformed with an empty vector (‘Empty pRS315’) 
(Figure 3.2). Furthermore, compared to yeast expressing wild-type TYS1, expression of E196K 
and E196Q TYS1 are unable to fully complement deletion of TYS1, resulting in a reduction but 
not complete abrogation of cell growth. E196Q expressing yeast grew less robustly than E196K 
expressing yeast (Figure 3.2). These data indicate that E196K and E196Q are both hypomorphic 
alleles and are consistent with the previous functional characterization of E196K (Jordanova et 
al. 2006). To further quantify the decreased growth observed for yeast expressing E196Q TYS1, 
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Table 3.2. Human YARS Variants Modeled in the Yeast Ortholog TYS1 
 
Human YARSa
 
 Yeast TYS1b
 
 
G41R
 
G45R 
E196K E200K 
E196K E200Q 
aAmino-acid coordinates correspond to GenBank accession number AAH16689.1. 
bAmino-acid coordinates correspond to GenBank accession number AAB59329.1. 
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Figure 3.2. Yeast complementation assay for E196Q TYS1. A haploid yeast strain with a 
deletion of TYS1 and bearing a URA3 maintenance vector was transformed with a LEU2-bearing 
pRS315 vector containing wild-type TYS1, the indicated mutant form of TYS1, or no insert 
(‘Empty pRS315’) (labeled along the top). Cultures for each strain were grown for 2 days and 
plated on medium containing 5-FOA to determine if the TYS1 alleles complement loss of 
endogenous TYS1 or on –leu -ura medium as a positive growth control. Two independently 
generated constructs (indicated as ‘A’ and ‘B’ across the top) were evaluated for each mutation. 
Note the severe reduction of growth for E196K and E196Q at 1:10 and 1:100 dilutions.  
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growth curve assays were performed in liquid 5-FOA selective media comparing wild-type, 
G41R, and E196Q TYS1 and empty vector containing strains. Growth curves of yeast expressing 
G41R TYS1 did not grow in liquid 5-FOA media, consistent with the G41R TYS1 yeast 
phenotype observed on solid media (Figure 3.3). Yeast carrying the E196Q TYS1 allele 
demonstrated slower growth than wild-type TYS1, with a delay of ~15 hours between the mid-
log phase of wild-type and E196Q yeast strains (Figure 3.3). These studies indicate that E196Q 
YARS is a functional hypomorph and, in conjunction with the segregation studies, supports a 
pathogenic role for E196Q YARS in DI-CMT disease. 
AARS mutation identified in a family with myeloneuropathy. 
 
Four siblings with clinical and electrophysiologic evidence of mild, inherited peripheral 
neuropathy were found to be heterozygous for the missense mutation G102R [c.304G>C; 
p.Gly102Arg] AARS (Figure 3.4A and B). Interestingly, 3 of 4 siblings had lower extremity 
hyperreflexia indicative of myelopathy, a neurologic deficit involving the spinal cord. A sural 
nerve biopsy from one sibling demonstrated evidence of chronic axonal loss. Importantly, the 
G102R AARS allele was not identified in control patients or in general population databases. 
G102R AARS is located in the activation domain of the AARS enzyme and is conserved from 
human to bacteria (Figure 3.4C).  
G102R AARS does not complement in yeast.  
 
To determine if G102R AARS alters the function of the AARS protein, we employed a yeast 
complementation assay previously used to assess the activity of CMT-associated R329H and 
N71Y AARS mutations (McLaughlin et al. 2011). Using this assay, we modeled G102R and 
R329H AARS in the yeast ortholog ALA1 (Table 3.3) and transformed the ΔALA1 yeast strain, 
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Figure 3.3. Growth curves of yeast expressing E196Q TYS1. Pseudo-heterozygous yeast carry 
both the wild-type TYS1 gene on a URA3-bearing vector and wild-type, G41R, or E196Q TYS1 
or an empty LEU2-bearing vector were normalized and grown at 30°C in 0.1% FOA liquid 
media to select for loss of the URA3 maintenance vector (Boeke et al. 1987). Growth was 
assessed via OD600 absorbance readings measured at indicated time points. Each time point 
represents the average of three biological replicates. Error bars indicate standard deviation. Note 
the ~15 hour lag between mid-log phase for yeast carrying E196Q TYS1 compared to yeast 
carrying the wild-type TYS1 allele. 
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Figure 3.4. Segregation and conservation of G102R AARS. (A) Pedigree of a family with 
myeloneuropathy. All four affected siblings are heterozygous for G102R AARS, as indicated 
by the red base below their respective symbol. Empty symbols indicate unaffected 
individuals and filled symbols indicate affected individuals. (B) Representative traces from 
Sanger sequencing confirm the presence of G102R AARS in an affected individual (II.5) and 
the absence of the mutation in her unaffected sister (II-1). (C) A fragment of the activation 
domain sequence that contains G102 (red, bold text) is aligned in divergent species.  
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Table 3.3. Human AARS Variants Modeled in the Yeast Ortholog ALA1 
Human AARSa
 
 Yeast HTS1b
 
 
G102R
 
G106R 
R329H R329H 
aAmino-acid coordinates correspond to GenBank accession number BAA06808.1. 
bAmino-acid coordinates correspond to GenBank accession number EDV1089. 
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which has the endogenous ALA1 gene deleted and a vector that expresses wild-type ALA1 and 
URA3 to maintain viability, with a LEU2-bearing vector containing either wild-type, G102R, or 
R329H ALA1 or no insert (‘Empty pRS315’). When plated on selection media containing 5-FOA 
to select for yeast that have spontaneously lost the maintenance vector (Boeke et al. 1987), the 
wild-type ALA1 expression vector sustained yeast viability, while the empty vector was unable to 
complement the knockout allele, consistent with ALA1 being an essential gene (Figure 3.5). 
Yeast expressing G102R or R329H ALA1 were unable to survive on 5-FOA media (Figure 3.5). 
These results illustrate that G102R ALA1 is unable to complement loss of endogenous ALA1 and 
suggests that G102R AARS is a loss-of-function AARS allele.  
HARS mutations were identified in seven families with peripheral neuropathy. 
 
Genetic studies have identified seven HARS mutations that each segregate in seven unrelated 
families with dominantly inherited peripheral neuropathy. T132I [c.395C>T; p.Thr132Ile] HARS 
was identified in a German family (Figure 3.6, Family A) with phenotypic and 
electrophysiological characteristics consistent with axonal neuropathy. Interestingly, this 
mutation affects the same amino acid residue as a rare single nucleotide polymorphism (SNP), 
T132S HARS (rs143473232). T132S is present in 1/13,006 alleles surveyed in the Exome 
Variant Server (EVS).  A Moroccan family (Figure 3.6, Family B) was diagnosed with 
intermediate CMT due to MNCVs that correspond to axonal CMT, demyelinating CMT, or both 
axonal and demyelinating CMT disease in individual family members. All affected individuals, 
regardless of the type of CMT disease indicated by electrophysiologic studies, were found to be 
heterozygous for the same HARS variant, P134H [c.401C>A; p.Pro134His]. Two additional 
mutations, D175E [c.525T>G; p.Asp175Glu] HARS and D364Y [c.1090G>T; p.Asp364Tyr] 
HARS were identified in a Czech-Belgian (Figure 3.6; Family C) and Belgian family (Figure 3.6; 
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Figure 3.5. Yeast complementation assays for G102R ALA1. Haploid ΔALA1 yeast strains were 
transformed with a vector containing no insert (pRS315 Empty) or an insert to express wild-type, 
G102R or R329H ALA1 (labeled across the top panel). Cultures resulting from each transformation 
condition are spotted undiluted and diluted (1:10 and 1:100) on plates containing 5-FOA complete 
medium or SD -leu -ura growth medium. Experiments were performed using two independently 
generated ALA1 expression constructs (labeled A and B) for G102R.  
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Figure 3.6. Segregation of HARS mutations in families with peripheral neuropathy. The mutation identified in each family is listed above 
the corresponding pedigree. Circles indicate female family members, while male family members are represented in squares. Empty 
symbols represent unaffected individuals, while filled symbols indicate affected individuals. Generations are indicated in Roman 
numerals. Arabic numerals are used to identify each genotyped family member. In all pedigrees, the mutation of interest was identified in 
all affected members and was absent in unaffected individuals.  
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Family D), respectively, each with family history and electrophysiologic studies consistent with 
dominantly inherited axonal CMT disease. V155G [c.464A>C is p.Val155Gly] HARS was 
identified in five affected individuals in a three generation family with a pure motor neuropathy 
and evidence of myelopathy (pedigree structure currently unavailable). Y330C [c.989A>G is 
p.Tyr330Cys] HARS was identified in a mother-son pair with sensory and motor neuropathy with 
normal MNCVs and decreased amplitudes consistent with a diagnosis of axonal CMT disease. 
Finally, S356N [c.1067G>U is p.Ser356Asn] HARS was identified in a woman with peripheral 
neuropathy and her mother who is unaffected, indicating a potential for incomplete penetrance in 
this family. All seven affected residues are conserved between human and yeast, with Y330C 
and D364Y being conserved to bacteria (Figure 3.7).  
The majority of disease-associated HARS mutations demonstrate loss of function in yeast.  
 
As a pattern of loss-of-function characteristics is becoming increasingly evident for CMT-
associated ARS mutations (Wallen and Antonellis 2013). Yeast complementation assays can be 
applied to functionally assess variants of unknown significance in ARS genes not previously 
implicated in disease to determine if these variants demonstrate characteristics consistent with 
disease-associated alleles. This approach was used to study R137Q HARS, a variant that was 
identified in a patient with sporadic axonal CMT and demonstrated loss-of-function similar to 
other CMT-associated ARS alleles (Vester et al. 2012). To test the functional consequences of 
the seven conserved HARS missense variants identified in the families described above, we 
modeled these missense variants in the yeast ortholog HTS1 (Table 3.4). Additionally, we 
modeled the rare variant T132S HARS, which is listed in dbSNP but has no known association 
with peripheral neuropathy. This variant affects the same residue as T132I HARS that was 
identified in this study. We independently tested each mutation for the ability to support yeast 
 106 
 
Figure 3.7. Conservation of HARS mutations. Protein sequence fragments from multiple, 
evolutionarily diverse species were aligned to assess for conservation of the amino acid residues 
affected by HARS mutations. The amino acid alteration is listed above the protein fragment. The 
affected amino acid is in bold, red text.   
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Table 3.4. Human HARS Variants Modeled in the Yeast Ortholog HTS1 
Human HARSa Yeast HTS1b 
T132I 
T132S 
T131I 
T131S 
P134H 
V155G 
D175E 
Y330C 
P133H 
V154G 
D174E 
Y330C 
S356N 
D364Y 
S370N 
D378Y 
aAmino acid coordinates correspond to GenBank accession number NP_002100.2. 
bAmino acid coordinates correspond to GenBank accession number AAA34696.1. 
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cell growth compared to wild-type HTS1 or an empty vector. Briefly, a haploid yeast strain (with 
the endogenous HTS1 locus deleted and a maintenance vector to express wild-type HTS1 and 
URA3) was transformed with either a pRS315 vector with no insert (‘Empty pRS315’) or a 
pRS315 vector harboring wild-type, T132I, T132S, P134H, D175E, D364Y, V155G, Y330C, or 
S356N HTS1. Yeast cells were then selected on media containing 5-FOA, which is toxic to yeast 
carrying the URA3-bearing maintenance vector (Boeke et al. 1987). Thus, only yeast cells 
expressing a functional HTS1 allele from the pRS315 vector will grow in this assay.  
Yeast transformed with a wild-type HTS1 expression vector demonstrated significant growth, 
while those transformed with an empty vector did not (Figure 3.8; Figure 3.9), consistent with 
HTS1 being an essential gene (Vester et al. 2012). Regarding the newly identified HARS 
mutations described here, yeast expressing T132I, P134H, D175E, or D364Y HTS1 were unable 
to grow on 5-FOA media (Figure 3.8) indicating that these are complete loss-of-function alleles. 
Yeast expressing Y330C or S356N HTS1 had a pronounced decrease, but not complete 
abrogation, of growth at 1:10 and 1:100 dilutions compared to wild-type HTS1 (Figure 3.9), 
indicating that these are partial loss-of-function alleles. In contrast, V155G HTS1 was able to 
support yeast cell growth to levels comparable to wild-type HTS1 (Figure 3.9). Finally, unlike 
the disease-associated variant T132I, the rare variant T132S HTS1 supported yeast growth to the 
same extent as wild-type HTS1 (Figure 3.8) indicating that this variant has no significant effect 
on HARS activity in yeast. With the exception of V155G HARS, these data suggest that all HARS 
variants that segregate with disease are loss-of-function mutations.  
DISCUSSION 
 
This chapter describes the identification and functional characterization of YARS, AARS, and 
HARS mutations identified in patients with in peripheral neuropathy. The genetic and functional 
 109 
 
 
 
Figure 3.8. Yeast complementation assay of HTS1 variants. Haploid ΔHTS1 yeast strains were transformed with a vector 
containing no insert (pRS315 Empty) or an insert to express wild-type, T132I, T132S, P134H, D175E, or D364Y HTS1. Two 
colonies (indicated by ‘A’ and ‘B’) from transformations with T132I, T132S, P134H, D175E, or D364Y HTS1 are shown. 
Resulting colonies (undiluted, diluted 1:10, or diluted 1:100) were grown on agar plates containing 0.1% 5-FOA. Note the 
wild-type level of growth associated with the non-disease associated allele T132S HTS1 (green). 
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Figure 3.9. Yeast complementation assay of HTS1 variants. Haploid ΔHTS1 yeast strains were 
transformed with a vector containing no insert (pRS315 Empty) or an insert to express wild-
type, V155G, Y330C, or S356N HTS1. Two colonies (indicated by ‘A’ and ‘B’) from 
transformations with V155G, Y330C, or S356N HTS1 are shown. Resulting colonies 
(undiluted, diluted 1:10, or diluted 1:100) were grown on agar plates containing 0.1% 5-FOA or 
media lacking uracil and leucine. Note the severe depletion of growth associated with Y330C 
and S356N HTS1 at 1:10 and 1:100 dilutions.  
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data presented here implicate nine previously unreported variants in CMT disease. The majority 
of tested variants demonstrate characteristics typical of disease-associated ARS alleles, 
specifically conservation between diverse species and loss-of-function in yeast complementation 
assays. Specifically, genetic data suggest that E196Q YARS results in DI-CMT, while G102R 
AARS causes axonal myeloneuropathy. Importantly, the identification of multiple HARS variants 
that segregate in families with a spectrum of neuropathy phenotypes, including axonal and 
intermediate forms of CMT disease, provides the necessary genetic evidence to fully implicate 
HARS as a CMT-associated locus. Taken together, we conclude that loss-of-function is a 
common characteristic of disease-associated ARS mutations and an important component of 
ARS-mediated peripheral neuropathy.  
The number of ARS mutations being identified in individuals with peripheral neuropathy has 
increased rapidly over the past few years. In this chapter alone, we have described and 
functionally characterized nine newly identified mutations in YARS, AARS, and HARS mutations. 
The identification of new variants provides the unique opportunity to understand both the clinical 
and allelic heterogeneity associated with ARS mutations. The clinical heterogeneity of ARS 
mutations is only beginning to be appreciated. The first mutations in GARS were identified by 
pooling linkage data from five families who suffered from upper limb predominant peripheral 
neuropathy (Antonellis et al. 2006); however, phenotypes in these families varied and included 
both motor and sensory (CMT2D) and exclusively motor (dSMA-V) disease. In contrast, YARS 
and AARS mutations have only been implicated in lower limb predominant motor and sensory 
peripheral neuropathy (Jordanova et al. 2006; Latour et al. 2010). While the only phenotype 
reported for YARS mutations, including E196Q described here, remains DI-CMT, this study 
expands the phenotypic spectrum observed for AARS mutations. R329H and N71Y AARS were 
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previously implicated in CMT2N, an axonal CMT phenotype (Latour et al. 2010; Lin et al. 2011; 
McLaughlin et al. 2011).  Although evidence of myelopathy was reported in two families with 
GARS mutations (Sivakumar et al. 2005), the G102R AARS mutation represents the first example 
of myelopathy associated with an AARS mutation. Studies at other CMT-associated loci have 
demonstrated that identical coding mutations can result in variable phenotypes (Thomas et al. 
1997). In the studies described here, we observed variable phenotypes for individuals 
heterozygous for G102R AARS (i.e. neuropathy versus myeloneuropathy), as well as in family 
members carrying P134H HARS (i.e. axonal versus demyelinating versus intermediate CMT 
disease). This further illustrates the observation that members of the same family who carry an 
identical coding mutation can be differently affected in regards to age of onset, inclusion of 
upper motor neuron defects, and axonal versus demyelinating electrophysiologic findings, to 
name a few examples (Thomas et al. 1997).  These variations may be due to genetic modifiers or 
environmental exposures that vary between individuals and may be interesting avenues for future 
studies.  
Expanding the allelic heterogeneity of ARS alleles through the identification of new ARS 
variants, both rare variants associated with disease and those in the general population, provides 
opportunities to identify distinguishing characteristics of disease-associated mutations. 
Cataloging the functional consequences will not only provide a pipeline for characterization of 
variants of unknown significance, but also will provide insight into the mechanism of CMT 
disease. In this chapter, we have shown that eight of nine disease-segregating mutations 
described here result in loss-of-function in yeast complementation studies, demonstrating the 
utility of the yeast assay in predicting pathogenicity. Interestingly, in silico prediction programs 
classified both T132I (the disease-associated allele) and T132S HARS (an allele with no known 
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role in disease) as pathogenic variants. When modeled in yeast, however, the disease-associated 
allele T132I HTS1 does not support yeast viability, while the T132S variant supports growth to 
wild-type levels. This illustrates that the yeast assay may be sensitive enough to distinguish 
between pathogenic and non-pathogenic amino acid changes at the same residue in some cases. 
In addition we were able to ascertain subtle differences in activity between variants that affect 
E196 YARS. Our results indicate that alteration of this glutamate residue to either lysine or 
glutamine results in generation of a hypomorphic allele; however, E196K appears to retain 
slightly more activity than E196Q when comparing yeast growth. While currently no correlation 
has been made between disease severity and aminoacylation activity of ARS variants, further 
study into the kinetic differences of these two variants may provide important insights into the 
structure-function relationship of YARS.  
Yeast complementation studies allow for in vivo assessment of ARS function. All mutations that 
demonstrate loss-of-function in yeast also demonstrate dramatic reduction in aminoacylation 
assays in vitro (Wallen and Antonellis 2013). Although the majority of disease-associated 
variants demonstrate loss of function in yeast, some disease-associated variants and all non-
pathogenic variants tested to date can complement in this assay (McLaughlin et al. 2011). Thus 
growth cannot be used to rule out the pathogenicity of a variant. As performed presently, yeast 
complementation assays utilize the yeast ortholog, not the human protein, to model mutations. In 
contrast, the aminoacylation assay tests the human enzyme. Thus, it is important to further 
characterize mutations that grow in yeast using aminoacylation studies to determine if they result 
in a defect in tRNA charging that is not appreciated when modeled in yeast. Of the mutations 
studied in this chapter, only two variants, V155G and T132S HARS, supported yeast cell growth. 
Aminoacylation assays are the logical next step to completing the functional assessment for these 
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variants. In fact, evaluation of V155G HARS was recently performed and demonstrated impaired 
tRNA charging compared to wild-type HARS (Chris Franklyn, University of Vermont, personal 
communication). This datum classifies V155G HARS as a loss-of-function mutation and 
indicates V155G is likely pathogenic.  
Previously, R137Q HARS was shown to result in abnormalities of the nervous system when 
overexpressed in C. elegans GABA neurons, indicating dominant toxicity for this allele (Vester 
et al. 2012). Asim Beg at the University of Michigan assessed the D367Y HARS variant 
described in this chapter for dominant toxicity in worm. Similar to R137Q, D367Y HARS 
overexpression resulted in a dramatic effect on GABA neuron morphology. Worms expressing 
the D367Y HARS allele showed dorsal and ventral nerve gaps, axonal blebbing, and severely 
aberrant axonal processes. Thus D367Y HARS was deemed to be dominantly toxic in this model, 
consistent with the inheritance pattern observed for the D367Y HARS-associated peripheral 
neuropathy. This model system should be applied to test the dominant pathogenicity of mutations 
presented in this chapter that have weak or no genetic evidence for their role in dominant 
disease. Specifically, assessing for dominant toxicity is necessary before implicating V155G and 
S356N HARS mutations in dominantly inherited CMT disease and prior to classifying the T132S 
HARS variant as non-pathogenic. 
The identification of novel disease associated ARS alleles in this chapter not only provides the 
necessary evidence to implicate the HARS locus in CMT disease, but also expanded our 
understanding of the clinical and allelic heterogeneity resulting from ARS mutations. These data 
illustrate a role for loss of ARS function in the pathomechanism of YARS, AARS, and HARS-
mediated CMT disease. This indicates that a common pathogenic mechanism is likely in all 
ARS-mediated CMT disease. Future work, both included in this thesis (see Chapters 5 and 6) 
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and studies to be subsequently performed, should now focus on elucidating the pathomechanism 
of ARS-mediated CMT so that we may develop appropriate therapies to treat patients in the 
future.
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CHAPTER 4 
Impaired function is a common characteristic of previously 
identified GARS mutations 
INTRODUCTION 
Functional studies performed on a subset of CMT-associated ARS mutations have revealed loss-
of-function characteristics (Antonellis et al. 2006; Chihara et al. 2007; Nangle et al. 2007; Xie et 
al. 2007; Stum et al. 2011). As discussed in chapter 3, all of the YARS, AARS, and HARS 
mutations tested to date cause a severe decrease in enzyme activity and/or demonstrate an 
inability to rescue deletion of the endogenous ARS gene in yeast complementation assays 
(Jordanova et al. 2006; McLaughlin et al. 2011; Vester et al. 2012; Gonzaga-Jauregui et al. 2015; 
Motley et al. 2015; Safka Brozkova et al. 2015). However, the majority of CMT-associated ARS 
mutations have been identified in GARS, and there are conflicting data regarding the presence or 
absence of loss-of-function characteristics of these alleles (Wallen and Antonellis 2013).  
The functional consequences of human GARS mutations have been assessed in aminoacylation 
assays, yeast and fly complementation assays, and localization studies in cultured neurons. While 
many of the mutations demonstrate a loss-of-function effect in at least one of these assays 
(Antonellis et al. 2006; Chihara et al. 2007; Nangle et al. 2007; Xie et al. 2007; Stum et al. 
2011), nine of the thirteen identified GARS mutations have not been rigorously tested (see Table 
1.4) (Wallen and Antonellis 2013). Indeed, this includes five mutations (A57V, D146N, S211F, 
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P244L, and I280F) (Lee et al. 2004; James et al. 2006; Rohkamm et al. 2007; Abe and Hayasaka 
2009) that have not been evaluated in any assay. Characterizing the full panel of GARS mutations 
will be necessary to determine whether a loss-of-function mechanism is a component of CMT2D 
and dSMA-V. These data will be critical for a better understanding of the molecular pathology of 
ARS mutations and for developing effective therapies for patients with ARS-related CMT 
disease.  
This chapter focuses on the genetic, enzyme kinetic, yeast complementation, and protein 
localization studies that elucidate the functional consequences of CMT-associated GARS 
mutations. Consistent with studies on YARS, AARS, and HARS mutations, we hypothesize that 
disease-associated GARS mutations will demonstrate loss-of-function characteristics in at least 
one assay, while non-pathogenic variants will show wild-type activity in all assays.  
The data presented in this chapter were previously published in Human Mutation (Griffin et al. 
2014). Permission was requested to reproduce figures and tables. The author performed all the 
studies in this chapter with the following exceptions: (1) Aminoacylation studies were performed 
by Reiko Sakaguchi and Ya-Ming Hou at Thomas Jefferson University; (2) The identification of 
the S581L GARS mutation in two unrelated probands was performed by Michael Gonzalez and 
Stephan Zuchner at the University of Miami and Charles Searby at the University of Iowa; (3) 
Sequencing reactions were performed at the University of Michigan Sequencing Core.  
MATERIALS AND METHODS 
Computational assessment of GARS mutations  
 
GARS protein sequences were collected from the NCBI Protein Database 
(http://www.ncbi.nlm.nih.gov/protein/) for the indicated species using the following accession 
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numbers: human (Homo sapiens, accession number AAA57001.1), mouse (Mus musculus, 
accession number AAH21747.1), zebrafish (Danio rerio, accession number XP 692410.4), 
roundworm (Caenorhabditis elegans, accession number NP 498093.1), and baker’s yeast 
(Saccharomyces cerevisiae, accession number NP 009679.2). Multiple species amino acid 
sequence alignments were then generated using ClustalW2 software (Larkin et al. 2007).  
GARS and GRS1 expression constructs  
 
DNA constructs for aminoacylation, yeast complementation, and localization studies were 
generated using Gateway cloning technology (Invitrogen, Carlsberg, CA). Briefly, the human 
GARS open reading frame was amplified from a human cDNA sample, and the S. cerevisiae 
GRS1 locus was amplified from S. cerevisiae genomic DNA. Primers were designed with 
flanking Gateway sequences attB1 (forward) and attB2 (reverse; primer sequences in Appendix 
A). Entry clones were generated by recombining PCR-purified amplicons into the pDONR221 
vector using BP clonase per manufacturer’s specifications. After transformation into E. coli, 
DNA from individual entry clones was isolated and subjected for DNA sequencing analysis to 
confirm the presence of the appropriate wild-type gene. For each mutation studied here, 
mutation-containing oligonucleotides were generated, and the QuickChange II XL Site-Directed 
Mutagenesis Kit (Stratagene, Santa Clara, CA) was used as per the manufacturer’s instructions. 
After transformation into E. coli, DNA from individual clones was purified and sequenced to 
confirm the presence of each mutation and the absence of any cycle-induced errors. 
Subsequently, validated entry clones were purified and recombined into the appropriate 
Gateway-compatible vector using LR clonase and the manufacturer’s specifications. The vectors 
included pET-21a(+) (aminoacylation assays), pEGFP-N2 (for expressing GARS with a C-
terminal EGFP tag), and pRS315 (yeast complementation assays). DNA from the resulting 
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expression constructs was purified and digested with the restriction enzyme BsrGI (New England 
Biosystems, Ipswich, MA) to confirm the presence of the appropriate insert.  
Aminoacylation assays  
 
Wild-type and mutant human GARS proteins were expressed in E. coli Rosetta 2 (DE3) pLys 
cells with a C-terminal in-frame 6xHis tag and purified with nickel affinity resin according to the 
manufacturer’s protocol (Novagen, Rockland, MA). The T7 transcript of human tRNAGly/UCU 
(UCU, anticodon) was prepared and purified as previously described (Hou et al. 1993), heat 
denatured at 85°C for 3 min, and annealed at 37°C for 20 min before use. Steady-state 
aminoacylation assays were monitored at 37°C in 50 mM HEPES (pH 7.5), 20 mM KCl, 10 mM 
MgCl2, 4 mM DTT, 2 mM ATP, and 50 mM 
3H-glycine (Perkin Elmer, Waltham, MA) at a 
specific activity of 16,500 dpm/pmole. The reaction was initiated by mixing GARS enzyme (20–
600 nM) with varying concentrations of tRNAGly/UCU (0.3–20 μM). Aliquots of a reaction 
mixture were spotted on filter paper, quenched with 5% trichloroacetic acid, washed, dried, and 
measured for radioactivity by a liquid scintillation counter (LS6000SC; Beckman Coulter Inc., 
Fullerton, CA). The amount of radioactivity retained on filter pads was corrected for quenching 
effects to determine the amount of Gly-tRNAGly present on the filter paper. Steady-state kinetics 
(Km and kcat) were determined by fitting the initial rate of aminoacylation as a function of tRNA 
concentration to the Michaelis–Menten equation (Schreier and Schimmel 1972).  
Yeast complementation assays  
The RJT3/II-1 haploid yeast strain [MATα grs1::HIS3, his3Δ200, leu2Δ1, lys2Δ202, trpΔ63, 
ura3–52, pTsscII-maint (cen, GRS1, URA3)] carrying a deleted endogenous GRS1 allele and 
wild-type GRS1 on a URA3-bearing pRS316 maintenance vector was previously generated 
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(Turner et al. 2000). The ΔGRSI haploid yeast strain was transformed with a 200 ng of LEU2-
bearing pRS315 vector containing wild-type or mutant GRS1 (described above) or pRS315 with 
no insert as previously reported (Antonellis et al. 2006). Each transformation was performed at 
least four times with at least three independent plasmid DNA preparations. Four colonies were 
selected from each transformation for additional analysis. Each colony was grown to saturation 
in media lacking leucine and uracil (-leu -ura) for 48 hours. Next, 10 μl of undiluted and diluted 
(1:10 and 1:100 in H2O) samples from each culture were spotted on plates containing 0.1% 5-
FOA (Boeke et al. 1987) complete medium, yeast extract– peptone–glycerol (YPG) plus 0.1% 5-
FOA medium, or SD -leu -ura growth medium (Teknova, Hollister, CA) and incubated at 30°C 
or 37°C for 72 hr. Yeast cell growth was determined by visual inspection.  
Cell culture and protein localization studies  
 
The mouse motor neuron, neuroblastoma fusion cell line (MN-1) (Salazar-Grueso et al. 1991) 
was cultured and transfected with constructs to express wild-type or mutant GARS in-frame with 
a C-terminal enhanced green fluorescent protein (EGFP) tag as previously described (Antonellis 
et al. 2006). Cells were counted using the Countess Automated Cell Counter (Invitrogen, 
Calsbad, CA) and ~1.25 X 105 of MN-1 cells were plated in each well of a 4-well polystyrene 
tissue culture treated glass slide (BD Biosystems, Sparks, MD). Slides were incubated overnight 
at 37°C in 5% CO2 in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% 
fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 50 µg/ml of streptomycin 
(Invitrogen, Carlsbad, CA). Each well was transfected using the lipofectamine 2000. 
Specifically, for each transfection reaction, 125 µl of OptiMEM I minimal growth medium and 
1.25 µl of Lipofectamine 2000 were mixed and incubated together for 10 min at room 
temperature. 1.5 µg of pEGFP-N2 plasmid was combined with 125 µl of OptiMEM I. 
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Subsequently, the Lipofectamine-OptiMEM I mixture was combined with the plasmid-
OptiMEM I solution to yield 250 µl of the final transfection solution and incubated at room 
temperature for 20 min. Each well of the 4-well slide was washed with 500 µl of 1X PBS. The 
entire transfection solution was then added directly to the flask and incubated at 37°C in 5% CO2 
for 4 hours. After 4 hours, the transfection solution was removed and replaced with 500 ml of 
complete DMEM media (described above). Cells were allowed to recover for 2 days at 37°C in 
5% CO2. After 48 hours, growth medium was removed, and cells were washed in 1× PBS and 
then incubated in 1× PBS/0.4% paraformaldehyde for 10 min at room temperature. Cells were 
washed in 1× PBS, co-stained with 300 nM DAPI for 5 min, washed again in 1× PBS, and 
finally coated with Pro-Long antifade reagent (Invitrogen). Images were obtained with an IX71 
Inverted Microscope using cellSens Standard image software (Olympus, Center Valley, PA).  
Population screening and segregation analysis  
 
The presence of each GARS variant in the general population was assessed using the Exome 
Variant Server (snp.gs.washington.edu/EVS), the 1000 Genomes Project database 
(www.1000genomes.org), and dbSNP (www.ncbi.nlm.nih.gov/snp). Additionally, a search of the 
GEM.app exome-sequencing database was performed for GARS variants in patients with CMT 
disease (genomics.med.miami.edu). For S581L GARS segregation studies, oligonucleotide 
primers were designed to amplify GARS exon 16, which harbors the second and third nucleotides 
of the serine 581 codon (primer sequences in Appendix A). Patient DNA samples were subjected 
to PCR amplification under standard conditions along with a “no DNA” PCR-negative control 
reaction. Subsequently, PCR products were purified on Mini Spin Columns (Epoch Life Science, 
Inc., Missouri City, TX), eluted, and then subjected to Sanger DNA sequencing analysis using 
the “forward” and “reverse” amplification primers in separate reactions. The appropriate review 
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boards of each participating institution approved these studies.  
RESULTS 
Localization and conservation of human GARS mutations  
GARS mutations found in patients with CMT disease are distributed throughout the primary 
structure of the protein (Antonellis et al. 2003). Notably, the mutations affect conserved residues, 
which are often conserved between human and yeast, suggesting a critical role in protein 
function (Antonellis et al. 2003). To determine if newly reported GARS mutations demonstrate a 
similar level of conservation, we mapped the residues onto the human protein and generated an 
alignment with evolutionarily diverse organisms (Figure 4.1A and B). Mutations were evenly 
distributed throughout the major functional domains of the protein (Xie et al. 2007) (Figure 
4.1A): (1) A57V affects a residue in the disordered WHEP-TRS domain (residues 13–63; 
pfam00458 in the NCBI Conserved Domain Database), which is putatively involved in tRNA 
binding and interacting with other aminoacyl-tRNA synthetases in enzyme complexes (Ray et al. 
2011), but is not critical for GARS function (Xie et al. 2007); (2) D146N, P244L, and I280F 
affect amino acids in the catalytic core (residues 92–168, 241–305, and 350-418; pfam 00587) 
responsible for ligation of the amino acid to tRNA; (3) S211F, H418R, and D500N affect amino 
acids within insertion domains of uncertain function; and (4) S581L and G598A reside in the 
anticodon-binding domain (residues 557–655; pfam03129) that binds to glycine-specific tRNAs.  
The evolutionary conservation of mutated GARS residues varies greatly (Figure 4.1B). D146, 
P244, I280, and H418 are identical from human and yeast, while S211 and G598 are conserved, 
but to a lesser degree (e.g., from human through worm). In contrast, A57 is conserved among 
mammals and worm, but not zebrafish, and D500 and S581 are conserved only among 
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Figure 4.1. Localization and conservation of GARS variants. (A) GARS mutations (top) are 
depicted on a cartoon of the known functional and structural domains of GARS including the 
WHEP-TRS domain (blue), catalytic domain (red), insertion domains (yellow) and anticodon-
binding domain (green). The amino-acid positions for each domain are indicated below the 
cartoon. (B) GARS protein sequence alignments from multiple, evolutionarily diverse species 
are depicted. The amino acid change is listed at the top of each protein fragment. The affected 
amino acid is highlighted in red, bold text. 
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vertebrates. Thus D146, S211, P244, I280, H418, and G598 are predicted to be critical for 
enzyme function, while A57, D500, and S581 are less likely to be essential for GARS activity. 
The majority of GARS mutations reduce aminoacylation activity. 
 
The primary function of ARS enzymes is to charge tRNA molecules with cognate amino acids 
(Delarue 1995) in a two-step aminoacylation reaction: (i) binding and activation of the amino  
acid with ATP and (ii) conjugation of the activated amino acid to the 3’ end of the appropriate 
tRNA (Antonellis and Green 2008). The aminoacylation assay evaluates the combined reactions 
of both steps and has been used to establish if CMT-associated ARS mutations disrupt this 
canonical function (Nangle et al. 2007; McLaughlin et al. 2010; Froelich and First 2011; 
McLaughlin et al. 2011). Here, we assessed previously untested GARS variants (A57V, D146N, 
S211F, P244L, I280F, H418R, and G598A) for the ability to charge human cytoplasmic tRNAGly 
with tritium-labeled glycine. For comparison purposes, we included two GARS mutations 
previously shown to impair enzyme kinetics: G240R and G526R (Nangle et al. 2007). With 
regard to the untested variants, D146N, S211F, P244L, I280F, H418R, and G598A GARS 
demonstrate less than 10% aminoacylation activity compared to wild-type GARS (Table 4.1). In 
contrast, A57V displayed the ability to charge tRNAGly molecules with a much higher efficiency 
than other mutant proteins, albeit with a 50% reduction relative to wild-type GARS. 
The majority of testable GARS mutations dramatically reduce yeast cell viability.  
 
Yeast complementation assays have been performed to determine the functional consequences of 
CMT-associated ARS mutations in the context of a living cell (Wallen and Antonellis 2013). 
Mutations are modeled in the S. cerevisiae GARS ortholog GRS1, and cellular growth is used as a 
proxy for enzyme function. This assay employs a haploid yeast strain with the endogenous GRS1 
locus deleted and viability maintained via expression of wild-type GRS1 on a URA3-bearing 
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Table 4.1. Aminoacylation kinetics of GARS protein variants 
 
Variant Km (μM) kcat (s-1) kcat/Km (μM-1s-1) Relative to WT 
Wild-type 1.03 ± 0.03 0.14 ± 0.02 0.14 ± 0.02 1 
A57V 0.92 ± 0.22 0.07 ± 0.01 0.07 ± 0.02 1 / 2 
D146N 0.6 ± 0.1 0.006 ± 0.002 0.01 ± 0.01 1 / 14 
S211F - - (3.2 ± 1.5) x 10-5 1 / 4,400 
G240R 3.2 ± 0.6 (4.2 ± 0.3) x 10-3 (1.3 ± 0.4) x 10-3 1 / 110 
P244L - - undetectable undetectable 
I280F - - (7.9 ± 2.0) x 10-5 1 / 1,700 
H418R 0.004 ± 0.001 (3.9 ± 0.1) x 10-5 0.01 ± 0.01 1 / 16 
G526R 7.1 ± 1.3 (2.3 ± 0.4) x 10-5 (3.2 ± 2.0) x 10-6 1 / 44,000 
G598A 1.4 ± 0.3 (1.1 ± 0.1) x 10-3 (7.9 ± 3.0) x 10-4 1 / 180 
Amino-acid coordinates correspond to GenBank accession number AAA57001.1 
± indicates standard deviations 
- indicates that kcat and km are not directly measured; the value for kcat/Km (where applicable) 
was measured under an approximate condition where the substrate concentration is below an 
estimated Km. 
“Undetectable" indicates that values are below the limits of detection 
 126 
maintenance vector (Turner et al. 2000; Antonellis et al. 2006; Stum et al. 2011). Based upon 
ClustalW2 alignments (Figure 4.1B), we identified the orthologous GRS1 amino acid of each 
previously untested GARS mutation and performed site-directed mutagenesis to model the 
human mutations in yeast. We were able to confidently model D146N, P244L, and I280F GARS 
at the orthologous residues in GRS1 based on homology (Table 4.2); A57V, S211F, D500N, and 
S581L are not conserved between human and yeast and thus could not be modeled in this assay. 
For clarity GRS1 mutations are referred by the human mutation nomenclature.   
Yeast cells were transformed with the experimental alleles on a LEU2-harboring vector and 
plated on solid growth medium containing 0.1% 5-Fluoroorotic Acid (5-FOA; Figure 4.2). 5-
FOA is toxic to yeast cells expressing URA3 and thus selects for cells that have spontaneously 
lost the maintenance vector (Boeke et al. 1987). Only yeast cells containing a functional GRS1 
allele on the LEU2-bearing experimental plasmid are able to complement the deleted endogenous 
GRS1 allele and survive on 5-FOA plates. Our wild-type GRS1 expression construct allowed 
robust yeast cell growth and our experimental vector without a GRS1 gene (‘Empty’ in Figure 
4.2) was unable to complement the null allele in yeast cells (Figure 4.2A). These results are 
consistent with the construction of a functional GRS1 experimental system and with GRS1 being 
an essential gene, respectively (Turner et al. 2000; Antonellis et al. 2006). With regard to the 
modeled mutations, I280F GRS1 was able to maintain yeast viability (Figure 4.2A) in a 
comparable manner to wild-type GRS1. In contrast, D146N and P244L GRS1 resulted in a severe 
reduction of yeast cell growth compared to wild-type GRS1 (Figure 4.2A). We also evaluated 
yeast cells incubated at 37°C to assess for temperature-sensitive effects of the studied mutations. 
These analyses did not reveal any further depletion of growth associated with the modeled 
mutations compared to wild-type GRS1 (Figure 4.2B). Finally, since GARS is a bi-functional
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Table 4.2. Human GARS Variants Modeled in the Yeast Ortholog GRS1 
Human GARS1
 
 Yeast GRS12
 
 
D146N
 
D96N 
P244L P227L 
I280F I255F 
 
1Amino-acid coordinates correspond to GenBank accession number AAA57001.1. 
2Amino-acid coordinates correspond to GenBank accession number NP_009679.2. 
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Figure 4.2. Characterization of yeast expressing wild-type and mutant GRS1. Each yeast strain 
was transformed with a LEU2-bearing pRS315 vector containing wild-type GRS1, the indicated 
mutant form of GRS1, or no insert (‘Empty pRS315’). Cultures for each strain (labeled along the 
top for each panel in A, B, and C) were grown for two days in liquid media and spotted on 
selective solid growth medium directly or after dilution as indicated. Strains were plated on 
medium containing 5-FOA to determine if the GRS1 alleles complement loss of endogenous GRS1 
gene at 30°C (A) and 37°C (B). (C) Strains were plated on solid medium containing 5-FOA and 
glycerol (YPG) and grown at 30°C to assess for an effect on mitochondrial GARS function. 
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ARS enzyme responsible for charging tRNA in both the cytoplasm and mitochondria (Antonellis 
and Green 2008), yeast were grown on medium containing glycerol and 5-FOA at 30°C to 
require yeast to rely solely on mitochondrial respiration, which allows the detection of impaired 
mitochondrial function. Similar to the studies at 37°C, the relative pattern of viability remained 
consistent when comparing mutant and wild-type GRS1 and therefore did not reveal any further 
mutation-dependent depletion in yeast cell growth (Figure 4.2C). Thus, two of the three human 
GARS mutations modeled in GRS1 dramatically decrease cell viability in vivo, consistent with a 
loss-of-function effect. 
The majority of GARS mutations reduce punctate localization in cultured neurons. 
 
The wild-type GARS protein localizes to ‘puncta’ within axons in the human peripheral nerve 
where it likely functions in local protein translation (Antonellis et al. 2006). Certain GARS 
mutations impair the punctate localization in cultured neurons, suggesting that reduced 
localization to axons is a component of CMT2D and dSMA-V disease pathogenesis (Antonellis 
et al. 2006). However, not all GARS mutations have been tested for an effect on puncta formation 
in neuronal cells. We therefore expressed wild-type and the eight untested mutant GARS-EGFP 
fusion proteins in a mouse motor neuron, neuroblastoma fusion cell line (MN-1 cells) (Salazar-
Grueso et al. 1991; Antonellis et al. 2006). Fluorescence microscopy revealed that wild-type, 
A57V, D146N, D500N, and S581L GARS-EGFP all demonstrated a punctate localization 
pattern in MN-1 cells (Figure 4.3A, B, C, G, and H). In contrast, S211F, P244L, I280F, and 
G598A GARS-EGFP proteins did not associate with puncta in MN-1 cells (Figure 4.3D, E, F, 
and I). Importantly, for the mutant GARS-EGFP proteins that did form puncta, these structures 
were also observed in MN-1 neurite projections, consistent with previous observations of wild-
type GARS localization (data not shown) (Salazar-Grueso et al. 1991; Fallini et al. 2012).
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Figure 4.3. Expression of wild-type and mutant GARS in mouse motor neuron-derived cells. 
MN-1 cells expressing EGFP-tagged wild-type (A), A57V (B), D146N (C), S211F (D), 
P244L (E), I280F (F), D500N (G), S581L (H), or G598A GARS (I) were evaluated for the 
presence or absence of granules by fluorescence microscopy. 
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S581L GARS does not segregate with disease in newly discovered pedigrees. 
 
The A57V variant was identified in a single individual with weakness and muscle wasting in the 
upper extremities (Rohkamm et al. 2007) and S581L was identified in a single proband with an 
extensive family history of lower limb predominant axonal CMT disease (James et al. 2006). No 
further segregation analyses were performed on either mutation. Furthermore, ethnically-
matched control populations were not screened for the absence of A57V or S581L GARS. 
Therefore, we searched genome variant databases for the occurrence of these two mutations. 
A57V and S581L were both identified by the NHLBI GO Exome Sequencing Project database at 
a low frequency of 1/11,842 (rs370531212:C>T) and 16/119,342 (rs201358272:C>T), 
respectively. Of the 11 additional GARS mutations associated with disease, D500N was 
identified at a frequency of 3/112,608 in control or general populations, while the remaining 10 
have not been reported in control or general populations. 
Our on-going mutation analyses revealed S581L GARS in two unrelated probands with dominant 
axonal CMT disease. To determine if this mutation is associated with disease in the two 
respective families, we performed segregation studies. DNA sequence analysis of additional 
affected individuals revealed that S581L GARS does not segregate with disease in either family 
(Figure 4.4A and B). Specifically, clinically affected individuals in both families did not carry 
S581L GARS. Combined with the identification of this variant in the general population, these 
data indicate that S581L GARS should not be considered a disease-causing mutation. 
DISCUSSION 
 
Prior to the completion of this work, thirteen GARS mutations had been associated with CMT 
disease; however, only four of the 13 reported GARS mutations had previously been rigorously 
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Figure 4.4. S581L GARS does not segregate with CMT disease. DNA samples from affected individuals from 
two presumably unrelated families with autosomal dominant, axonal CMT disease were genotyped for S581L 
GARS. Female patients are indicated with circles and male patients are indicated with squares. Filled symbols 
represent affected individuals with a diagnosis of dominant axonal CMT disease and empty symbols indicate 
unaffected individuals. Where applicable, an individual’s genotype is indicted with + (for the wild-type allele) 
or S581L (for the variant allele). (A) Samples from individuals in Family 1 were anonymized resulting in loss 
of the pedigree structure for this family; however, individuals 1178-1 and 1178-2 are directly related, both 
affected, and reside in a pedigree originally described as dominant axonal CMT disease. Representative 
chromatographs from sequencing analysis of genomic DNA from affected individuals are shown. The 
sequence includes the AG splice site acceptor at the 3’ end of intron 15 followed by the first 12 nucleotides of 
exon 16 (intron/exon junction marked by dashed line). The S581 codon (TCG) is encoded by the last 
nucleotide of exon 15 (T; not shown) and the first two nucleotides (CG) of exon 16. Individual 1178-1 is 
heterozygous for a C>T mutation (red arrow) in the first base of exon 16 resulting in the S581L allele. 1178-2 
is homozygous for the wild-type genotype at this nucleotide (C). (B) The pedigree for Family 2 illustrates the 
affected status of each family member and the S581L genotypes of two affected individuals with dominant 
axonal CMT disease.  
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tested (Wallen and Antonellis 2013). The four mutations that had been previously characterized 
all demonstrated loss-of-function in at least one assay. To determine the functional consequences 
of GARS mutations, we evaluated the remaining nine GARS mutations in aminoacylation, yeast 
complementation, and localization studies and report a high correlation between impaired 
enzyme function and CMT disease. We determined that the D146N, H418R, and G598A GARS 
alleles encode a protein product with a severe defect in tRNA charging. Additionally, S211F, 
P244L, I280F, and G598A GARS fail to form puncta that were previously associated with wild-
type GARS in human neuronal tissues and cultured cells (Antonellis et al. 2006). Importantly, 
our genetic analyses rule out S581L GARS as a pathogenic GARS mutation. Combined with 
previous reports, the data presented here reveal that 10 of the 12 disease-associated GARS 
mutations identified to date demonstrate loss-of-function characteristics (Table 4.3) (Antonellis 
et al. 2006; Nangle et al. 2007; Xie et al. 2007; Stum et al. 2011). The two mutations that do not 
meet this criterion, A57V and D500N GARS, are discussed in detail below. This work furthers 
our understanding of the allelic spectrum of GARS-associated CMT disease and strongly 
suggests that impaired GARS function is an important component of the axonal peripheral 
neuropathy. 
The in vitro aminoacylation assay is performed with tRNA and a single purified enzyme to 
determine the activity of wild-type or mutant GARS proteins (Hou et al. 1993). This assay 
employs catalytic amounts of the enzyme (nM) with saturating amounts of substrate tRNA (in 
mM). Combining previous studies, data presented here, and recent aminoacylation data collected 
that demonstrates >95% reduction in aminoacylation for E71G GARS (Ya-ming Hou, personal 
communication), it is now known that 10 of the 12 disease-associated GARS mutation lead to at 
least a 90% decrease in tRNA charging capacity (Table 4.3) However, while aminoacylation
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Table 4.3. Summary of functional studies on GARS variants 
Variant 
Enzyme 
Activity 
Yeast 
Viability 
Granule 
Formation References 
Wild-type Normal Viable Yes Antonellis et al. 2006, this study 
A57V Normal1 NA Yes This study 
E71G Reduced Viable Yes 
Antonellis et al. 2006, Nangle et 
al. 2006, Hou, unpublished 
L129P Reduced Reduced No 
Antonellis et al. 2006, Nangle et 
al. 2006 
D146N Reduced Reduced Yes This study 
S211F Reduced NA No This study 
G240R Reduced Viable No 
Antonellis et al. 2006, Nangle et 
al. 2006 
P244L Reduced Lethal No This study 
I280F Reduced Viable No This study 
H418R Reduced Lethal No 
Antonellis et al. 2006, Nangle et 
al. 2006, and this study 
D500N Normal NA Yes Nangle et al. 2006, and this study 
G526R Reduced Lethal Yes 
Antonellis et al. 2006, Nangle et 
al. 2006, and Xie et al. 2007 
S581L Normal NA Yes Nangle et al. 2006, Cader et al. 
2007, and this study 
G598A Reduced Viable No Stum et al. 2011, and this study 
Amino-acid coordinates correspond to GenBank accession number AAA57001.1 
Red text indicates a result consistent with a loss-of-function effect. 
1This variant was associated with ~50% activity compared to wild-type GARS and we 
considered a >90% reduction in activity as dramatically ‘Reduced’. 
NA – not applicable; mutation could not be modeled in yeast ortholog
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assays provide key information on enzyme function, the reaction is performed outside the 
context of a living cell. Therefore, it may not faithfully represent the ability of mutant enzymes 
to meet in vivo requirements for tRNA charging. In contrast, yeast complementation assays 
provide an in vivo system to characterize the functional consequences of GARS mutations 
(Turner et al. 2000; Antonellis et al. 2006). Importantly, all GARS mutations that fail to 
complement yeast cell growth also have a severe reduction in aminoacylation activity. However, 
certain mutations, such as I280F, show reduced aminoacylation activity in vitro but complement 
yeast cell growth in a manner similar to the wild-type enzyme (Table 4.3). One possible 
explanation for the discrepancy between aminoacylation and yeast complementation studies is 
that bacterially produced proteins may lack post-translational modifications important for 
enzyme function in human cells or for proper activity in specific cellular contexts. Additionally, 
other cellular components may stabilize the mutant protein product in the yeast system, allowing 
for improved function and viability. The yeast assay could not be used to evaluate all GARS 
mutations due to a lack of conservation with human residues. Alternative assays (see below) 
should be explored to determine the in vivo consequences of such mutations. While yeast offers 
insight into the functional consequences of GARS mutations in vivo, it does not reveal how GARS 
mutations affect axons. The function of GARS and other ARS enzymes in axons remains 
unclear; however, there is strong evidence that they provide tRNA charging for local protein 
translation (Ingoglia et al. 1983). One possibility is that GARS mutations reduce enzyme activity 
below some required threshold of tRNA charging necessary for axon function (see chapter 5). 
Indeed, mutations that reduce catalytic activity but sustain yeast cell viability, such as I280F, 
may not have enough activity to sustain axon-specific translation requirements.  
Proper localization within a cell can be critical for protein function, with impaired localization 
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resulting in a cell-compartment specific loss of function. Wild-type endogenous GARS forms 
discrete puncta in cultured neurons and in peripheral neurons and axons from healthy human 
subjects (Antonellis et al. 2006). Data collected to date show that seven of the 12 disease-
associated GARS mutations give rise to proteins that are unable to associate with granules in 
cultured neurons (Table 4.3). In another study, Nangle et al also showed that mutant GARS 
proteins mislocalize (Nangle et al. 2007). However, their experiments did not reveal discrete 
GARS puncta, which is likely due to differential placement of the fluorescent protein tag (i.e. N-
terminal versus C-terminal tag). The impaired association with puncta observed for certain 
GARS mutant proteins may be due to altered protein structure and/or reduced binding to specific 
protein or RNA partners required for puncta formation. It will be critical to identify proteins 
and/or RNAs that interact with GARS in these structures to further understand puncta function 
and how disruption of these structures may lead to CMT disease (see Chapter 6).  
Although impaired function is correlated with GARS-mediated CMT disease, two disease-
associated mutations have not demonstrated impaired function in any of the assays used in this 
study: A57V and D500N (Table 4.3). D500N GARS segregates with disease in a large pedigree 
with dominantly inherited, upper limb predominate axonal neuropathy (Del Bo et al. 2006), 
providing strong genetic and phenotypic evidence supporting a role in CMT2D disease 
pathogenesis. It is important to note that this variant has been detected at a frequency of 
3/112,608 in the ExAC database. However, since individuals included in the ExAC database are 
not subjected to a neurologic assessment and since CMT is often a late onset disease, inclusion in 
this database does not exclude D500N from having a causative role in CMT disease. In contrast, 
A57V has weak genetic evidence for a role in CMT disease. First, this variant was identified in a 
single individual with upper limb predominant CMT disease and no additional family members 
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were available for segregation studies (Rohkamm et al. 2007). Second, ethnically matched 
controls were not tested to determine the presence of this allele in appropriate populations. 
Additionally, A57V was identified by the NHLBI GO Exome Sequencing Project 
(rs370531212:C>T) at a low frequency (1/11841). Since the role of A57V in disease is still 
unclear and D500N has not demonstrated loss of function characteristics, we propose that both 
GARS alleles should be evaluated in the fly neuron complementation assay to assess impaired 
function that cannot be detected by other assays (Chihara et al. 2007) and in worm neurotoxicity 
assays to assess for dominant toxicity (Vester et al. 2012; Safka Brozkova et al. 2015). These 
efforts will complete the functional evaluation of these variants, reveal if they have a potential 
role in dominantly inherited CMT disease, and, if so, determine if loss of function is an 
important component of the pathogenic mechanism. 
With the completion of the human genome project and the development of rapid, affordable 
sequencing technologies, DNA sequencing is increasingly employed for research and diagnostic 
purposes. Once a gene has been implicated in disease, patients with a similar phenotype can be 
quickly screened for variants at that locus. These studies provide a large cache of information 
that allows for a better understanding of the locus and allelic heterogeneity of human genetic 
disease. However, rare variants identified in individual patients or small pedigrees are difficult to 
implicate in disease phenotypes due to the absence of strong genetic evidence (MacArthur et al. 
2014). Recent studies have utilized computational, functional, and clinical data to determine that 
a subset of variants reported in disease-associated genes are likely to be functionally neutral and 
not responsible for disease. For example, Easton et al. computationally evaluated 1,433 variants 
of unknown significance identified in the BRCA1 gene and predict that only 20% of those 
variants are deleterious based on genetic and clinical assessments compared to known disease-
 138 
causing mutations (Easton et al. 2007). In a separate study, evaluation of 149 variants in the 
CFTR gene identified in patients with cystic fibrosis revealed that 12 do not meet clinical and 
functional criteria necessary to cause disease (Sosnay et al. 2013). These results reiterate the 
need for clinical and functional assessments when determining the role of variants in human 
disease in the absence of strong genetic evidence.  
Here, we demonstrate that S581L GARS, a variant previously implicated in CMT disease, does 
not segregate with disease in two newly identified families with dominant axonal CMT disease 
and is present at a low frequency in the general population (16/119,342). This variant was 
originally identified in individuals with lower limb predominant CMT disease (James et al. 
2006), which is uncharacteristic of GARS-associated CMT2D. Interestingly, S581L has normal 
aminoacylation activity and localization in neurons, as demonstrated by its ability to charge 
tRNA at the same rate as wild-type GARS (Nangle et al. 2007) and to form puncta similar to 
wild-type GARS (Figure 4.3). Taken together, these data strongly indicate that this variant is not 
disease causing and warrant removing it from the list of disease-associated variants. Instead, 
S581L GARS should be tested alongside disease-associated alleles as a control in mechanistic 
studies.  
In conclusion, our data indicate that loss of function is highly correlated with GARS-mediated 
CMT disease and that loss of ARS function is likely a necessary first step for disease 
pathogenesis. However, additional research is needed to determine the mechanism by which 
impaired tRNA charging leads CMT2D disease (see Chapter 5). Importantly, determining the 
precise mechanism of mutant GARS pathogenicity in axons will be essential for designing 
effective therapies for patients with CMT2D. 
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CHAPTER 5 
Evaluating the pathogenic mechanism of ARS-mediated CMT 
disease  
 
INTRODUCTION 
A growing body of evidence, both previously published and included in this work, demonstrates 
that disease-associated ARS mutations result in impaired enzyme function (Antonellis et al. 
2003; Jordanova et al. 2006; Latour et al. 2010; McLaughlin et al. 2011; Vester et al. 2012; 
Gonzalez et al. 2013). In total, 30 dominant disease-associated ARS alleles have been 
functionally characterized revealing that:  (i) 15 result in impaired tRNA charging in biochemical 
assays (Jordanova et al. 2006; Nangle et al. 2007; McLaughlin et al. 2010; McLaughlin et al. 
2011; Griffin et al. 2014); (ii) 19 impair yeast cell growth (Antonellis et al. 2006; Jordanova et 
al. 2006; McLaughlin et al. 2010; McLaughlin et al. 2011; Vester et al. 2012; Gonzalez et al. 
2013; Griffin et al. 2014; Motley et al. 2015; Safka Brozkova et al. 2015); (iii) nine mislocalize 
in cultured neurons (Antonellis et al. 2006; Jordanova et al. 2006; Nangle et al. 2007) (Griffin et 
al. 2014); and (iv) two are unable to complement deletion of the fly ortholog (Chihara et al. 
2007). Together, 28 of 30 ARS variants show reduced function in at least one assay, indicating 
that impaired ARS function is a component of ARS-mediated CMT disease. Interestingly, the 
two mutations that have not shown loss-of-function characteristics, A57V and D500N GARS, are 
both reported in general populations and additionally, A57V has weak genetic evidence for a role 
in dominant CMT disease. However, the precise mechanism by which impaired ARS function 
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leads to CMT disease is unknown. Thus, studies focused on determining the pathology of ARS-
mediated CMT disease should focus on investigating mechanisms of impaired function in 
dominant disease. 
There are two major mechanisms by which loss-of-function mutations lead to dominant disease: 
haploinsufficiency and a dominant-negative effect. Mice heterozygous for a gene-trap null Gars 
allele are phenotypically normal despite having a ~50% reduction in Gars protein levels (Seburn 
et al. 2006). This suggests that haploinsufficiency is not the pathological mechanism in GARS-
mediated CMT disease. In a dominant-negative mechanism, a loss-of-function mutant protein 
binds the wild-type gene product and antagonizes its function, depleting overall enzyme activity 
in the cell to ~25-33% of normal levels. Lymphoblastoid cell lines from patients with GARS-
associated CMT disease (+/G240R) have an ~87% reduction in aminoacylation in vitro 
compared to control cell lines (Ya-Ming Hou, personal communication). A dominant-negative 
mechanism is further supported by data that mice heterozygous for Gars loss-of-function 
missense mutations (C201R and P234KY) demonstrate a dominant axonal neuropathy, (Seburn 
et al. 2006; Achilli et al. 2009), while mice heterozygous for a null gene-trap Gars allele are 
phenotypically normal, indicating that expression of a mutant protein is required for GARS-
mediated CMT disease. Furthermore, ARS null alleles (e.g., deletions and nonsense mutations) 
in patients with ARS-mediated CMT disease (Wallen and Antonellis 2013) have not been 
identified. In fact, all ARS missense mutations tested to date result in stable proteins. To exert a 
dominant-negative effect, the mutant gene product must dimerize with the wild-type gene 
product. All ARS enzymes with strong genetic evidence for a role in CMT disease (GARS, 
YARS, AARS, and HARS) function as oligomers (Antonellis et al. 2003; Jordanova et al. 2006; 
McLaughlin et al. 2011; Vester et al. 2012) and mutant GARS and YARS proteins maintain the 
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ability to form wild-type/mutant heterodimers (Jordanova et al. 2006; Nangle et al. 2007). 
Importantly, there is direct experimental evidence in support of a dominant-negative mechanism 
in YARS-mediated CMT disease. Pseudo-heterozygous yeast expressing wild-type and mutant 
YARS alleles demonstrated decreased growth (Jordanova et al. 2006). However, GARS, AARS, 
and HARS mutations when co-expressed with wild-type ARS have not demonstrated a dominant-
negative effect in yeast. Still, the experimental evidence warrants a thorough investigation of a 
dominant-negative mechanism in ARS-mediated CMT-disease.  
In this chapter we will investigate a dominant-negative mechanism for GARS mutations using a 
trans-complementation assay in yeast.  Data suggests that dramatically reduced levels of ARS 
activity may be sufficient to support yeast cell growth (McLaughlin et al. 2010). Therefore, co-
expression of wild-type and mutant ARS may not be sufficient to deplete ARS activity to below 
the threshold for yeast viability. We hypothesized that a dominant-negative effect would be 
observed by expressing mutant ARS in a sensitized yeast strain whose ARS activity is already 
greatly reduced. To test this hypothesis, we will express loss-of-function, missense GRS1 alleles 
in a hypomorphic GRS1 yeast strain and assess for effects on yeast viability.   
 
The author performed all the studies in this chapter with the following exception: (1) The 
University of Michigan Sequencing core performed the DNA sequencing reactions; and (2) 
ΔGRS1 haploid yeast strain was previously generated by the Schimmel Laboratory at Scripps 
Institute (Turner et al. 2000).  
 
MATERIALS AND METHODS 
GRS1 expression constructs  
 
GRS1/pDONR221 construct was generated as described in chapter 4.  Briefly, the yeast GRS1 
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locus was amplified with primers containing Gateway adapter sequences (primer sequences 
included in Appendix A), cloned into pDONR221 using BP clonase, and sequence verified. 
Mutation-containing oligonucleotides were generated, and the QuickChange II XL Site-Directed 
Mutagenesis Kit (Stratagene, Santa Clara, CA) was used as per the manufacturer’s instructions to 
induce the desired mutations in the pDONR construct (primer sequences included in Appendix 
A). After transformation into E. coli, DNA from individual clones was purified and sequenced to 
confirm the presence of each mutation and the absence of any cycle-induced errors. 
Subsequently, validated entry clones were purified and recombined into the appropriate 
Gateway-compatible vector using LR clonase per manufacturer’s specifications. pRS315 (LEU2-
bearing vector) and pRS414 (TRP2-bearing vector) were used for the yeast complementation 
assays. DNA from the resulting expression constructs was purified and digested with the 
restriction enzyme BsrGI (New England Biosystems) to confirm the presence of the appropriate 
insert.  
Yeast complementation assays 
 
Yeast complementation assays were used to test the activity of GRS1 alleles (L129P, H418R, 
G526R, L129P:H418R cis, and L129P:H526R cis) as previously described in chapter 4 
(Antonellis et al. 2006). The ΔGRS1 haploid yeast strain [harboring a pRS316 maintenance 
vector to express wild-type GRS1 and URA3 (Turner et al. 2000)] was transformed with 200 ng 
of wild-type or mutant GRS1 in a LEU2-bearing pRS315 vector and selected on medium lacking 
uracil and leucine (Teknova, Hollister, CA, USA). For each transformation, two colonies were 
selected for further analysis. Each colony was grown to saturation in –leu-ura selection medium 
for 48 hr. Next, 10 μl of undiluted and diluted (1:10 and 1:100 in H2O) samples from each 
culture were spotted on plates containing 0.1% 5-FOA complete medium or SD –leu -ura growth 
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medium (Teknova) and incubated at 30°C for 72 hr. Yeast cell growth was determined by visual 
inspection. 
Yeast trans-complementation assays 
 
The ΔGRS1 haploid yeast strain [harboring a pRS316 maintenance vector to express wild-type 
GRS1 and URA]  (described above) (Turner et al. 2000; Antonellis et al. 2006) was transformed 
with a 200 ng of a TRP2-bearing pRS414 vector containing wild-type, L129P, H418R, or G526R 
GRS1 or pRS414 with no insert and were selected on plates lacking uracil and trytophan. The 
resulting pseudo-heterozygous strains (containing both the URA3- and TRP2-bearing vectors) 
were transformed with 200 ng of a LEU2-bearing vector containing a GRS1 allele (wild-type, 
L129P, H418R, G526R, L129P:H418R cis, or L129P:G526R cis) or no insert. Yeast were grown 
on media lacking uracil, leucine, and tryptophan for 3 days at 30°C to select for yeast harboring 
all three vectors. Resulting yeast were grown to saturation for 2 days in media lacking leucine, 
uracil, and tryptophan at 30°C and subsequently spotted undiluted or diluted (1:10 or 1:100 in 
H2O) on plates containing 5-FOA and lacking leucine and tryptophan to select for the 
spontaneous loss of the URA3-bearing maintenance vector (Boeke et al. 1987) and the presence 
of the two experimental vectors or on media lacking leucine, uracil, and tryptophan as a control. 
Yeast were grown for 3 days at 30°C and visual inspection of growth was used to determine the 
effect of co-expression of mutant GRS1 alleles. 
RESULTS 
A subset of GRS1 alleles complement in trans to support yeast viability. 
 
A body of evidence suggests that a dominant-negative mechanism may be involved in ARS- 
mediated CMT disease. In fact, previous studies have demonstrated that co-expression of mutant 
and wild-type YARS lead to decreased viability in yeast (Jordanova et al. 2006). We hypothesized 
 144 
that if a dominant-negative effect is involved in GARS-mediated CMT disease, the growth of a 
hypomorphic strain would be further suppressed by the co-expression of a loss-of-function, 
missense ARS allele. To assess GARS mutations for a dominant-negative effect in vivo, we 
utilized a yeast strain that expresses the hypomorphic GARS allele L129P (Antonellis et al. 
2003). When modeled in yeast (Table 5.1), L129P results in decreased cell growth compared to 
wild-type GARS expression (Figure 5.1). We selected two disease-associated GARS mutations, 
H418R and G526R, which were previously shown to be unable to support yeast cell viability 
(Antonellis et al. 2006) (Table 5.1; Figure 5.1), to co-express in our sensitized L129P GRS1 
yeast strain. Importantly, H418R and G526R GARS are known to retain dimerization ability 
(Nangle et al. 2007; Xie et al. 2007).  A LEU2-bearing vector containing wild-type, L129P, 
H418R or G526R GRS1 or no insert was introduced into the L129P strain or a wild-type control 
strain (Figure 5.2A). After selection on 5-FOA media, yeast expressing wild-type GRS1 from 
two vectors (wild-type/wild-type) showed robust growth, while yeast containing an L129P-
expressing vector and an empty vector (L129P/Empty) showed intermediate growth, consistent 
with previous observations for L129P yeast strains (Figure 5.2B) (Antonellis et al. 2006). 
Expression of L129P from two plasmids (L129P/L129P) improved yeast viability, but did not 
completely rescue yeast growth to wild-type levels, indicative of a gene dosage effect of L129P 
GRS1 on yeast viability. Surprisingly, co-expression of L129P and either H418R 
(L129P/H418R) or G526R (L129P/G526R) resulted in robust growth similar to wild-type levels 
(Figure 5.2A). To determine if H418R and G526R retained some basal level of activity that was 
not sufficient to sustain yeast cell growth independently but that could increase overall enzyme 
activity in an additive manner based on gene dosage, yeast strains expressing H418R or G526R 
from two plasmids (H418R/H418R or 
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Table 5.1. Human GARS variants modeled in the yeast ortholog GRS1 
Human GARSa Yeast GRS1b 
L129P L79P 
H418R H402R 
G526R G521R 
aAmino acid coordinates correspond to GenBank accession number AAA57001.1. 
bAmino acid coordinates correspond to GenBank accession number NP_009679.2. 
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Figure 5.1. Confirmation of mutant GRS1 phenotypes in yeast. (A) L129P, H418R, and G526R 
GARS are mapped (top) on a cartoon depiction of the GARS protein domains that includes the 
WHEP domain (blue), catalytic domains (red), insertion domains (red), and anticodon-binding 
domain (green). The amino acid positions of the domains are listed below the cartoon. (B) L129P, 
H418R, and G526R GRS1 were transformed into haploid ΔGRS1 yeast and selected on 5-FOA 
media to confirm the phenotypes previously reported in yeast for these alleles (Antonellis et al., 
2006). Note the intermediate growth pattern for yeast expressing L129P GRS1.  
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Figure 5.2. Yeast trans-complementation assay of GRS1 alleles. (A) The cartoon depicts the 
yeast trans-complementation assay used in this study. A haploid ΔGRS1 yeast strain expressing 
wild-type GRS1 from a URA3-bearing vector (blue) is transformed with TRP2-bearing pRS414 
plasmid containing either wild-type, L129P, H418R, or G526R GRS1 (purple) or no insert and is 
selected on media lacking tryptophan and uracil. The resulting yeast are subsequently 
transformed with a LEU2-bearing pRS315 vector containing a wild-type, L129P, H418R, or 
G526R GRS1 allele or no insert (‘Empty’) and yeast are selected on media lacking uracil, 
tryptophan, and leucine. Individual yeast colonies are then grown to saturation in media lacking 
uracil, tryptophan, and leucine (not shown) and spotted on plates lacking tryptophan and leucine 
and containing 5-FOA to select for yeast containing the two experimental GRS1 alleles and 
lacking the URA3 maintenance vector (Boeke et al. 1987). (B) Yeast carrying all three vectors 
were spotted undiluted or diluted (1:10 and 1:100) on media lacking uracil, tryptophan, and 
leucine (–leu-trp-ura) or media lacking tryptophan or leucine and containing 5-FOA (+5-FOA-
leu-trp). The allele on the pRS414 vector is in green text, while the allele on the pRS315 vector 
is in purple text. Note the robust growth for yeast co-expression L129P and either H418R 
(L129P/H418R) or G526R (L129P/G526R).  
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G526R/G526R) or co-expressing H418R and G526R (H418R/G526R) were generated. In 
contrast to L129P/H418R or L129P/G526R expressing yeast, H418R/H418R, G526R/G526R, 
and H418R/G526R yeast strains were unable to grow on 5-FOA (Figure 5.2). Taken together, 
these data suggest that L129P and H418R or G526R can trans-complement in yeast to improve 
enzymatic activity. 
One explanation for the trans-complementation observed is intragenic complementation (Yook 
2005).  Intragenic complementation occurs when two mutant alleles are in trans in the same gene 
locus and each allele itself produces a defective gene product; however, when the two defective 
products associate, a product with increased activity is produced. We hypothesized intragenic 
complementation was occurring in our systems via one of two mechanisms. In the first 
mechanism, the H418R or G526R gene product stabilizes the L129P product to improve L129P 
catalytic function (i.e. structural complementation). Alternatively, wild-type motifs on the 
opposing subunits could compensate in trans for the lack of function in the opposing GARS 
subunit (i.e. functional complementation). All three of the tested mutations affect residues in 
different motifs of GARS (Figure 5.1).  L129P GARS is located in motif 1 of the catalytic 
domain, while H418R is located in insertion domain 3, and G526R resides in motif 3 of the 
catalytic domain (Xie et al. 2007).   
To distinguish the mechanism by which trans-complementation was occurring in our yeast 
model, we utilized a genetic approach.  We hypothesized that if the mechanism was structural 
complementation, the H418R or G526R mutations would have the same stabilizing effect on the 
L129P mutation even when present in cis (i.e. L129P:H418R cis homodimers would be 
functional). Conversely, if the mechanism was functional complementation by opposing 
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domains, mutations in cis would ablate the synergistic growth effect when expressed in trans 
with L129P (i.e. L129P/L129P:H418R heterodimers would support yeast growth only to levels 
equivalent to L129P homodimers). First we generated and assessed the function of the L129P: 
H418R and L129P:G526R cis alleles. When expressed in the ΔGRS1 yeast strain, neither the 
GRS1 L129P:H418R cis allele, nor the L129P:G526R cis allele was able to complement deletion 
of endogenous GRS1 (Figure 5.3). This result indicated that the presence of H418R or G526R in 
the dimer were not sufficient to stabilize and improve the function of L129P on the opposing 
subunit. To test for functional trans-complementation between opposing subunits, we co-
expressed L129P and either the L129P:H418R cis or L129P:G526R cis allele. Important to note, 
in yeast co-expressing L129P and a cis allele, three dimer states exist. For example, co-
expression of L129P and L129P/H418R would results in L129P/L129P homodimers, L129P/ 
L129P:H418R heterodimers, and L129P:H418R/ L129P:H418R homodimers. Since we already 
know that L129P:H418R/ L129P:H418R homodimers are non-functional and L129P/L129P 
homodimers have an intermediate level of activity, if complementation is occurring in the 
heterodimer, we would expect an increase in growth compared to the presence of L129P/L129P 
dimers only.  Yeast co-expressing L129P and a cis allele (L129P/L129P:H418R or 
L129P/L129P:G526R) grew to comparable levels as L129P expression alone (Figure 5.4), 
indicating that the L129P/cis allele heterodimers are not functional. Taken together, we conclude 
that the mechanism of intragenic complementation is the result of functional complementation by 
wild-type motifs on opposing mutant subunits.  
DISSCUSSION 
 
In this chapter, we tested GARS mutations for a dominant-negative effect. We developed a yeast 
trans-complementation assay to assess for the ability of null GRS1 alleles to suppress activity of 
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Figure 5.3. Yeast complementation assays using GRS1 cis alleles. To test the effects of null mutations 
on the stabilization of the L129P, cis alleles containing both L129P and either H418R (L129P:H418R) 
or G526R (L129P:G526R) were generated. Yeast transformations of the haploid ΔGRS1 yeast strain 
were performed to introduce a LEU2-bearing vector containing wild-type, L129P, L129P:H418R, 
L129P:G526R or no insert (‘Empty’) and resulting yeast were spotted on 5-FOA or –leu-ura plates to 
assess the complementation ability of the cis alleles. Two independently generated plasmids of each cis 
allele were used (A and B).  
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Figure 5.4. Yeast trans-complementation assays with GRS1 cis alleles. A haploid ΔGRS1 yeast 
strain containing a URA3-maintenance vector was transformed with a L129P GRS1 allele on the 
TRP2-bearing pRS414 vector (green) and either wild-type, L129P, L129P:H418R, L129P:G526R or 
no insert on a LEU2-bearing pRS315 vector (purple).  Yeast carrying all three vectors were spotted 
undiluted or diluted (1:10 and 1:100) on media lacking uracil, tryptophan, and leucine (–leu-trp-ura) 
or media lacking tryptophan or leucine and containing 5-FOA (+5-FOA-leu-trp) media.   
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a hypomorphic GRS1 allele. Contrary to our hypothesis that antagonization would occur, co-
expression of the hypomorphic L129P GRS1 allele and the null H418R or G526R allele 
improved yeast viability to wild-type levels. A series of genetic experiments testing mutations in 
cis and trans, revealed that the intragenic complementation was due functional motifs on each 
subunits compensating for the lack of function on the opposing subunit to improve heterodimer 
activity.  
This is not the first report of intragenic complementation of GARS mutations. In mouse models, 
homozygosity for either C201R or P234KY Gars, missense Gars alleles that result in a dominant 
peripheral neuropathy in heterozygous animals, results in reduced viability (Seburn et al. 2006; 
Achilli et al. 2009); however, animals that are compound heterozygous for these two alleles have 
normal viability, but decreased lifespan, indicating that C201R/P278KY heterodimers have 
increased function compared to homodimers of either mutation (Motley et al. 2011). Importantly, 
C201R and P234KY Gars affect different functional motifs in GARS, insertion domain I and 
motif 2 of the catalytic domain, respectively (Xie et al. 2007). Although viable, compound 
heterozygous mice have a more severe disease phenotype and a decreased life span compared to 
mice heterozygous for either missense allele, indicating that GARS activity in compound 
heterozygotes was not increased to levels equivalent to those in heterozygous cells (Motley et al. 
2011). The observation of intragenic complementation in two in vivo systems raises the 
hypothesis that for each domain of the GARS dimer, only one wild-type subunit is needed for 
normal GARS activity levels. Thus wild-type/mutant heterodimers would be hypothesized to be 
fully functional. This would refute the dominant-negative hypothesis as overall GARS activity in 
heterozygous cells would be 66-75% of wild-type, an overall activity greater than in the cases of 
haploinsufficiency. This level of activity is unlikely as experimental evidence from G240R 
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GARS heterozygous lymphoblastoid cells shows an 87% percent decrease in aminoacylation 
compared to wild-type cells (Ya-ming Hou, personal communication). To further explore this 
observation, collaborators are assessing GARS activity in tissues from Gars heterozygous mice 
(Seburn et al. 2006; Achilli et al. 2009). Importantly, these studies will not only inform us 
regarding the dominant negative hypothesis, but may also provide valuable insight into the tissue 
specificity of ARS-mediated disease. Furthermore, our yeast data actually argue against the 
hypothesis that only one wild-type motif per dimer is necessary for dimer function. Specifically, 
the observation that when expressed in trans, H418R/G526R dimers do not increase yeast 
viability. These data indicate that the presence of a wild-type motif on the opposing subunit is 
not sufficient for complementation in all cases. These studies have neither implicated nor refuted 
the dominant negative hypothesis and thus efforts should continue to understanding how and 
why an expressed stable protein is necessary for disease pathogenesis.  
Recently, collaborators in Dimitris Beis’ laboratory at the Biomedical Research Foundation 
Academy of Athens (Athens, Greece) identified a mutation in zebrafish gars, T209K, which 
results in abnormal cardiac development and embryonic lethality in homozygous zebrafish. 
Interestingly, heterozygous animals are phenotypically normal (Malissovas et al., in press). 
Studies on the zebrafish T209K Gars protein revealed that T209K is unable to dimerize with 
itself or wild-type Gars. We performed functional studies and determined this mutation has 
impaired function in yeast complementation and localization assays. Therefore, this mutation 
provided an excellent opportunity to experimentally assess if dimerization was critical in ARS-
mediated disease. To do so, zebrafish embryos were injected with zebrafish gars mRNA 
harboring the T209K mutation or the CMT-associated mutation G526R, a loss-of-function allele 
that has increased dimerization capacity (Xie et al. 2007). Overexpression of G526R gars, but 
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not T209K gars, resulted in dominant neurotoxicity. Together, these data suggest that both loss-
of-function and an ability to dimerize are important components of GARS-mediated 
neurotoxicity in zebrafish.  
Zebrafish and mouse studies argue for a dominant-negative mechanism in GARS-mediated CMT 
while our yeast studies offer some evidence to refute this hypothesis. This may be due to the use 
of yeast GRS1 versus vertebrate GARS orthologs in the respective studies. We know that CMT-
associated GARS mutations modeled in GRS1 do not always recapitulate the functional 
consequences of those mutations in the human protein.  For example, G240R and I280F GRS1 
complement loss of endogenous GRS1, suggesting these mutations are functional in vivo; 
however, when modeled in the truncated human GARS open reading frame that has been shown 
to complement in yeast (Chien et al. 2014), both G240R and I280F GARS fail to support yeast 
growth indicating loss of function (Stephanie Oprescu, personal communication). Therefore, we 
must repeat the dominant negative studies in the humanized yeast model to test a dominant 
negative effect using human wild-type and mutant GARS. Importantly, GARS variants described 
in this thesis, such as T209K (dimerization mutant) and S581L (functional, non-pathogenic 
mutant), would serve as excellent controls for these and other mechanistic studies.  
In conclusion, in this chapter we provide evidence in yeast that some mutant alleles can 
functionally complement one another, casting doubt on the role of a dominant-negative effect in 
ARS-mediated CMT disease. However, understanding the effects of the human wild-type/mutant 
heterodimer remains an open question. We are optimistic that the recent developments in the 
yeast tools and variant identification are finally sufficient to properly address the dominant-
negative hypothesis for ARS-mediated disease. 
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CHAPTER 6 
Investigating the role of GARS puncta in axonal health and disease 
 
INTRODUCTION 
Although ARS enzymes are ubiquitously expressed, essential enzymes, heterozygosity for loss-
of-function ARS mutations leads to an axon-specific neuropathy. A growing body of literature 
demonstrates that disruption of RNA metabolism or protein translation leads to 
neurodegenerative diseases (Wang et al. 2007; Scheper et al. 2007a; Liu-Yesucevitz et al. 2011). 
For example, mutations in CLP1, a RNA kinase involved in tRNA splicing, results in a 
neurological syndrome affecting both the central and peripheral nervous system, including 
axonal sensory and motor neuropathy (Hanada et al. 2013; Karaca et al. 2014; Schaffer et al. 
2014). One possible explanation for this observation is that neurons, especially those in the 
peripheral nervous system (Antonellis and Green 2008), are uniquely sensitive to impaired 
protein translation (Scheper et al. 2007b). These latter cells are long-lived, terminally 
differentiated, and harbor axons that must be supported over long distances and time. It is known 
that mRNA is transported to axons (Ingoglia et al. 1983) and proteins are translated locally in 
response to cell signals (Liu-Yesucevitz et al. 2011). Local protein translation is highly regulated 
and disruption of multiple aspects of this process, from mRNA transport (e.g. FUS mutations in 
ALS (Vance et al. 2009)) to translation repressors (e.g. FMR1 mutations in Fragile X Syndrome 
(Garber et al. 2006)) have been implicated in neurological disease. Why mutations in different 
components of this process lead to dramatically different neurologic phenotypes is currently 
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unknown.  
Interestingly, endogenous wild-type GARS proteins localize to ‘puncta’ within axons in the 
human peripheral nerve (Antonellis et al. 2006). When modeled in vitro, seven of the 12 GARS 
mutations impair the punctate localization in cultured neurons, suggesting that reduced 
localization to axons is a component of CMT2D and dSMA-V disease pathogenesis (Antonellis 
et al. 2006; Antonellis and Green 2008; Wallen and Antonellis 2013) (see chapter 4). The 
remaining five mutant GARS proteins form puncta in MN-1 cell bodies and neurite projections, 
consistent with previous observations of wild-type GARS localization to axons (Antonellis et al. 
2006; Fallini et al. 2012; Griffin et al. 2014). Since proper localization within a cell can be 
critical for protein function, impaired localization can result in a cell compartment-specific loss 
of function (reviewed in (Hung and Link 2011)). Interestingly, while no strong correlation 
between genotype and phenotype has been appreciated for GARS-mediated peripheral 
neuropathy, G598A and 245-248ΔETAQ, the two GARS mutations that cause infantile spinal 
muscular atrophy (SMA), both fail to form puncta, indicating loss-of-puncta formation may 
correlate with a more severe phenotype. The molecular components and function of GARS 
puncta is unknown. Therefore, it is critical to identify proteins that interact with GARS in puncta 
to help define the function of these structures and begin to understand how disruption may lead 
to axonal dysfunction. Furthermore, these studies may be important in determining potential drug 
targets for the treatment of GARS-mediated CMT disease. 
Prior to initiation of this project, our lab performed proteomic analysis on lymphoblastoid cell 
lines derived from patients heterozygous for G240R GARS, a mutation that disrupts puncta 
formation (Antonellis and Green 2008). These studies revealed reduced levels of 22 proteins 
with known roles in neuron function, including DYNC1H1 (a molecular motor involved in 
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retrograde axonal transport (Michaelevski et al. 2010)) and RAB7 (a protein that regulates 
vesicle trafficking (Cantalupo et al. 2001)). Interestingly, mutations in DYNC1H1 and RAB7 are 
associated with CMT2O (Weedon et al. 2011) and CMT2B (Spinosa et al. 2008), respectively. 
mRNA for both genes localizes to axons, suggesting that they are translated locally (Gumy et al. 
2011). Furthermore, recent studies have demonstrated decreased protein translation in the motor 
neurons of gars mutant flies (Niehues et al. 2015), but the mechanism by which this occurs 
remains to be elucidated. In archaea, AARS and SARS have been shown to associate with 
ribosomes, presumably to facilitate tRNA recycling and translation efficiency (Godinic-Mikulcic 
et al. 2014). Thus, CMT-associated GARS mutations may affect the axonal translation efficiency 
of key proteins by inhibiting association with ribosomal proteins and/or RNAs critical for 
efficient translation in axons. Determining if GARS interacts with ribosomal proteins and if 
mutant GARS disrupts these interactions will help us investigate the observation of decreased 
protein translation in patient cells and fly neurons.  
The studies presented in this chapter focus on understanding the differential interacting partners 
of wild-type and mutant GARS that are important for puncta formation and/or failure to form 
these structures. Importantly, these studies have the potential to identify both loss- and gain-of-
function interactions of mutant GARS. Identifying proteins that differentially interact with wild-
type and mutant GARS will provide insight into basic GARS biology, ARS-mediated disease 
mechanisms, and potential avenues for therapeutic development.  
Recently, 245-248ΔETAQ GARS was identified in a patient with severe early onset spinal 
muscular atrophy (SMA). Due to the severity of the phenotype, 245-248ΔETAQ GARS is an 
excellent candidate for initial immunoprecipitation / mass spectrometry studies comparing wild-
type and mutant interacting partners. We hypothesize that this mutation will demonstrate the 
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functional characteristics appreciated of other CMT-associated GARS mutations, including 
decreased aminoacylation, failure to complement in yeast, and mislocalization in neurons, and 
will have altered protein interactions in MN-1 cells compared to wild-type GARS.  
The author performed all the work presented in this chapter with the following exceptions: (1) 
Clinical characterization and mutation identification was performed by collaborators; (2) 
Aminoacylation assays were performed by Ya-ming Hou at Thomas Jefferson University; (3) 
Mass spectrometry was performed at the Proteomics Core at the Fred Hutchinson Cancer 
Institute in Seattle, Washington and the Proteomics Resource Facility at the University of 
Michigan; and (4) Bioinformatics of the mass spectrometry data was performed by Dattatreya 
Mellacheruvu in Alexey Nesvizhskii’s laboratory at the University of Michigan.   
MATERIALS AND METHODS 
GARS and GRS1 expression constructs  
DNA constructs were generated for aminoacylation, yeast complementation, localization, and 
immunoprecipitation studies. Vectors used included pET-21a(+) (aminoacylation assays), 
pEGFP-N2 (for expressing GARS with a C-terminal EGFP tag), pRS315 (yeast 
complementation assays), and pTM3xFLAG_GW (for expressing GARS with a C-terminal 
3xFLAG tag for immunoprecipitations). For immunoprecipitation studies, pTM3xFLAG_GW 
vector was generated using the Gateway Vector Conversion System (Invitrogen) per 
manufacturer’s instructions to insert Gateway Cassette B in frame with the 3xFLAG tag in the 
pTM3xFLAG vector (generously provided by Tomo-ichiro Miyoshi, Moran Laboratory, 
University of Michigan). Briefly, pTM3xFLAG was digested with XhoI and AfeI, blunted with 
the Quick Blunt enzyme kit (New England Biolabs, Ipswich, MA), gel purified, and ligated with 
Gateway Conversion Cassette B. Sequencing using primers designed to the backbone of 
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pTM3xFLAG upstream and downstream of XhoI and AfeI sites, respectively, were used to 
sequence verify the proper orientation of the gateway cassette (primer sequences in Appendix 
A).   
To model 245-248ΔETAQ GARS, mutation-containing oligonucleotides were generated and the 
QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, CA) was used as 
per the manufacturer’s instructions (primer sequences in Appendix A) to mutate 
GRS1/pDONR221 and GARS-C-term/pDONR221.  GARS-C-term/pDONR221 contains the open 
reading frame of human GARS but lacks a stop codon and is used to generate C-terminal fusion 
proteins. Native GARS/pDONR221, which contains the stop codon, was used to generate the 
untagged native GARS control plasmid for IP/mass spec studies (see Chapter 4 for cloning details 
of pDONR221 constructs). Sequence verification was performed to confirm the presence of each 
mutation and the absence of any cycle-induced errors. Subsequently, validated entry clones were 
purified and recombined into the appropriate Gateway-compatible vector (see above) using LR 
clonase per the manufacturer’s specifications. DNA from the resulting expression constructs was 
purified and digested with the restriction enzyme BsrGI (New England Biosystems) to confirm 
the presence of the appropriate insert and sequencing was performed to confirm the presence of 
in frame tags when appropriate.  
Aminoacylation assays  
 
Wild-type and 245-248ΔETAQ GARS human proteins were expressed in E. coli Rosetta 2 
(DE3) pLys cells with a C-terminal in-frame His tag and purified with nickel affinity resin 
according to the manufacturer’s protocol (Novagen, Rockland, MA). The T7 transcript of human 
tRNAGly/UCU (UCU, anticodon) was prepared and purified as previously described (Hou et al. 
1993), was heat denatured at 85°C for 3 min, and annealed at 37°C for 20 min before use. 
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Steady-state aminoacylation assays were monitored at 37°C in 50 mM HEPES (pH 7.5), 20 mM 
KCl, 10 mM MgCl2, 4 mM DTT, 2 mM ATP, and 50 mM 
3H-glycine (Perkin Elmer, Waltham, 
MA) at a specific activity of 16,500 dpm/pmole. The reaction was initiated by mixing GARS 
enzyme (20–600 nM) with varying concentrations of tRNA (0.3–20 μM). Aliquots of a reaction 
mixture were spotted on filter papers, quenched by 5% trichloroacetic acid, washed, dried, and 
measured for radioactivity by a liquid scintillation counter (LS6000SC; Beckman Coulter Inc., 
Fullerton, CA). The amount of radioactivity retained on filter pad was corrected for quenching 
effects to determine the amount of synthesis of Gly-tRNAGly. Steady-state kinetics was 
determined by fitting the initial rate of aminoacylation as a function of tRNA concentration to 
the Michaelis–Menten equation (Schreier and Schimmel 1972).  
Yeast complementation assays  
 
The RJT3/II-1 haploid yeast strain [MATα grs1::HIS3, his3Δ200, leu2Δ1, lys2Δ202, trpΔ63, 
ura3–52, pTsscII-maint (cen, GRS1, URA3)] carrying a deleted endogenous GRS1 allele and 
wild-type GRS1 on a URA3-bearing pRS316 maintenance vector was previously reported 
(Turner et al. 2000; Antonellis et al. 2006). RJT3/II-1 was transformed with a LEU2-bearing 
pRS315 vector containing wild-type or GARS 245-248ΔETAQ GRS1 (described above) or 
pRS315 with no insert as previously reported (Antonellis et al. 2006). Each transformation was 
performed at least three times with at least three independent plasmid DNA preparations. Four 
colonies were selected from each transformation for additional analysis. Each colony was grown 
to saturation in –leu -ura selection medium for 48 hours. Next, 10 μl of undiluted and diluted 
(1:10 and 1:100) samples from each culture were spotted on plates containing 0.1% 5-
fluoroorotic acid (5-FOA) (Boeke et al. 1987) complete medium or SD -leu -ura growth medium 
(Teknova, Hollister, CA) and incubated at 30°C for 72 hr. Yeast cell growth was determined by 
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visual inspection.  
Cell culture and protein localization studies  
 
The mouse motor neuron, neuroblastoma fusion cell line (MN- 1) was cultured and transfected 
with constructs to express human wild-type or 245-248ΔETAQ GARS in-frame with a C-
terminal enhanced green fluorescent protein (EGFP) tag as previously described in chapter 4 
(Salazar-Grueso et al. 1991; Antonellis et al. 2006). After 48 hours, growth medium was 
removed, and cells were washed in 1× PBS and then incubated in 1× PBS/0.4% 
paraformaldehyde for 10 min at room temperature. Cells were washed in 1× PBS, co-stained 
with 300 nM DAPI for 5 min, washed again in 1× PBS, and finally coated with Pro-Long 
antifade reagent (Invitrogen). Images were obtained with an IX71 Inverted Microscope using 
cellSens Standard image software (Olympus, Center Valley, PA).  
MN-1 transfections for immunoprecipitation 
 
MN-1 cells were grown at 37°C in 5% CO2 to 60% confluency in T-175 flasks in Dulbecco’s 
modified eagle medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 U/ml penicillin, and 50 µg/ml of streptomycin (Invitrogen, Carlsbad, CA). Each 
flask was transfected using the lipofectamine 2000. Specifically, for each transfection reaction, 5 
ml of OptiMEM I minimal growth medium and 50 µl of Lipofectamine 2000 were mixed and 
incubated together for 10 min at room temperature. 15 µg of wild-type, 245-248ΔETAQ or 
native GARS pTM3xFLAG plasmid was combined with 5 ml of OptiMEM I. Subsequently, the 
Lipofectamine-OptiMEM I mixture was combined with the plasmid-OptiMEM I solution to 
yield 10 ml of the final transfection solution and incubated at room temperature for 20 min. The 
60% confluent T-175 flask of cells was washed in 1X PBS. The entire transfection solution was 
then added directly to the flask and incubated at 37°C in 5% CO2 for 4 hours. After 4 hours, the 
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transfection solution was removed and replaced with 20 ml of complete DMEM media 
(described above). Cells were allowed to recover for 2 days at 37°C in 5% CO2. After 2 days, 
cells were harvested using trypsin, centrifuged at 2000 rpm for 2 minutes, and washed twice with 
1X PBS. For our initial mass spectrometry studies performed at the Proteomics Core at the Fred 
Hutchinson Cancer Institute, one T-175 flask per sample was used. For mass spectrometry 
studies performed at the University of Michigan Proteomics Resource Facility, four T-175 flasks 
were pooled prior to cell lysis for each experimental plasmid and used for immunoprecipitations 
performed according to the protocol described below that was appropriately scaled 4X to account 
for the increase in cellular protein input.  
Immunoprecipitation 
 
25 µl of Dynabeads Protein G Magnetic beads (Invitrogen) were used for each reaction (i.e. per 
cell lysate from one T175 flask). Using a magnetic rack, beads were washed twice in 1000 µl of 
wash solution (0.5% bovine serum albumin and 0.1% Triton X-100 in PBS) and subsequently 
resuspended in 1000 µl of the wash solution. 2 µg anti-Flag M2 antibody (Sigma, F3165) was 
added to the beads and incubated rocking at 4˚C overnight. Harvested transfected cells (see 
above) were resuspended in 1.5 ml lysis buffer [20 mM Tris-HCl (pH7.5) 2.5mM MgCl2, 
300mM KCl, 0.1% NP-40, 1mM DTT, 0.2mM PMSF, 1x HaltTM Protease Inhibitor Cocktail 
(EDTA free) (Thermo Scientific)] and incubated gently rocking at 4°C for 90 min. Cell lysate 
was centrifuged at 12,000 rpm for 5 min at 4°C. Protein containing supernatant was removed and 
utilized as the input for the subsequent IP reaction in a clean tube. Protein was quantified using 
the PierceTM BCA Protein Assay Kit (Thermo Scientific) and 1 mg of protein was used as input 
for each sample. Western blot with anti-Flag M2 antibody (Sigma, F3165) (1:2500 dilution) was 
used to confirm expression of 3xFLAG tagged proteins in input samples.  Immediately before 
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use, the αFlag-conjugated magnetic beads were washed twice with 500µl of lysis buffer using a 
magnetic rack, resuspended in 25 µl lysis buffer and added directly to the protein sample. The 
protein and beads were incubated at 4°C for 2 hours with gentle rocking. Using a magnetic rack, 
supernatant was removed from the beads and discarded. The beads were washed 5 times with 1 
ml of wash buffer [20 mM Tris-HCl (pH7.5) 2.5mM MgCl2, 300mM KCl, 0.1% NP-40, 1mM 
DTT]. Beads were resuspended in 30 µl of wash buffer per 25 µl of starting beads for samples 
destined for the Proteomics Core at the Fred Hutchinson Cancer Institute and 50 µl of wash 
buffer per 25 µl of starting beads for samples destined for the University of Michigan Proteomics 
Resource Facility. Competitive elution of the flag tagged protein was performed using 200 µg/ml 
of 3xFlag peptide and incubate for 3 hours at 4°C rocking gently. Using a magnetic rack, 
supernatant was removed and saved for further analysis. 
Silver staining for analysis of IP products 
 
To visualize proteins for band excision for mass spectrometry studies performed at the 
Proteomics Core at the Fred Hutchinson Cancer Institute, IP products were separated on a 
denaturing 4-20% Tris-Glycine gel and silver stained. Briefly, 30 µl of the IP elution supernatant 
was boiled with 20 µl of 2X Tris-glycine SDS Sample Buffer (Life technologies, Carlsbad, CA) 
and 2 µl β-mercaptoethanol. Samples were run on a NovexTM 4-20% Tris-Glycine gel (Life 
technologies) for 2.5 hours at 100V. Gels were stained with the SilverQuestTM Staining Kit 
(Invitrogen) per manufacturer’s instructions. All gel incubations and washes were performed at 
room temperature with gentle agitation and all solutions were made using ultra pure H2O 
(uH2O). The gel was rinsed in uH2O, and subsequently fixed overnight in 100 ml of fix solution 
(40% ETOH, 10% acetic acid) agitating gently at room temperature. Gel was washed in 100 ml 
of 30% ETOH for 10 min, incubated in 100 ml of sensitization solution (30% ETOH, 10% 
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Sensitization Solution), washed in 100 ml of 30% ETOH for 10 min, washed in 100 ml of uH2O 
for 10 min, stained in 100 ml of staining solution (1% Staining Solution) for 15 min, washed in 
100 ml of uH2O for 20 sec, and developed in 100 ml of developing solution (10% Developer 
solution, 1 drop Developer Enhancer) until bands appeared. 10 ml of Stopper solution was then 
added directly to the developing solution and incubated for 10 min. For mass spectrometry, 
bands were excised for two independently generated samples sets (A and B in Figure 6.8) and 
sent to the Proteomics Core at the Fred Hutchinson Cancer Institute. 
Trichloroacetic acid (TCA) precipitation 
 
For mass spectrometry performed at the University of Michigan Proteomics Resource Facility, 
IP products were concentrated using a TCA precipitation protocol.  2 µl of 2% sodium 
deoxycholate was added to 200 µl of IP product and incubated on ice for 30 min.  20 µl of 100% 
(w/v) TCA was added and incubated on ice for 1 hour. The IP product was then centrifuged at 
max speed at 4˚C for 10 min. The supernatant was discarded and the remaining pellet was 
washed in 500 µl of acetone, and incubated on ice for 10 min. The acetone solution was 
centrifuged at max speed at 4˚C for 10 min. The resulting pellet was resuspended in 30 µl of a 
solution containing 20 mM HEPES and 8M Urea (pH=8.0). Three independently generated IP 
products for each wild-type, 245-248ΔETAQ, and untagged native GARS control sample were 
sent for analysis.  
Mass Spectrometry and bioinformatics 
 
Tandem mass spectrometry was performed using the Orbi-elite Tandem Mass Spectrometer 
(Thermo Scientific) at Proteomics Core at the Fred Hutchinson Cancer Institute and the Orbitrap 
Fusion Mass Spectrometer (Thermo Scientific) at the University of Michigan Proteomics 
Resource Facility. The open source proteomics search engine X!Tandem (The Global Proteome 
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Machine Organization), was used to match tandem mass spectrometry data with peptide spectra. 
Peptide Prophet was used to validate peptide assignments (Keller et al. 2002) and Protein 
Prophet was employed to group peptides into proteins (Nesvizhskii et al. 2003).  ABACUS 
extracted spectral counts for the data for quantitative analysis (Fermin et al. 2011).  Finally, 
interactions were scored to remove background and comparison of interacting proteins was 
performed to calculate the relative fold changes for protein interactions between wild-type and 
245-248ΔETAQ GARS.  
 
RESULTS 
245-248ΔETAQ GARS is a loss-of-function allele. 
 
A young female child presented with an inability to crawl and impaired hand function at 11 
months of age.  Clinical evaluation subsequently diagnosed her with infantile spinal muscular 
atrophy (SMA). Sequencing revealed that she is heterozygous for the GARS mutation 245-
248ΔETAQ. Her fraternal twin brother is unaffected and is homozygous for wild-type GARS. 
245-248ΔETAQ GARS results in the deletion of four amino acids in the glycine binding pocket 
that are responsible for amino acid binding in the catalytic domain of GARS (Figure 6.1A) 
(Freist et al. 1996). Conservation analysis demonstrated that these residues are invariably 
conserved in all taxa from bacteria through human, illustrating the critical role they play in 
enzyme function (Figure 6.1B). 
Since GARS mutations have been implicated in both CMT disease and SMA, including infantile 
SMA (Antonellis et al. 2006; James et al. 2006), we functionally characterized 245-248ΔETAQ 
GARS to determine if this mutation resulted in impaired function characteristic of disease- 
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Figure 6.1. Localization and conservation of GARS 245-248ΔETAQ. (A) The cartoon displays 
the functional domains of GARS: WHEP-TRS (blue), catalytic domain (red), insertion domain 
(yellow), and anticodon-binding domain (green). 245-248ΔETAQ is located in the catalytic 
domain (top). (B) Alignments of evolutionarily diverse species illustrates that residues 245-248 
ETAQ are conserved from human to E. coli.
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associated GARS mutations. Aminoacylation assays revealed that 245-248ΔETAQ GARS had 
almost a complete loss of tRNA charging capacity compared to wild-type GARS (1/11,000) 
(Figure 6.2). When modeled in GRS1, the yeast ortholog of GARS (Table 6.1), 245-248ΔETAQ 
GRS1 was unable to complement deletion of the endogenous GRS1 allele (Figure 6.3). Finally, 
when assessed for localization patterns, 245-248ΔETAQ GARS failed to form puncta in MN-1 
cells (Figure 6.4). Taken together, 245-248ΔETAQ GARS demonstrates loss-of-function 
characteristics in all three assays commonly used to study ARS variant activity and consistent 
with the characteristics previously described for disease-associated GARS mutations. Due to the 
severity of this mutation, we deemed that 245-248ΔETAQ GARS would be an excellent 
candidate for initial studies comparing protein-binding patterns of wild-type GARS and non-
puncta forming mutant GARS.  
Immunoprecipitation and mass spectrometry analysis of GARS proteins 
 
To determine the differential protein binding partners of wild-type and 245-248ΔETAQ GARS, 
immunoprecipitation (IP) and mass spectrometry was performed. Specifically, wild-type and 
245-248ΔETAQ GARS open reading frames lacking the stop codon and a wild-type GARS open 
reading frame containing the stop codon (native GARS) were cloned into the pTM3xFLAG_GW 
mammalian expression vector to generate plasmids for the expression of wild-type GARS-
3xFLAG, 245-248ΔETAQ GARS-3xFLAG and untagged native GARS, respectively. MN-1 
cells were transfected with each plasmid, grown for two days, and harvested. Protein lysates 
were isolated and a western blot was performed using an antibody directed at the FLAG tag to 
confirm the expression of ~87 kDa protein corresponding to GARS-3xFLAG and 245-
248ΔETAQ GARS-3xFLAG and absence of a tagged peptide in the untagged native GARS 
sample (Figure 6.5). An antibody targeting the C-terminus of GARS was used to confirm the 
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Figure 6.2. Aminoacylation assays of 245-248ΔETAQ GARS . Human recombinant wild-type 
and 245-248ΔETAQ GARS were assessed for tRNA charging activity in vitro. Using the 
Michaelis-Menten equation, the velocity of aminoacylation (pmole/min/pmole of enzyme) of 
tRNAgly was calculated as a function of tRNA concentration for wild-type GARS (black) and 
245-248ΔETAQ GARS (blue). Error bars indicated standard deviation.  
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Table 6.1. Human 245-248ΔETAQ GARS Modeled in the Yeast Ortholog GRS1 
 
Human GARS1
 
 Yeast GRS12
 
 
245-248ΔETAQ
 
228-331ΔETAQ 
 
1Amino-acid coordinates correspond to GenBank accession number AAA57001.1 
2Amino-acid coordinates correspond to GenBank accession number NP_009679.2 
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Figure 6.3. Yeast complementation studies of 245-248ΔETAQ GRS1. Yeast lacking endogenous 
GRS1 were transformed with a LEU2-bearing vector containing wild-type or 245-248ΔETAQ 
GRS1 or no insert (‘Empty’). Saturated cultures for each strain (labeled on top) were spotted 
undiluted or diluted (1:10 and 1:100) on media contain 5-FOA or lacking leucine and uracil, and 
grown for 72 hours at 30°C to determine if the 245-248ΔETAQ GRS1 sustained yeast viability. 
Two independent plasmid preparations of 245-248ΔETAQ GRS1 (1 and 2) were transformed 
into yeast and two colonies from each transformation were assessed (A and B).  
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Figure 6.4. Localization studies of 245-248ΔETAQ GARS. MN-1 cells were transfected with 
expression constructs to express wild-type GARS (A) and 245-248ΔETAQ GARS (B) in frame 
with EGFP.  EGFP positive cells were evaluated for presence of GARS puncta.  
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Figure 6.5. Western blot of protein input for immunoprecipitations. Whole cell protein lysates 
from MN-1 cells transfected vectors to express wild-type or ETAQ GARS-3xFLAG or untagged 
native GARS (labeled on top) were separated on a denaturing protein gel and blotted with an 
anti-FLAG antibody to confirm the presence of wild-type and ETAQ GARS-3xFLAG proteins 
and the absence of a FLAG-tagged peptide in the native GARS untagged control. An antibody 
targeting the C-terminus of the GARS protein was used to detect expression of endogenous and 
untagged GARS.  Note the increase in GARS levels in the untagged native GARS control. An 
antibody to actin was used as a loading control.  
 174 
presence of endogenous GARS. We observed an increased signal with the GARS antibody in the 
native GARS sample. This indicates that the untagged native GARS pTM3xFLAG results in 
expression of an untagged GARS protein of comparable in size to endogenous GARS (~83 kDa). 
Since the GARS antibody targets the C-terminus of the protein, we hypothesize that the GARS 
epitope is blocked by the FLAG tag in the wild-type and 245-248ΔETAQ GARS-3xFLAG 
samples, explaining the absence of a band at the expected size for the FLAG-tagged GARS 
protein product.   
Equal amounts of total protein for each condition were subjected to IP using anti-FLAG 
conjugated magnetic beads. Beads were washed and proteins were eluted via a competitive 
elution with FLAG peptide. The isolated proteins were separated on a denaturing protein gel and 
either immunoblotted with antibodies to FLAG to confirm successful immunoprecipitations of 
tagged proteins (Figure 6.6) or silver stained to visualize the protein banding patterns in each 
sample (Figure 6.7). We classified bands observed on silver stained gels into four categories: (1) 
non-specific bands present in all samples including the untagged native GARS control; (2) bands 
that correspond to the approximate sizes of tagged and endogenous GARS, which were present 
in the tagged GARS samples but absent in the untagged native GARS control sample; (3) bands 
indicating proteins that bind both wild-type and 245-248ΔETAQ-3xFLAG GARS that were 
present in both tagged samples, but absent in the untagged control; and (4) protein bands 
observed exclusively in the 245-248ΔETAQ-3xFLAG sample, which may indicate novel 
interacting partners of 245-248ΔETAQ GARS. Resulting bands were isolated in four gel slices 
(Figure 6.8) and subjected to mass spectrometry at the Fred Hutchinson Cancer Institute 
proteomics core in Seattle Washington. Alternatively, IP products were TCA precipitated 
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Figure 6.6. Western blot of immunoprecipitation products. Products from immunoprecipitations of 
protein extracts from MN-1 cells transfected with constructs expressing wild-type (WT) and 245-
248ΔETAQ (ΔETAQ) GARS-3xFLAG or untagged native GARS were run on a denaturing gel and 
immunoblotted with an anti-FLAG antibody to confirm successful immunoprecipitation of the 
FLAG-tagged peptides.     
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Figure 6.7. Silver stained gel of immunoprecipitation products. Immunoprecipitation reactions 
using an anti-FLAG antibody were performed on protein lysates isolated from MN-1 cells 
expressing wild-type (WT) or 245-248ΔETAQ (ΔETAQ) GARS-3xFLAG or native GARS 
(untagged). Resulting products were separated on a denaturing gel and silver stained for visual 
inspection of protein bands. Four types of bands were appreciated. Black arrows indicate bands 
present in all lanes.  Red arrows indicate bands corresponding to the approximate sizes of tagged 
and endogenous GARS. Note the absence of these bands in the native GARS lane. White arrows 
indicate common interacting proteins between both wild-type and 245-248ΔETAQ-3xFLAG 
samples. Yellow arrows mark protein bands observed exclusively in the 245-248ΔETAQ-
3xFLAG sample.  
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Figure 6.8. Images of silver stained gel samples used for mass spectrometry. 
Immunoprecipitations products from MN-1 cells expressing with wild-type (WT) or 245-
248ΔETAQ (ΔETAQ) GARS-3xFLAG or untagged native GARS from two independent 
experiments (A and B) were run on a denaturing protein gel and silver stained to visualize 
bands. Gel lanes were each divided into four gel slices for mass spectrometry analysis as 
indicated (1-4). Gel slices were sent to the Fred Hutchinson Cancer Institute for mass 
spectrometry analysis.  
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immediately after IP and TCA samples were sent to University of Michigan Proteomics 
Resource Facility for mass spectrometry analysis.  
Resulting mass spectrometry data was assessed to determine both the identity of GARS-
interacting proteins, as well as to quantitate the abundance of each protein in the sample. For the 
Fred Hutchinson data set, the resulting quantifications of peptides between the wild-type and 
245-248ΔETAQ samples were compared to calculate the relative fold change for each putative 
interacting partner identified. Importantly, the top two proteins identified were human GARS 
(our bait protein) and mouse GARS, which is endogenous to the MN-1 cell line used in these 
studies (Salazar-Grueso et al. 1991). To date, the best characterized interacting partner of GARS 
is GARS itself, as the protein must homodimerize to form a functional enzyme capable of 
charging tRNA (Freist et al. 1996). As would be expected based on the estimated protein sizes of 
87 kDa and 83 kDa for human GARS-3xFLAG and mouse GARS, respectively, these proteins 
were present in high abundance in slices A2 and B2 (Figure 6.8) of both the wild-type and 245-
248ΔETAQ GARS-3xFLAG samples (Table 6.2). Interestingly, the wild-type GARS sample had 
a 1.3 fold higher interaction with the mouse GARS compared to the 245-248ΔETAQ GARS-
3xFLAG samples. It is important to note that this analysis wasdone using total spectral counts, 
not unique spectral counts for these two proteins so peptides are double counted.  
Data analysis of the Fred Hutchinson data set revealed that both wild-type and mutant GARS 
bind to many of the same proteins. One example is heat shock protein 90 (HSP90). HSP90 was 
the second most abundant protein present in both wild-type and 245-248ΔETAQ GARS-
3xFLAG samples. It was identified in slices A2 and B2 for both samples (Figure 6.8) as would 
be predicted by its molecular weight of 90 kDa. HSP90 is a molecular chaperone responsible for 
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Table 6.2. Spectral counts for GARS in immunoprecipitation samples 
Protein Species 
WT Spectral 
Counts* 
ΔETAQ Spectral 
Counts* Fold Change 
GARS Human 575 438 1.3 
GARS Mouse 282 204 1.3 
 
*Counts represent total spectral counts, not unique spectral counts. Shared peptides are double 
counted in this quantification.  
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assisting in proper protein folding and stabilization of other proteins during heat stress, and is 
involved in the degradation pathway of proteins (Csermely et al. 1998).  
Since our hypothesis for the disruption of GARS puncta was due to differential protein-protein 
interactions between wild-type and mutant GARS, we calculated the fold change differences for 
protein interactions in wild-type and 245-248ΔETAQ GARS-3xFLAG samples in the Fred 
Hutchinson data set and report here the top 10 fold changes in each direction (Table 6.3 and 
Table 6.4). The top two proteins with increased binding to wild-type GARS compared 245-
248ΔETAQ GARS were PLEC (3.29 fold) and ACTN4 (2.67 fold) (Table 6.3). PLEC interlinks 
intermediate filaments with microtubules and microfilaments (Svitkina et al. 1996), while 
ACTN4 is an F-actin cross-linking protein that anchors actin intracellular structures (Rual et al. 
2005), indicating the interaction with the cytoskeleton may be critical for GARS puncta 
formation. Conversely, UBA1, the protein that catalyzes the first step in ubiquitin conjugation to 
mark cellular proteins for degradation (Kudo et al. 1991), demonstrated a 4.8 fold increase in 
binding to 245-248ΔETAQ compared to wild-type GARS (Table 6.4). Ubiquitination is used to 
mark misfolded proteins for degradation. This may indicate that 245-248ΔETAQ GARS is 
misfolded, and may explain the inability of 245-248ΔETAQ GARS to form puncta in cells.  
Analysis of TCA precipitated IP products by the University of Michigan Proteomics Resource 
Facility is still ongoing. However, preliminary results from a single set of samples shows an 
abundance of GARS protein in the samples. In addition, wild-type GARS and 245-248ΔETAQ 
GARS were both found to interact with HSPa8, chaperone protein in the heat shock 70 family 
that has been implicated in neurodegenerative disease (Mayer and Bukau 2005). The remaining 
samples are currently being processed and will used for comparison with the data set generated 
at the Fred Hutchinson Institute. 
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Table 6.3. Protein demonstrating increased binding to wild-type GARS 
Protein Function 
Max Fold 
Change 
WT Spectral 
Counts 
ΔETAQ Spectral 
Counts 
PLEC 
Interlinks intermediate filaments 
with microtubules and 
microfilaments 
3.29 19 3 
ACTN4 
F-actin cross-linking protein 
anchors actin intracellular 
structures 
2.67 28 8 
COR1C 
May be involved in cytokinesis, 
motility, and signal transduction 
2.6 35 11 
MYPT1 
Key regulator of protein 
phosphatase 1C (PPP1C) 
2.6 9 1 
SRC8 
Contributes to organization of actin 
cytoskeleton and cell shape 
2.47 75 28 
NFL 
Neurofilament involved in the 
maintenance of neuronal caliber 
2.2 7 1 
FLII 
May co-activate in transcriptional 
activation by hormone-activated 
nuclear receptors (NR) 
2.17 9 2 
WDR1 
Induces disassembly of actin 
filaments 
2.7 17 6 
6HBB1 
Involved in oxygen transport from 
the lung to peripheral tissues 
2 4 0 
CYTSA 
Involved in cytokinesis and spindle 
organization 
1.8 5 1 
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Table 6.4. Protein demonstrating increased binding to 245-248ΔETAQ GARS 
Protein Function 
Max Fold 
Change 
WT Spectral 
Counts 
ΔETAQ Spectral 
Counts 
UBA1 
Catalyzes the first step in ubiquitin 
conjugation to mark cellular 
proteins for degradation 
4.8 1 20 
RUVB2 
Component of the NuA4 histone 
acetyltransferase complex 
involved in transcriptional 
activation 
4.4 1 18 
VARS 
Catalyzes the attachment of valine 
to tRNAVal 
4 0 12 
RPL4 60S ribosomal protein L4 3.75 0 11 
VAT1 
Involved in organization of actin 
cytoskeleton  
3.5 0 10 
STIP1 
Mediates the association of the 
molecular chaperones HSC70 and 
HSP90 
3.4 1 13 
ENPL 
Molecular chaperone that 
functions in the processing and 
transport of secreted proteins 
3.33 5 26 
PLIN3 
Required for the transport of 
mannose 6-phosphate receptors 
(MPR) from endosomes to the 
trans-Golgi network 
3 0 8 
GOGA5 
Involved in maintaining Golgi 
structure 
3 0 8 
SMAD2 Receptor-regulated SMAD  3 0 8 
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DISCUSSION 
 
In this chapter, we have implicated a de novo GARS mutation in the pathogenesis of infantile 
SMA and have begun to understand GARS protein-protein interactions in neuronal cells. 245-
248ΔETAQ GARS deletes conserved residues critical for glycine binding and severely affects all 
aspects of GARS activity tested. Specifically, 245-248ΔETAQ GARS dramatically decreases 
GARS activity to <0.001% that of wild-type GARS in in vitro biochemical assays. In yeast, 245-
248ΔETAQ GARS fails to support cell viability, indicating this variant impairs activity in vivo. 
Finally, this mutation disrupts GARS puncta formation in MN-1 cells. Since 245-248ΔETAQ 
GARS results in a severe phenotype and displays loss-of-function characteristics in all assays 
commonly used to assess GARS mutations (Antonellis et al. 2006; Nangle et al. 2007; Stum et al. 
2011), we selected this mutation for IP/mass spectrometry studies. Although still on-going, these 
IP/mass spectrometry studies have the potential to offer novel insights into both GARS biology 
and mechanisms of GARS-mediated disease.   
The presence of GARS puncta was first appreciated over 10 years ago (Antonellis et al. 2006); 
however, no scientific advances have been published as to the structure, function, or role in 
disease of GARS puncta. Here we compare the protein-protein interactions of wild-type and 245-
248ΔETAQ GARS to begin to address these outstanding questions. Our preliminary mass 
spectrometry data raises some interesting hypotheses. For example, wild-type GARS binds 
PLEC and ACTN4, two proteins involved in cytoskeleton structure, with greater than 3-fold 
affinity compared to 245-248ΔETAQ GARS. This may indicate that interactions with the 
cytoskeleton are critical for GARS puncta structure or localization. The puncta may be anchored 
in specific locations in the cell to facilitate proper activity of GARS or the cytoskeleton itself 
may be a necessary structural component of GARS puncta. There are examples of cytoskeleton-
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dependent granule formation. For example, stress granules cannot form in the presence of 
nocodazole or vincristine, two pharmacologic agents that destabilize microtubules (Ivanov et al. 
2003). In contrast, the microtubule-stabilizing drug paclitaxel and actin filament-disrupting drug 
latrunculin B enhance stress granule formation. If the cytoskeleton is necessary for the 
stabilization of GARS puncta, decreased interactions with PLEC and ACTN4 by 245-
248ΔETAQ GARS may explain why this mutation fails to form puncta. If this interaction is 
confirmed via co-IP, careful follow-up studies should evaluate drugs that act on microtubules 
and actin filaments for an effect on wild-type and mutant puncta formation. If pharmacologic 
stabilization of the cytoskeleton enhances GARS puncta formation, as it does for stress granule 
formation, this may indicate a therapeutic avenue worth further investigation for GARS-
mediated CMT disease.  
In contrast to the proteins described above, multiple proteins showed a higher level of interaction 
with 245-248ΔETAQ GARS than wild-type GARS. Specifically, 245-248ΔETAQ GARS 
demonstrated a 4-fold higher interaction with UBA1, an E1 ubiquitin ligase that initiates the E1-
E2-E3 enzymatic cascade of the Ubiquitin-Proteasome System (UPS) that marks proteins for 
degradation (Schulman and Harper 2009). One potential explanation for this increased 
interaction is that the deletion of the ETAQ residues results in improper folding of 245-
248ΔETAQ GARS, leading to its ubiquitination by UBA1. Degradation of the mutant GARS 
gene product may be detrimental to the cell by leading to decreased GARS levels and/or the 
interaction of mutant GARS and UBA1 itself may be toxic to the cell.  UPS and UBA1 activity 
has been shown to be critical for neuron and synaptic development and health (Jiang et al. 2010; 
Deglincerti et al. 2015). Mutations in UBA1 are associated with Infantile-onset X-linked spinal 
muscular atrophy (SMAX; XL-SMA) a rare form of SMA that has both motor and sensory 
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involvement and cerebellar abnormalities (Ramser et al. 2008; Dlamini et al. 2013). Although it 
is not completely clear how UBA1 mutations lead to disease, it is known that all five UBA1 
mutations cluster in a domain responsible for interacting with gigoxonin, a protein that has been 
implicated in giant axonal neuropathy (GAN1) (Bomont et al. 2000). The gigaxonin-UBA1 
complex is responsible for regulating MAP1B levels, a microtubule-associated protein that is 
critical for neuronal development and has been implicated in neurodegenerative diseases 
(Bomont et al. 2000; Gordon-Weeks and Fischer 2000). Loss-of-function mutations in UBA1 
result in axon pruning defects in drosophila (Watts et al. 2003) and loss of UBA1 in adult C. 
elegans leads to late on-set paralysis (Kulkarni and Smith 2008). In addition, reduced UBA1 
levels in Schwann cells result in myelin defects in mice (Aghamaleky Sarvestany et al. 2014; 
Hunter et al. 2014). UBA1 dysfunction has also been linked to multiple neurodegenerative 
diseases, including other forms of SMA and Huntington’s disease (reviewed in (Groen and 
Gillingwater 2015)). If UBA1 is shown to be important in CMT disease pathogenesis, this would 
indicate a common pathway is involved in many forms of neurodegeneration.  
Both wild-type and mutant GARS appear to interact with members of the heat shock protein 
pathway, specifically HSP90 and HSPa8, also known as heat shock cognate protein 70 (HSC70). 
Recent studies in Niemann-Pick type C have demonstrated that HSP90 and HSP70 have a role in 
stabilizing NPC1 (the protein mutated in Niemann-Pick Type C), while HSPa8/HSC70 
destabilizes the NPC1 leading to its degradation (Nakasone et al. 2014). Thus a fine balance of 
interactions between GARS and these proteins may play a critical role in peripheral nerve health 
and maintenance, and alterations to these interactions may be involved in the pathogenesis of 
ARS-mediated CMT disease.   
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While preliminary data demonstrates altered protein binding between wild-type and 245-
248ΔETAQ GARS, follow-up studies are needed to confirm these interactions. Additional mass 
spectrometry experiments are underway to increase the power of our study. Co-IPs can be used 
to confirm putative interactions, and immunofluorescence studies will be necessary to determine 
if interactions are occurring in the puncta themselves or elsewhere in the cell. Once interactions 
are confirmed, studies of other disease-associated GARS mutations are needed to determine if the 
abnormal interactions of 245-248ΔETAQ GARS are universal to all non-puncta forming 
mutations and if puncta-forming mutations retain wild-type GARS binding partners.  
In conclusion, the data in this chapter not only expand the allelic spectrum of GARS mutations by 
implicating 245-248ΔETAQ GARS in disease, but also provide an excellent starting point for 
ongoing studies into the role of GARS puncta and the mechanism of GARS-mediated CMT 
disease.  
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CHAPTER 7 
Summary and Future Directions 
 
SUMMARY OF DISSERTATION FINDINGS 
 
The data presented in this thesis have contributed to expanding the allelic heterogeneity of ARS 
mutations in human disease and have added to the understanding of the molecular pathology of 
ARS-mediated CMT disease. Prior to this thesis work, 21 ARS loci had strong genetic evidence 
for their role in human disease, including 18 ARS genes in recessive syndromes and three in 
dominantly inherited CMT disease. We present genetic and functional evidence of pathogenicity 
for alleles identified at five ARS loci in patients with recessive disease and at four loci for 
dominantly inherited peripheral neuropathy (Table 7.1).  
Recessive mutations in ARS genes have been implicated in a broad spectrum of disease 
phenotypes that range from multi-organ to tissue specific. The genetic studies presented here 
mark the first implication of AARS, YARS, GARS, and FARSB in recessive disease. Recessive 
mutations in AARS, YARS, GARS, and DARS lead to a severe central nervous system phenotype 
and is consistent with previous reports that the majority of ARS mutations cause phenotypes that 
include a neurologic component. FARSB, in contrast, leads to lung and liver disease similar to 
what has been observed for recessive disease caused by MARS mutations. The reason for the 
tissue specificity of ARS-mediated disease remains unknown. Although characterization is not 
complete for all mutations, functional studies indicate that impaired function is likely the 
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Table 7.1. Human diseases associated with ARS mutations 
Gene Locus 
Location of 
Function 
Mode of 
Inheritance Disease OMIM no. Clinical Description Reference 
GARS 7p15 
Cytoplasm & 
Mitochondria 
Autosomal 
dominant 
CMT2D or 
dSMA-V 
601472 
600794 
Upper limb predominant, axonal motor 
neuropathy with variable sensory 
involvement 
(Antonellis et al. 2006) 
GARS 7p15 
Cytoplasm & 
Mitochondria 
Autosomal 
recessive 
Unknown NA 
Growth retardation in utero, decreased body 
weight, short stature, atrial septal defect, 
abnormal facial features, failure to thrive 
This study 
YARS 1p35.1 Cytoplasm 
Autosomal 
dominant 
DI-CMT 608323 
Motor and sensory neuropathy with 
intermediate nerve conduction velocities 
(Jordanova et al. 2006) 
YARS 1p35.1 Cytoplasm 
Autosomal 
dominant 
Unknown NA Microcephaly, infantile lethality,  This study 
AARS 16q22 Cytoplasm 
Autosomal 
dominant 
CMT2N 613287 
Motor and sensory neuropathy with variable 
sensorineural deafness 
(Latour et al. 2010) 
AARS 16q22 Cytoplasm 
Autosomal 
recessive 
EEIE29 616339 
Early-onset epileptic encephalopathy, 
failure to thrive, vertical tali, spasticity, 
microcephaly 
This study 
HARS 5q31.3 Cytoplasm 
Autosomal 
dominant 
CMT2W 142810 
Single individual with sensory > motor 
axonal neuropathy 
(Vester et al. 2012), This 
study 
MARS 12q13.3 Cytoplasm 
Autosomal 
dominant 
CMT2U 616280 Motor and sensory neuropathy (Gonzalez et al. 2013) 
MARS 12q13.3 Cytoplasm 
Autosomal 
recessive 
ILLD 615486 Interstitial lung and liver disease (Hadchouel et al. 2015) 
KARS 16q23.1 
Cytoplasm & 
Mitochondria 
Autosomal 
recessive 
RI-CMTB 613641 
Single individual with intermediate CMT, 
developmental delay, self-abusive behavior, 
dysmorphic features and vestibular 
Schwannoma 
(McLaughlin et al. 2010) 
DARS 2q21.3 Cytoplasm 
Autosomal 
recessive 
HBSL 615281 
Hypomyelination with brainstem and spinal 
cord involvement and leg spasticity 
(Taft et al. 2013) 
FARSB 2q36.1 Cytoplasm 
Autosomal 
recessive 
Unknown NA Interstitial lung and liver disease This study 
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Gene Locus 
Location of 
Function 
Mode of 
Inheritance Disease OMIM no. Clinical Description Reference 
QARS 3p21.31 
Cytoplasmic & 
Mitochondria 
Autosomal 
recessive 
MSCCA 615760 
Microcephaly, progressive, seizures, and 
cerebral and cerebellar atrophy 
(Zhang et al. 2014) 
RARS 5q34 Cytoplasmic 
Autosomal 
recessive 
Leuko-
dystrophy 
 
616140 Leukodystrophy, hypomyelination (Wolf et al. 2014) 
AARS2 6p21.1 Mitochondria 
Autosomal 
recessive 
Mitochondria
l Infantile 
CMP 
614096 Mitochondrial infantile cardiomyopathy (Götz et al. 2011) 
DARS2 1q25.1 Mitochondria 
Autosomal 
recessive 
LBSL 611105 
Leukoencephalopathy with brainstem and 
spinal cord involvement and lactate 
elevation 
(Scheper et al. 2007a) 
EARS2 16p12.2 Mitochondria 
Autosomal 
recessive 
LTBL 614924 
Infantile leukoencephalopathy involving 
thalamus and brainstem, high lactate, 
myopathy, hypotonia, seizures, retinitis 
pigmentosa, respiratory failure 
(Steenweg et al. 2012) 
FARS2 6p25.1 Mitochondria 
Autosomal 
recessive 
Alpers 
encephalo-
pathy 
614946 
Neonatal encephalopathy, developmental 
delay, refractory seizures, lactic acidosis, 
liver disease 
(Elo et al. 2012) 
HARS2 5q31.3 Mitochondria 
Autosomal 
recessive 
Perrault 
Syndrome 2 
614926 
Sensorineural deafness (both sexes), ovarian 
dysgenesis (females) 
(Pierce et al. 2011) 
IARS2 1q41 Mitochondria 
Autosomal 
recessive 
CAGSSS; 
Leigh 
Syndrome 
616007 
Cataracts, growth hormone deficiency with 
short stature, partial sensorineural deafness, 
peripheral neuropathy 
(Schwartzentruber et al. 
2014) 
LARS2 3p21.31 Mitochondria 
Autosomal 
recessive 
Perrault 
Syndrome 4 
615300 
Premature ovarian failure (POF) in females 
and by progressive hearing loss in both 
females and males 
(Pierce et al. 2013) 
MARS2 2q33.1 Mitochondria 
Autosomal 
recessive 
Spastic 
Ataxia 3 
611390 Spastic ataxia, leukoencephalopathy (Bayat et al. 2012) 
RARS2 6q16.1 Mitochondria 
Autosomal 
Recessive 
Spastic 
Ataxia 3 
611390 Spastic ataxia, leukoencephalopathy (Edvardson et al. 2007) 
SARS2 19q13.2 Mitochondria 
Autosomal 
Recessive 
HUPRA 
Syndrome 
613845 
Hyperuricemia, pulmonary hypertension, 
infantile renal failure, and alkalosis 
syndrome 
(Belostotsky et al. 2011) 
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Gene Locus 
Location of 
Function 
Mode of 
Inheritance Disease OMIM no. Clinical Description Reference 
YARS2 12p11.21 Mitochondria 
Autosomal 
Recessive 
MLASA2 613561 
Myopathy, lactic acidosis, and sideroblastic 
anemia, muscle weakness, dysphagia, 
exercise intolerance 
(Riley et al. 2010) 
TARS2 1q21.2 Mitochondria 
Autosomal 
Recessive 
COXPD21 615918 
Axial hypotonia, limb hypertonia, 
psychomotor delay, and increased serum 
lactate, thin corpus callosum, cerebral 
spongiosis, hepatic stenosis 
(Diodato et al. 2014) 
VARS2 6p21.33 Mitochondria 
Autosomal 
Recessive 
COXPD20 615917 Ophthalmoplegia, ptosis, ataxia, seizure 
(Diodato et al. 2014; Taylor 
et al. 2014) 
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pathomechanism of recessive ARS-mediated disease and suggest that screening of ARS 
mutations in patients with similar phenotypes should be performed to help build the genetic 
argument for these loci in recessive disease.  
In addition to implicating ARS genes in novel phenotypes, we have identified and characterized 
alleles in GARS, YARS, AARS, and HARS in individuals with dominant peripheral neuropathy 
(Table 7.2). Evaluations of these new alleles led to three significant contributions in the field of 
ARS-mediate CMT research. First, the identification of multiple HARS alleles was critical to 
implicating HARS as a CMT disease locus. Second, we were able to expand the phenotypic 
spectrum observed for AARS, GARS, and HARS disease. Lastly, combined with functional 
studies of previously implicated GARS mutations, we determined that the majority of CMT-
associated ARS alleles demonstrate loss-of-function characteristics, indicating that loss-of-
function is an important component of ARS-mediated disease.  
Our studies offer valuable insights into the functional consequences of ARS mutations and the 
pathomechanism of ARS-mediated disease. While loss-of-function is generally accepted as the 
mechanism in recessive ARS phenotypes, the pathomechanism for dominant ARS-mediated 
CMT disease is widely debated. Our studies revealed that AARS and YARS mutations identified 
in both dominant and recessive disease led to a dramatic reduction in ARS activity. This suggests 
a direct correlation between levels of ARS activity and the severity of disease (i.e. the greater the 
reduction in enzyme function, the more severe the phenotype). Direct evidence supporting this 
correlation is observed for the P167T YARS allele. P167T YARS is a loss of function allele that 
when in the heterozygous state leads to peripheral neuropathy, while in the homozygous state, 
leads to recessive microcephaly (Table 7.1). Combined with the studies 
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Table 7.2. ARS variants identified in dominantly inherited CMT disease 
Gene 
 
Variant 
 
Conservation 
Enzyme 
Activity 
Yeast 
Viability 
Fly 
Comp. 
Puncta 
Formation 
 
Dimerization References 
GARS A57V Mammals Normal1 NA NP Yes NP (Rohkamm et al. 2007) 
GARS E71G Yeast Reduced Viable Reduced Yes NP 
(Antonellis et al. 2006; 
Nangle et al. 2007) 
GARS L129P Bacteria Reduced Reduced No No Reduced 
(Antonellis et al. 2006; 
Nangle et al. 2007) 
GARS D146N Yeast Reduced Reduced NP NP NP (Lee et al. 2012a) 
GARS S211F Worm Reduced NA NP NP NP (Lee et al. 2012a) 
GARS G240R Bacteria Reduced Viable NP No Reduced 
(Antonellis et al. 2006; 
Nangle et al. 2007) 
GARS P244L Yeast Reduced Lethal NP NP NP 
(Abe and Hayasaka 
2009) 
GARS 
245-248 
ΔETAQ 
Bacteria Reduced Lethal NP No NP This study 
GARS I280F Yeast Reduced Viable NP NP NP (James et al. 2006) 
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Gene 
 
Variant 
 
Conservation 
Enzyme 
Activity 
Yeast 
Viability 
Fly 
Comp. 
Puncta 
Formation 
 
Dimerization References 
GARS H418R Yeast Reduced Lethal NP No Reduced 
(Antonellis et al. 2006; 
Nangle et al. 2007) 
GARS D500N Zebrafish Normal NA NP NP Normal 
(Del Bo et al. 2006; 
Nangle et al. 2007; 
Stum et al. 2011) 
GARS G526R Bacteria Reduced Lethal NP Yes Normal 
(Antonellis et al. 2006; 
Nangle et al. 2007; 
Xie et al. 2007) 
GARS S581L Zebrafish Normal NA NP NP Normal 
(James et al. 2006; 
Cader et al. 2007; 
Nangle et al. 2007) 
GARS G598A Worm Reduced Viable NP No NP 
(James et al. 2006; 
Stum et al. 2011) 
YARS G41R Bacteria Reduced Lethal NP No NP (Jordanova et al. 2006) 
YARS E196K Yeast Reduced Reduced NP No NP (Jordanova et al. 2006) 
YARS E196Q Yeast Reduced Reduced NP No NP This study 
YARS 
153-156Δ 
VKQV 
Yeast NP NP NP NP NP (Jordanova et al. 2006) 
AARS N71Y Yeast Reduced Lethal NP NA NP 
(Lin et al. 2011; 
McLaughlin et al. 
2011) 
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Gene 
 
Variant 
 
Conservation 
Enzyme 
Activity 
Yeast 
Viability 
Fly 
Comp. 
Puncta 
Formation 
 
Dimerization References 
AARS G102R Bacteria NP Lethal NP NA NP This study 
AARS R329H Zebrafish Reduced Lethal NP NA NP 
(Latour et al. 2010; 
McLaughlin et al. 
2011) 
AARS D893N Mouse NP NP NP NA NP (Zhao et al. 2012) 
HARS R137Q Yeast NP Lethal NP NA NP (Vester et al. 2012) 
HARS T132I Yeast NP Lethal NP NA NP This study 
HARS P134H Yeast NP Lethal NP NA NP This study 
HARS V155G Yeast NP Lethal NP NA NP This study 
HARS D175E Yeast NP Lethal NP NA NP This study 
HARS Y330C Bacteria NP Reduced NP NA NP This study 
HARS S356N Yeast NP Reduced NP NA NP This study 
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Gene 
 
Variant 
 
Conservation 
Enzyme 
Activity 
Yeast 
Viability 
Fly 
Comp. 
Puncta 
Formation 
 
Dimerization References 
HARS D364Y Bacteria NP Lethal NP NA NP This study 
MARS R618C Bacteria NP Lethal NP NA NP (Gonzalez et al. 2013) 
Red text indicates a result consistent with a loss-of-function effect. 
1This variant was associated with ~50% activity compared with wild-type GARS.  
We considered a >90% reduction in activity as dramatically ‘Reduced’. 
NA – not applicable; mutation could not be modeled in yeast ortholog. 
NP- not performed; analysis not included in the literature. 
Fly Comp- Fly complementation assays 
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demonstrating loss-of-function characteristics for dominant ARS mutations, these data support a 
loss-of-function mechanism for ARS-mediated CMT disease.  
We explored two loss-of-function mechanisms for GARS-mediated CMT disease: a dominant 
negative effect and protein mislocalization. We developed a trans-complementation assay to 
assess for a dominant negative effect of GARS mutations in vivo. Co-expression of a 
hypomorphic GARS allele (L129P) and a null allele (H418R or G526R) revealed that motifs on 
opposing subunits could complement one and other to improve overall dimer function. This 
appears to refute the dominant negative hypothesis and instead suggests that a wild-type GARS 
subunit can compensate for mutations on the opposing subunit. However, not all motifs 
complement in trans as evidenced by a lack of growth observed for yeast co-expressing H418 
and G526R alleles. Thus, further studies on the human wild-type/mutant heterodimer are 
necessary to fully understand the effects of mutations on overall enzyme activity in heterozygous 
cells. To address the role of GARS puncta in CMT disease, we performed IP/mass spec studies 
on wild-type and 245-248ΔETAQ GARS and identified multiple putative binding partners for 
both proteins. These experiments will provide the basis for future studies aimed at understanding  
the role of GARS puncta in neurons and how disruption of these structures leads to disease.  
OUTSTANDING QUESTIONS AND FUTURE DIRECTIONS 
Defining the complete spectrum of ARS-mediated disease 
 
While four cytoplasmic ARS loci have been implicated in peripheral neuropathy, it is still 
unknown if all cytoplasmic ARS genes can lead to dominant disease. To address this, I propose a 
two-pronged observational and experimental approach. First, individuals who are heterozygous 
for ARS variants that are implicated in recessive disease should be periodically evaluated for 
evidence of peripheral neuropathy. Since most ARS-associated CMT cases are late onset and 
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many of the parents of the affected children are young individuals themselves, longitudinal 
observation is necessary. To date, only carriers of the P167T YARS allele have reported 
symptoms of a mild neuropathy (discussed above). Currently, evidence indicates that 
cytoplasmic, not mitochondrial, ARS dysfunction leads to CMT disease (Wallen and Antonellis 
2013). Thus of the 21 ARS enzymes implicated in recessive syndromes, only heterozygous 
individuals in families with mutations in cytoplasmic ARS genes (AARS, DARS, GARS, FARSB, 
KARS, MARS, QARS, RARS, and YARS (McLaughlin et al. 2010; Taft et al. 2013; Wolf et al. 
2014; Zhang et al. 2014; Hadchouel et al. 2015; Simons et al. 2015)) would be hypothesized to 
develop symptoms of peripheral neuropathy. Based on mouse studies showing that an expressed, 
stable mutant GARS protein is necessary to cause dominant disease (Seburn et al. 2006), we 
hypothesize that parents carrying missense ARS mutations, but not those carrying null (i.e. frame 
shift and nonsense) alleles, would be at risk for developing a peripheral neuropathy. Zebrafish 
studies on T209R Gars, a loss-of function mutant that fails to dimerize (briefly discussed in 
chapter 5), and the observation that only dimeric ARS enzymes have been implicated in CMT 
disease indicate that both impaired function and an ability to dimerize are both critical 
components of ARS-mediated CMT disease pathogenesis. QARS, MARS, and RARS enzymes 
all function as monomers and have been implicated in recessive disease (Wolf et al. 2014; Zhang 
et al. 2014; Hadchouel et al. 2015). Thus if missense mutations in these three genes lead to CMT 
disease in heterozygous individuals, this would refute the hypothesis that oligomerization is an 
important component of disease.  
Since natural history studies are fraught with complications such as the length of the study, 
attrition rates of participants, and inability to control confounding variables, an experimental 
approach should be performed in parallel. Our lab is currently employing Programmed Allelic 
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Series (PALS) mutagenesis (Kitzman et al. 2015) to perform large scale mutagenesis on a subset 
of ARS loci to catalog all the variants that result in loss of function. In this technique, a single 
mutation is introduced per DNA template (i.e. the ARS open reading frame in yeast expression 
construct) in a high throughput manner such that every possible allele is generated for that DNA 
sequence. The pool of ARS alleles can be introduced into a ΔARS haploid yeast strain harboring 
a URA3 maintenance vector and grown in either media lacking uracil and leucine or in complete 
media containing 5-FOA (Boeke et al. 1987). DNA is then extracted from yeast that survive in 
both conditions, and high throughput sequencing is used to identify the alleles that are present in 
each condition. Comparison of the two conditions will indicate which variants are able to sustain 
viability and which are lost during selection, allowing us to catalog all the alleles that are loss of 
function. Importantly, the functional consequences of variants of unknown significance 
identified in patients with CMT disease can be mined from the PALS data to rapidly determine 
the likelihood of pathogenicity for new alleles. Computational analysis and dimerization assays 
can be used to classify the loss-of function-mutations based on their ability to form dimers. Loss-
of-function, dimer forming and loss-of-function, non-dimer forming mutations can expressed be 
in C. elegans to determine if dimerization is a critical component of ARS-mediated dominant 
neurotoxicity. Finally, a dominantly toxic variant can be modeled in mice to see if the mutation 
causes a peripheral neuropathy phenotype similar to the C201R or P234KY Gars mice. Studies 
similar to those outlined here are currently underway for threonyl-tRNA synthetase (TARS), a 
dimeric ARS enzyme not previously implicated in disease, to determine if TARS variants have 
the capacity to cause a peripheral neuropathy. To complement the TARS work, I propose 
performing PALS, yeast complementation, and C. elegans studies on a monomeric ARS enzyme 
that has not been previously implicated in disease (e.g. VARS) to determine if loss-of-function  of 
 199 
a monomeric ARS can lead to dominantly inherited peripheral neuropathy. These studies will 
provide valuable insight into the mechanism of ARS-mediated peripheral neuropathy and 
support the screening of additional ARS loci in idiopathic CMT disease.  
Defining the pathomechanism of ARS-mediated dominant disease 
 
As discussed in the introduction, there are five major hypotheses for the mechanism of ARS-
mediated CMT disease. Of the five, a loss-of-function dominant negative effect or a toxic gain of 
function are widely considered the most probable mechanisms. Although this work contributes to 
the literature that loss of function is an important component of dominant ARS-mediated CMT 
disease (Wallen and Antonellis 2013; Griffin et al. 2014; Gonzaga-Jauregui et al. 2015; Motley 
et al. 2015; Safka Brozkova et al. 2015), there is some evidence suggesting a toxic gain of 
function mechanism may also be involved. In a pure loss-of-function mechanism, improving 
enzyme activity would be hypothesized to rescue the phenotype. However, two groups have 
shown that overexpression of wild-type GARS is not sufficient to rescue phenotypes observed in 
fly and mouse models of GARS-mediated disease, leading investigators to hypothesize that 
mutant ARS has a neurotoxic gain of function (Motley et al. 2011; Niehues et al. 2015). A recent 
study of the mouse P234KY Gars mutation demonstrated abnormal interaction of mutant GARS 
and the neuronal receptor protein neuropilin-1 that may be responsible for the neurotoxicity in 
this model (He et al. 2015). It is important to note that loss- and gain-of-function mechanisms 
may not be mutually exclusive. Loss of normal ARS function could free the protein to participate 
in a toxic interaction with a neuronal protein, or the combination of loss-of-tRNA charging and 
increased demands on cellular machinery (e.g. the ubiquitin protease system) in the presence of a 
non-functional ARS protein may together be too much for neurons to overcome, resulting in 
disease. Both of these hypotheses would explain the tissue specificity of ARS-mediated CMT 
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disease and the discrepancy in the literature between loss and gain of function data.  Our studies 
investigating the binding partners of mutant and wild-type GARS described in Chapter 6 have 
the potential to identify both the lost and gained interactions of mutant GARS. Follow-up studies 
outlined in the following section can be used to understand the consequences of novel 
interactions.  
The majority of research into the precise mechanism of ARS-mediated peripheral neuropathy has 
focused on GARS mutations. Given the similarities in phenotypes between GARS-, HARS-, 
YARS-, and AARS-mediated CMT disease, it is hypothesized that all ARS-mediated peripheral 
neuropathy occurs via a common mechanism. However, this hypothesis needs to be explored. To 
date, all the data for YARS-, AARS-, and HARS-mediated CMT disease indicate a loss-of-function 
mechanism. Specifically, all identified mutations at these loci lead to decreased ARS function 
and studies of yeast co-expressing mutant and wild-type YARS showed decreased growth 
consistent with a dominant negative effect (Jordanova et al. 2006; McLaughlin et al. 2011; 
Gonzaga-Jauregui et al. 2015; Motley et al. 2015; Safka Brozkova et al. 2015). Carefully 
assessing AARS, HARS, and the newly identified YARS mutations for a dominant negative effect 
is critical to addressing the mechanism of pathogenicity. While it is unknown if HARS 
complements HTS1 in yeast, we can utilize humanized yeast strains to address a dominant 
negative effect for AARS and YARS mutations as both of these human genes have been shown to 
complement in yeast (Stephanie Oprescu, personal communication, (Jordanova et al. 2006; 
Kachroo et al. 2015)). Understanding the precise pathomechanism is critical to our understanding 
of the role of ARS in neuronal function and to providing important insights into therapeutic 
options for CMT disease. 
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The role of GARS puncta in disease 
 
Mislocalization is an important loss-of-function mechanism that should be considered for GARS-
mediated CMT disease as the majority of GARS alleles fail to form the punctate cellular 
structures observed for wild-type endogenous GARS. We hypothesize that GARS puncta are 
critical for axonal health and that disruption of these structures plays a role in pathogenicity. 
Currently, the function of GARS puncta, how mutations disrupt puncta formation, and what, if 
any, role loss of these structures play in disease pathogenesis remain open questions in the field. 
Although we have begun to address these questions using an IP/mass spectrometry approach to 
identify interacting partners of wild-type and mutant GARS, many follow up studies are needed. 
The top interacting candidates from the wild-type and 245-248ΔETAQ samples must be 
confirmed by co-IP and immunofluorescence. Lost or gained protein interactions of mutant 
GARS may increase or decrease activity of its binding partner, disrupting normal activity, and 
leading to dominant toxicity in cells. To determine the significance of these interactions in 
disease, interacting partners could be manipulated in zebrafish. Unpublished work in our lab 
demonstrates that overexpression of G240R GARS, but not wild-type GARS, results in gross 
developmental abnormalities and abnormal neuron projections in zebrafish embryos. We can use 
zebrafish embryos to assess the effect of knockdown and overexpression of candidate proteins 
and compare the resulting phenotypes to effects observed for mutant GARS expression.  
Importantly, UBA1, whose gene product appeared to preferentially bind mutant GARS, 
knockdown in zebrafish is known to result in motor neuron axonal defects (Wishart et al. 2014), 
providing an excellent rationale for the use of zebrafish to address these types of question. We 
would expect knockdown of proteins essential for puncta formation to result in abnormal motor 
axon morphology in zebrafish embryos. This would indicate that these components are critical to 
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axon health and that puncta disruption is an important component of GARS-mediated CMT 
disease. If depletion of proteins that specifically interact with wild-type GARS but not with 245-
248ΔETAQ GARS leads to a neuronal phenotype, this would suggest that loss of this interaction 
is important for disease pathogenesis. If overexpression or depletion of proteins that specifically 
bind to 245-248ΔETAQ GARS, but do not bind wild-type GARS, leads to an axonal phenotype, 
this would indicate a potential toxic gain-of-function mechanism for GARS mutations. 
Subsequent studies could then focus on identifying pharmacologic agents that alter these 
interactions as a next step toward developing a treatment for GARS-mediated CMT disease. 
Treatment of ARS-mediated disease 
 
Currently, there are no therapeutic interventions for patients with either recessive or dominant 
ARS-associated disease. Since it appears that loss of protein function is a key component in all 
ARS-mediated phenotypes, identifying ways to improve ARS function would have the potential 
to treat both dominant and recessive disease. A quantifiable high throughput system could be 
used to screen small molecules for effects on ARS function. Yeast assays can be adapted for this 
purpose. Yeast growth of strains expressing human ARS proteins can be used as a proxy for 
ARS activity in vivo. Specifically, liquid yeast cultures expressing mutant ARS can be treated 
with a library of compounds and serial OD600 readings could be used to assess for effects on 
yeast growth. Alternatively, a colorimetric assay, such as the pyrophosphate exchange assay, 
could be used in a similar high throughout manner to screen compounds that improve the first 
step of the aminoacylation reaction; however, this would only allow for visualization of changes 
to the Km, not the kcat, and would not reflect in vivo activity of the enzyme or the compound. 
Another aspect of ARS dysfunction that could be used for drug screening is GARS puncta 
formation. High throughput cell based florescence assays can be used to screen for compounds 
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that affect protein localization patterns in cells (Starkuviene and Pepperkok 2007). Cells 
expressing mutant GARS-EGFP can be treated with compounds and fluorescence intensity can 
be used to assess for alterations in puncta formation in cells. It should be noted that wild-type 
overexpression of GARS in both a mouse and a fly model of disease did not rescue the 
neurotoxic phenotype in the presence of the mutant allele (Motley et al. 2011; Niehues et al. 
2015). As such, if a toxic interaction is identified in our IP/mass spectrometry and zebrafish 
studies, therapies targeting this interaction may be needed. If so, a high throughput assay based 
on a read out of the toxic binding partner’s activity should be developed.  
CONCLUSIONS 
 
Implicating ARS variants in a variety of disease phenotypes highlights the complexity of ARS 
biology. In general, our work supports findings in the literature that neurons are exquisitely 
sensitive to perturbations of protein synthesis.  However, understanding why mutations in 
proteins involved in translation, particularly those within the same protein family (e.g. ARS 
enzymes), lead to dramatically different phenotypes is still an open question. It is our hope that 
studies presented here will serve as the basis for elucidating the pathogenic mechanism by which 
ARS mutations lead to recessive and dominant disease and will provide therapeutic targets for 
improving ARS function in patients.
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APPENDIX 
 
Appendix A. Oligonucleotide Primers (5’ to 3’) 
 
Appendix A1. Cloning primers for yeast complementation constructs 
Primer Sequence 
Sc_DPS1_locus_GWF ggggacaagtttgtacaaaaaagcaggctTGACCAAGCCAGTTGTTCC 
Sc_ DPS1_locus_GWR ggggaccactttgtacaagaaagctgggtAGGGAGCGTGCTACTTGACC 
Sc_FRS1_GWF ggggacaagtttgtacaaaaaagcaggctAGTGCCCAACTTGACAGGAA 
Sc_FRS1_GWR ggggaccactttgtacaagaaagctgggtGCTAAACATTTACTCAGTAGCGG 
GRS1_Sc_GWF 
 
ggggacaagtttgtacaaaaaagcaggctAAGAGAGACAAGAAGTGAATAGTGTTTGC 
GRS1_Sc_GWR ggggaccactttgtacaagaaagctgggtGTCCGACCATGCGCAGAGCTGC 
Sc_TYS1_amp_F ggggacaagtttgtacaaaaaagcaggctCTTCAACTGCCTTTGTCC 
Sc_TYS1_amp_R ggggaccactttgtacaagaaagctgggtTCGAGCATCACTAAGAACG 
*Gateway adapter sequences are depicted in lower case and the locus specific primer sequences are depicted in upper case.  
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Appendix A2. Sequencing primers for pTM3xFLAG_GW constructs 
Primer Sequence 
pTM_Upstream_Seq_For CCAGAAAGGACATCTACACC 
pTM_Downstream_Seq_Rev GAACCTGAAACATAAAATGAATGC 
 
Appendix A3. Mutagenic primers for yeast 
Primer Sequence  
Sc_ALA1_K81T_MutF CAGAGCTGGTGGTACACACAACGATTTAGAA 
Sc_ALA1_K81T_MutR TTCTAAATCGTTGTGTGTACCACCAGCTCTG 
Sc_ALA1_G102R_MutF TTTTTTGAAATGCTGCGTAACTGGTCGTTTG 
Sc_ALA1_G102R_MutR CAAACGACCAGTTACGCAGCATTTCAAAAAA 
Sc_ALA1_R329H_MutF GGTAGAGGATATGTTTTGAGACGCATTCTACATAGAGGTGCCCGTTACG 
Sc_ALA1_R329H_MutR CGTAACGGGCACCTCTATGTAGAATGCGTCTCAAAACATATCCTCTACC 
Sc_ALA1_R751G_MutF GCAAAGGGTATCAGAGGAATTGTTGCTGTTA 
Sc_ALA1_R751G_MutR  TAACAGCAACAATTCCTCTGATACCCTTTGC 
Sc_DPS1_A274V_MutF GGCCTGTGTTCAGGGTTGAAAACTCCAACAC 
Sc_DPS1_A274V_MutR GTGTTGGAGTTTTCAACCCTGAACACAGGCC 
Sc_DPS1_D367H_MutF ATTGGTGATTTTGAACACTTGAGTACCGAAA 
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Primer Sequence  
Sc_DPS1_D367H_MutR TTTCGGTACTCAAGTGTTCAAAATCACCAAT 
Sc_DPS1_D367Y_MutF ATTGGTGATTTTGAATACTTGAGTACCGAAA 
Sc_DPS1_D367Y_MutR TTTCGGTACTCAAGTATTCAAAATCACCAAT 
Sc_DPS1_H280L_MutF AAAACTCCAACACCCTCCGTCACATGACCGA 
Sc_DPS1_H280L_MutR TCGGTCATGTGACGGAGGGTGTTGGAGTTTT 
Sc_DPS1_R460H_MutF TACTGTGACGGCTTCCACTATGGGTGTCCTCC 
Sc_DPS1_R460H_MutR GGAGGACACCCATAGTGGAAGCCGTCACAGTA 
Sc_DPS1_R494G_MutF GCTTCATTGTTCCCAGGAGATCCAAAGAGAT 
Sc_DPS1_R494G_MutR ATCTCTTTGGATCTCCTGGGAACAATGAAGC 
Sc_FRS1_T256M_mutF TTTTGATTGATATAATGGCCACCGATAAGACC 
Sc_FRS1_T256M_mutR GGTCTTATCGGTGGCCATTATATCAATCAAAA 
Sc_GRS1_L129P_MutF GTTGATTGTACTATGCCAACTCCATATGAGG 
Sc_GRS1_L129P_MutR CCTCATATGGAGTTGGCATAGTACAATCAAC 
Sc_GRS1_D146N_MutF  GTTGACAAATTTTCTAATTGGATGTGTAGAG 
Sc_GRS1_D146N_MutR  CTCTACACATCCAATTAGAAAATTTGTCAAC 
Sc_GRS1_P244L_MutF   AGGGTTACTTGAGGCTAGAAACTGCCCAAGG 
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Primer Sequence  
Sc_GRS1_P244L_MutR  CCTTGGGCAGTTTCTAGCCTCAAGTAACCCT 
Sc_GRS1_245-248ETAQdel_MutF AAAGGGTTACTTGAGGCCAGGTCAATTCTTGAATTTTAA 
Sc_GRS1_245-248ETAQdel _MutR TTAAAATTCAAGAATTGACCTGGCCTCAAGTAACCCTTTA 
Sc_GRS1_R256Q_MutF TTCTTGAATTTTAACCAGTTGTTAGAATTTA 
Sc_GRS1_R256Q_MutR TAAATTCTAACAACTGGTTAAAATTCAAGAA 
Sc_GRS1_I280F_MutF   CATTTAGAAATGAGTTTTCCCCAAGGGCCG 
Sc_GRS1_I280F_MutR   CGGCCCTTGGGGAAAACTCATTTCTAAATGA 
Sc_GRS1_H418R_MutF ATGATTTGACCGTTCGTTCCAAAAAGACCA 
Sc_GRS1_H418R_MutR TGGTCTTTTTGGAACGAACGGTCAAATCAT 
Sc_GRS1_G526R_MutF ATTGAACCATCTTTCCGTATTGGCCGTATCAT 
Sc_GRS1_G526R_MutR ATGATACGGCCAATACGGAAAGATGGTTCAAT 
Sc_HTS1_T132I_MutF TACGTTACGATTTGATCGTTCCTTTTGCCAG 
Sc_HTS1_T132I_MutF CTGGCAAAAGGAACGATCAAATCGTAACGTA 
Sc_HTS1_T132S_MutF TACGTTACGATTTGAGCGTTCCTTTTGCCAG 
Sc_HTS1_T132S_MutF CTGGCAAAAGGAACGCTCAAATCGTAACGTA 
Sc_HTS1_P134H_MutF ACGATTTGACCGTTCATTTTGCCAGGTACGT 
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Primer Sequence  
Sc_HTS1_P134H_MutR ACGTACCTGGCAAAATGAACGGTCAAATCGT 
Sc_HTS1_R137Q_MutF CCGTTCCTTTTGCCCAGTACGTTGCCATGAA 
Sc_HTS1_R137Q_MutR TTCATGGCAACGTACTGGGCAAAAGGAACGG 
Sc_HTS1_V155G_MutF ATCACATTGCAAAAGGCTACAGAAGAGACCA 
Sc_HTS1_V155G_MutR TGGTCTCTTCTGTAGCCTTTTGCAATGTGAT 
Sc_HTS1_D175E_correctMutF ATTTTACCAGTGTGAGTTTGACGTTGCAGGC 
Sc_HTS1_D175E_correctMutR GCCTGCAACGTCAAACTCACACTGGTAAAAT 
Sc_HTS1_Y330C_mutF CAAGAGGTTTGGATTGCTATACAGGTTTGAT 
Sc_HTS1_Y330C_mutR ATCAAACCTGTATAGCAATCCAAACCTCTTG 
Sc_HTS1_S356N_MutF TTCGTTGGTGTCGGCAATATTGCAGCCG 
Sc_HTS1_S356N_MutR CGGCTGCAATATTGCCGACACCAACGAA 
Sc_HTS1_D364Y_MutF GCCGGTGGTCGATATTATAATTTGGTCAACA 
Sc_HTS1_D364Y_MutR TGTTGACCAAATTATAATATCGACCACCGGC 
Sc_TYS1_G41R_MutF ACATTTGAAATTATACTGGCGTACCGCGC 
Sc_TYS1_G41R_MutF GCGCGGTACGCCAGTATAATTTCAAATGT 
Sc_TYS1_P167T_Mut F GGGCTTATCTATACTTTAATGCAAGCG 
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Primer Sequence  
Sc_TYS1_P167T_Mut R CGCTTGCATTAAAGTATAGATAAGCCC 
Sc_TYS1_E196K_MutF AGAGAAAAATTTTTGTCTTAGCGAAAGAA 
Sc_TYS1_E196K_MutF TTCTTTCGCTAAGACAAAAATTTTTCTCT 
Sc_TYS1_E196Q_MutF AGAGAAAAATTTTTGTCTTAGCGCAAGAA 
Sc_TYS1_E196Q_MutF TTCTTGCGCTAAGACAAAAATTTTTCTCT 
 
Appendix A4. Mutagenic primers for human 
Primer Sequence 
Hs_GARS_A57V_MutF GAAGCAAAGGAGCTGGTGTTACAGCCCAAAGAT 
Hs_GARS_A57V_MutR ATCTTTGGGCTGTAACACCAGCTCCTTTGCTTC 
Hs_GARS_D146N_mutF GTAGACAAATTTGCTAACTTCATGGTGAAAG 
Hs_GARS_D146N_mutR CTTTCACCATGAAGTTAGCAAATTTGTCTAC 
Hs_GARS_S211F_mutF ACTATAATGTAAAATTTCCCATTACTGGAAA 
Hs_GARS_S211F_mutR TTTCCAGTAATGGGAAATTTTACATTATAGT 
Hs_GARS_P244L_MutF CTGGGTACTTGAGACTAGAAACTGCACAGGGG 
Hs_GARS_P244L_MutR CCCCTGTGCAGTTTCTAGTCTCAAGTACCCAG 
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Primer Sequence  
Hs_GARS_245-
248ETAQdel_MutF ATGCCTGGGTACTTGAGACCGGGGATTTTCTTGAATTTCA 
Hs_GARS_245-
248ETAQdel_MutR TGAAATTCAAGAAAATCCCCGGTCTCAAGTACCCAGGCAT 
Hs_GARS_I280F_MutF TCTTTTAGAAATGAGTTCTCCCCTCGATCTG 
Hs_GARS_I280F_MutR CAGATCGAGGGGAGAACTCATTTCTAAAAGA 
Hs_GARS_D500N_MutF TTTCAGTTAACAAAAAACATGATCAATGTGA 
Hs_GARS_D500N_MutR TCACATTGATCATGTTTTTTGTTAACTGAAA 
Hs_GARS_S581L_MutF TTGTCAAGGAATTATTGGAAGCCCTGACCAG 
Hs_GARS_S581L_MutR CTGGTCAGGGCTTCCAATAATTCCTTGACAA 
Hs_GARS_G598A_MutF GTAGACGATTCCTCTGCGTCAATCGGAAGGCGC 
Hs_GARS_G598A_MutR GCGCCTTCCGATTGACGCAGAGGAATCGTCTAC 
 
Appendix A5. Sequencing primers for GARS Exon 16 
Primer Sequence 
HS_GARS_16F AGACAGTAGTTAGATAACACTGG 
Hs_GARS_16R TCCAACACAAATCAGTAAGAAGC 
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